The POS_DT O
`` POS_`` O
corrected POS_JJ O
'' POS_'' O
cesarean POS_JJ O
rate POS_NN O
( POS_( O
maternal-fetal POS_JJ O
medicine POS_NN MESH_TYPE_descriptor MESH_medicine O
and POS_CC O
transported POS_VBD O
patients POS_NNS MESH_TYPE_descriptor MESH_patients O
excluded POS_VBD O
) POS_) O
was POS_VBD O
12.4 POS_CD O
% POS_NN O
( POS_( O
273 POS_CD O
of POS_IN O
2194 POS_CD O
) POS_) O
, POS_, O
and POS_CC O
the POS_DT O
`` POS_`` O
corrected POS_JJ O
'' POS_'' O
primary POS_JJ O
rate POS_NN O
was POS_VBD O
9.6 POS_CD O
% POS_NN O
( POS_( O
190 POS_CD O
of POS_IN O
1975 POS_CD O
) POS_) O

Furthermore POS_RB O
, POS_, O
when POS_WRB O
all POS_DT O
deliveries POS_NNS O
were POS_VBD O
analyzed POS_VBN O
, POS_, O
regardless POS_RB O
of POS_IN O
risk POS_NN MESH_TYPE_descriptor MESH_risk O
status POS_NN O
but POS_CC O
limited POS_VBD O
to POS_TO O
gestational POS_JJ MESH_TYPE_descriptor MESH_gestational age O
age POS_NN MESH_TYPE_descriptor MESH_gestational age O
> POS_NN O
or POS_CC O
= POS_$ O
36 POS_CD O
weeks POS_NNS O
, POS_, O
the POS_DT O
rates POS_NNS O
did POS_VBD O
not POS_RB O
change POS_NN O
( POS_( O
12.6 POS_CD O
% POS_NN O
, POS_, O
280 POS_CD O
of POS_IN O
2214 POS_CD O
; POS_: O
primary POS_JJ O
9.2 POS_CD O
% POS_NN O
, POS_, O
183 POS_CD O
of POS_IN O
1994 POS_CD O
) POS_) O

Arrest POS_NNP O
of POS_IN O
dilation POS_NN MESH_TYPE_descriptor MESH_dilatation O
was POS_VBD O
the POS_DT O
most POS_RBS O
common POS_JJ O
indication POS_NN O
in POS_IN O
both POS_DT O
`` POS_`` O
corrected POS_VBN O
'' POS_'' O
subgroups POS_NNS O
( POS_( O
23.4 POS_CD O
and POS_CC O
24.6 POS_CD O
% POS_NN O
, POS_, O
respectively POS_RB O
) POS_) O

In POS_IN O
the POS_DT O
third POS_JJ MESH_TYPE_descriptor MESH_third pregnancy trimester O
trimester POS_NN MESH_TYPE_descriptor MESH_third pregnancy trimester O
, POS_, O
the POS_DT O
amniotic POS_JJ MESH_TYPE_descriptor MESH_amniotic fluid O
fluid POS_NN MESH_TYPE_descriptor MESH_amniotic fluid O
index POS_NN WORDNET_body_part.n.01 MESH_TYPE_descriptor MESH_amniotic fluid O
( POS_( O
AFI POS_NNP O
) POS_) O
may POS_MD O
be POS_VB O
affected POS_VBN O
by POS_IN O
maternal POS_JJ O
fluid POS_NN O
status POS_NN O

As POS_IN O
the POS_DT O
ambient POS_JJ O
temperature POS_NN MESH_TYPE_descriptor MESH_temperature O
increases POS_NNS O
, POS_, O
there POS_EX O
is POS_VBZ O
an POS_DT O
increase POS_NN O
in POS_IN O
insensible POS_JJ O
fluid POS_JJ O
loss POS_NN O
and POS_CC O
the POS_DT O
potential POS_NN O
for POS_IN O
dehydration POS_NN MESH_TYPE_descriptor MESH_dehydration O

This POS_DT O
relationship POS_NN O
should POS_MD O
be POS_VB O
taken POS_VBN O
into POS_IN O
account POS_NN O
when POS_WRB O
interpreting POS_VBG O
the POS_DT O
AFI POS_NNP O
as POS_IN O
a POS_DT O
measure POS_NN MESH_TYPE_descriptor MESH_weights and measures O
of POS_IN O
fetal POS_JJ O
well-being POS_NN O

The POS_DT O
most POS_RBS O
common POS_JJ O
indication POS_NN O
leading POS_VBG O
to POS_TO O
diagnosis POS_NN MESH_TYPE_qualifier MESH_diagnosis O
was POS_VBD O
abnormal POS_JJ O
ultrasound POS_JJ MESH_TYPE_qualifier MESH_diagnostic imaging O
finding POS_NN O
( POS_( O
48.2 POS_CD O
% POS_NN O
) POS_) O
, POS_, O
followed POS_VBN O
by POS_IN O
advanced POS_JJ O
maternal POS_JJ O
age POS_NN O
( POS_( O
44.4 POS_CD O
% POS_NN O
) POS_) O

Trisomy POS_$ D
18 POS_CD D
fetuses POS_NNS O
showed POS_VBD O
hydramnios POS_NNS O
, POS_, O
intrauterine POS_JJ O
growth POS_NN MESH_TYPE_qualifier MESH_growth & development O
retardation POS_NN O
, POS_, O
microcephaly POS_NN D
, POS_, O
spina POS_NN D
bifida POS_NN D
, POS_, O
and POS_CC O
nonimmune POS_JJ D
hydrops POS_NNS D
fetalis POS_VBP D

Student POS_NN O
's POS_POS O
t-test POS_NN O
, POS_, O
Fisher POS_NNP O
exact POS_JJ O
test POS_NN O
, POS_, O
and POS_CC O
Chi-square POS_NNP O
were POS_VBD O
used POS_VBN O
for POS_IN O
statistical POS_JJ O
analysis POS_NN MESH_TYPE_qualifier MESH_analysis O

The POS_DT O
rate POS_NN O
of POS_IN O
severe POS_JJ O
preeclampsia POS_NN D
was POS_VBD O
increased POS_VBN O
significantly POS_RB O
in POS_IN O
the POS_DT O
triplet POS_NN O
group POS_NN O
12 POS_CD O
of POS_IN O
53 POS_CD O
( POS_( O
22.6 POS_CD O
% POS_NN O
) POS_) O
as POS_IN O
compared POS_VBN O
with POS_IN O
the POS_DT O
twin POS_NN O
group POS_NN O
3 POS_CD O
of POS_IN O
53 POS_CD O
( POS_( O
5.7 POS_CD O
% POS_NN O
) POS_) O
( POS_( O
OR POS_NNP O
= POS_VBZ O
4.9 POS_CD O
, POS_, O
95 POS_CD O
% POS_NN O
CI POS_NNP O
1.2-23.5 POS_CD O
, POS_, O
p POS_VBZ O
= POS_NNP O
0.02 POS_CD O
) POS_) O

This POS_DT O
information POS_NN O
may POS_MD O
be POS_VB O
useful POS_JJ O
in POS_IN O
counseling POS_VBG O
patients POS_NNS O
with POS_IN O
high POS_JJ O
order POS_NN O
multifetal POS_JJ O
gestations POS_NNS O

The POS_DT O
survey POS_NN O
indicated POS_VBD O
a POS_DT O
variety POS_NN O
of POS_IN O
thermal POS_JJ O
care POS_NN O
styles POS_NNS O

Two POS_CD O
NICUs POS_NNP O
preferred POS_VBD O
to POS_TO O
admit POS_VB O
infants POS_NNS O
to POS_TO O
incubators POS_NNS O
, POS_, O
the POS_DT O
other POS_JJ O
three POS_CD O
favoring POS_VBG O
radiant POS_NN O
warmers POS_NNS O

Right POS_JJ WORDNET_body_part.n.01 O
temporal POS_NN O
and POS_CC O
cerebellar POS_JJ O
hemorrhages POS_NNS O
were POS_VBD O
present POS_JJ O

CONTEXT POS_NN O
: POS_: O
Four POS_CD O
genetic POS_JJ O
loci POS_NNS O
have POS_VBP O
been POS_VBN O
identified POS_VBN O
as POS_IN O
contributing POS_VBG O
to POS_TO O
Alzheimer POS_NNP D
disease POS_NN D
( POS_( D
AD POS_NNP D
) POS_) D
, POS_, O
including POS_VBG O
the POS_DT O
amyloid POS_NN WORDNET_chemical.n.01 O
precursor POS_NN O
protein POS_NN WORDNET_chemical.n.01 O
gene POS_NN O
, POS_, O
the POS_DT O
presenilin POS_NN O
1 POS_CD O
gene POS_NN O
, POS_, O
the POS_DT O
presenilin POS_NN O
2 POS_CD O
gene POS_NN O
, POS_, O
and POS_CC O
the POS_DT O
apolipoprotein POS_NN O
E POS_NNP O
gene POS_NN O
, POS_, O
but POS_CC O
do POS_VBP O
not POS_RB O
account POS_VB O
for POS_IN O
all POS_PDT O
the POS_DT O
genetic POS_JJ O
risk POS_NN O
for POS_IN O
AD POS_NNP O

Regional POS_JJ O
follow-up POS_NN O
included POS_VBD O
analysis POS_NN MESH_TYPE_qualifier MESH_analysis O
of POS_IN O
additional POS_JJ O
markers POS_NNS O
and POS_CC O
a POS_DT O
second POS_JJ O
data POS_NN O
set POS_NN O

A POS_DT O
second POS_JJ O
subset POS_NN O
of POS_IN O
38 POS_CD O
families POS_NNS O
( POS_( O
216 POS_CD O
total POS_JJ O
family POS_NN O
members POS_NNS O
, POS_, O
89 POS_CD O
of POS_IN O
whom POS_WP O
were POS_VBD O
patients POS_NNS O
with POS_IN O
AD POS_NNP O
) POS_) O
was POS_VBD O
used POS_VBN O
for POS_IN O
the POS_DT O
follow-up POS_JJ O
analysis POS_NN MESH_TYPE_qualifier MESH_analysis O

RESULTS POS_NN O
: POS_: O
Fifteen POS_NNP O
chromosomal POS_JJ O
regions POS_NNS O
warranted POS_VBD O
initial POS_JJ O
follow-up POS_NN O

Sibpair POS_NN O
analysis POS_NN MESH_TYPE_qualifier MESH_analysis O
( POS_( O
n=54 POS_JJ O
) POS_) O
resulted POS_VBD O
in POS_IN O
maximum POS_JJ O
lod POS_JJ O
scores POS_NNS O
( POS_( O
MLSs POS_NNP O
) POS_) O
of POS_IN O
1.5 POS_CD O
, POS_, O
2.6 POS_CD O
, POS_, O
3.2 POS_CD O
, POS_, O
and POS_CC O
2.3 POS_CD O
for POS_IN O
these POS_DT O
markers POS_NNS O
, POS_, O
with POS_IN O
a POS_DT O
peak POS_JJ O
multipoint POS_NN O
MLS POS_NNP O
of POS_IN O
3.5 POS_CD O

Chromosome POS_NNP O
12 POS_CD O
gave POS_VBD O
the POS_DT O
strongest POS_JJS O
and POS_CC O
most POS_RBS O
consistent POS_JJ O
results POS_NNS O
with POS_IN O
a POS_DT O
peak POS_JJ O
multipoint POS_NN O
MLS POS_NNP O
of POS_IN O
3.5 POS_CD O
, POS_, O
suggesting POS_VBG O
that POS_IN O
this POS_DT O
region POS_NN O
contains POS_VBZ O
a POS_DT O
new POS_JJ O
susceptibility POS_NN O
gene POS_NN O
for POS_IN O
AD POS_NNP O

Additional POS_JJ O
analyses POS_NNS O
are POS_VBP O
necessary POS_JJ O
to POS_TO O
identify POS_VB O
the POS_DT O
chromosome POS_NN O
12 POS_CD O
susceptibility POS_NN O
gene POS_NN O
for POS_IN O
AD POS_NNP O
and POS_CC O
to POS_TO O
follow POS_VB O
up POS_RP O
the POS_DT O
regions POS_NNS O
of POS_IN O
interest POS_NN O
on POS_IN O
chromosomes POS_NNS O
4 POS_CD O
, POS_, O
6 POS_CD O
, POS_, O
and POS_CC O
20 POS_CD O

OBJECTIVE POS_NN O
: POS_: O
To POS_TO O
investigate POS_VB O
phenotypic POS_NN O
characteristics POS_NNS O
of POS_IN O
families POS_NNS O
potentially POS_RB O
linked POS_VBN O
to POS_TO O
the POS_DT O
hereditary POS_JJ O
prostate POS_NN WORDNET_disease.n.01 O
cancer POS_NN WORDNET_disease.n.01 O
1 POS_CD O
( POS_( O
HPC1 POS_NNP O
) POS_) O
locus POS_NN O
on POS_IN O
chromosome POS_NN O
1q24-25 POS_JJ O

CONTEXT POS_NN O
: POS_: O
Susceptibility POS_NN O
to POS_TO O
multiple POS_VB WORDNET_disease.n.01 D
sclerosis POS_NN WORDNET_disease.n.01 D
( POS_( D
MS POS_NNP D
) POS_) D
involves POS_VBZ O
a POS_DT O
genetically POS_RB O
complex POS_JJ WORDNET_chemical.n.01 O
autoimmune POS_NN O
component POS_NN O

However POS_RB O
, POS_, O
except POS_IN O
for POS_IN O
genes POS_NNS O
in POS_IN O
the POS_DT O
HLA POS_NNP O
system POS_NN WORDNET_body_part.n.01 O
, POS_, O
specific POS_JJ O
susceptibility POS_NN O
loci POS_NN O
are POS_VBP O
unknown POS_JJ O
or POS_CC O
unconfirmed POS_JJ O

< POS_JJ O
TO_SEE POS_NNP O
> POS_NNP O
CONTEXT POS_NNP O
: POS_: O
There POS_EX O
is POS_VBZ O
a POS_DT O
substantial POS_JJ O
risk POS_NN O
of POS_IN O
a POS_DT O
second POS_JJ O
cancer POS_NN WORDNET_disease.n.01 O
for POS_IN O
persons POS_NNS O
with POS_IN O
hereditary POS_JJ O
retinoblastoma POS_NN WORDNET_disease.n.01 O
, POS_, O
which POS_WDT O
is POS_VBZ O
enhanced POS_VBN O
by POS_IN O
radiotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_radiotherapy O

DESIGN POS_NN O
: POS_: O
Cohort POS_NNP O
incidence POS_NN MESH_TYPE_qualifier MESH_epidemiology O
study POS_NN O
of POS_IN O
patients POS_NNS O
with POS_IN O
retinoblastoma POS_NN WORDNET_disease.n.01 O
followed POS_VBN O
for POS_IN O
a POS_DT O
median POS_NN O
of POS_IN O
20 POS_CD O
years POS_NNS O
, POS_, O
and POS_CC O
nested POS_VBD O
case-control POS_NN O
study POS_NN O
of POS_IN O
a POS_DT O
radiation POS_NN WORDNET_body_part.n.01 O
dose-response POS_NN O
relationship POS_NN O
for POS_IN O
bone POS_NN WORDNET_body_part.n.01 O
and POS_CC O
soft POS_JJ O
tissue POS_NN WORDNET_body_part.n.01 O
sarcomas POS_NN O

Urine POS_NNP MESH_TYPE_qualifier MESH_urine O
toxicology POS_NN WORDNET_medicine.n.01 O
screens POS_NNS O
were POS_VBD O
prospectively POS_RB O
obtained POS_VBN O
on POS_IN O
147 POS_CD O
women POS_NNS O
with POS_IN O
preterm POS_NN D
PROM POS_NNP D

Cocaine-positive POS_JJ O
women POS_NNS O
presented POS_VBN O
at POS_IN O
an POS_DT O
earlier POS_JJR O
gestational POS_JJ O
age POS_NN O
( POS_( O
32 POS_CD O
weeks POS_NNS O
' POS_POS O
, POS_, O
( POS_( O
24-34 POS_JJ O
) POS_) O
vs. POS_FW O
33 POS_CD O
weeks POS_NNS O
' POS_POS O
, POS_, O
( POS_( O
23-36 POS_JJ O
) POS_) O
, POS_, O
p POS_JJ O
= POS_NNP O
0.02 POS_CD O
) POS_) O
and POS_CC O
had POS_VBD O
a POS_DT O
significantly POS_RB O
longer POS_RBR O
membrane POS_JJ WORDNET_body_part.n.01 O
rupture POS_NN O
to POS_TO O
delivery POS_NN O
interval POS_NN O
than POS_IN O
women POS_NNS O
with POS_IN O
a POS_DT O
negative POS_JJ O
urine POS_JJ MESH_TYPE_qualifier MESH_urine O
drug POS_NN O
screen POS_NN O
( POS_( O
174 POS_CD O
hr POS_NN O
, POS_, O
( POS_( O
6-475 POS_JJ O
) POS_) O
vs. POS_FW O
33 POS_CD O
hours POS_NNS O
( POS_( O
1-833 POS_JJ O
) POS_) O
, POS_, O
p POS_JJ O
= POS_NNP O
0.01 POS_CD O
) POS_) O

Recent POS_JJ O
cocaine POS_NN O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
among POS_IN O
women POS_NNS O
with POS_IN O
preterm POS_JJ D
PROM POS_NNP D
is POS_VBZ O
common POS_JJ O
in POS_IN O
only POS_RB O
some POS_DT O
segments POS_NNS O
of POS_IN O
an POS_DT O
urban POS_JJ O
population POS_NN O

We POS_PRP O
present POS_VBP O
five POS_CD O
cases POS_NNS O
of POS_IN O
isolated POS_JJ O
pleural POS_JJ O
or POS_CC O
pericardial POS_JJ D
effusion POS_NN D
with POS_IN O
documented POS_JJ O
maternal POS_JJ O
parvovirus POS_NN D
infection POS_NN D
in POS_IN O
four POS_CD O
of POS_IN O
these POS_DT O
pregnancies POS_NNS O

In POS_IN O
the POS_DT O
absence POS_NN O
of POS_IN O
structural POS_JJ O
or POS_CC O
karyotypic POS_JJ O
abnormalities POS_NNS MESH_TYPE_qualifier MESH_abnormalities O
, POS_, O
spontaneous POS_JJ O
resolution POS_NN O
of POS_IN O
the POS_DT O
effusion POS_NN O
portends POS_VBZ O
for POS_IN O
a POS_DT O
successful POS_JJ O
pregnancy POS_NN O
outcome POS_NN O

Adverse POS_JJ O
drug POS_NN MESH_TYPE_qualifier MESH_drug effects O
effects POS_NNS MESH_TYPE_qualifier MESH_drug effects O
are POS_VBP O
manifold POS_JJ O
and POS_CC O
heterogenous POS_JJ O

During POS_IN O
the POS_DT O
initial POS_JJ O
2 POS_CD O
months POS_NNS O
of POS_IN O
the POS_DT O
study POS_NN O
, POS_, O
the POS_DT O
children POS_NNS O
were POS_VBD O
treated POS_VBN O
with POS_IN O
antiepileptic POS_JJ T
drugs POS_NNS T
( POS_( T
AEDs POS_NNP T
) POS_) T
only POS_RB O
, POS_, O
and POS_CC O
for POS_IN O
the POS_DT O
remaining POS_VBG O
2 POS_CD O
months POS_NNS O
, POS_, O
methylphenidate POS_NN T
was POS_VBD O
added POS_VBN O
at POS_IN O
a POS_DT O
morning POS_NN O
dose POS_NN O
of POS_IN O
0.3 POS_CD O
mg/kg POS_NNS O

They POS_PRP O
underwent POS_VBP O
neurologic POS_JJ O
assessment POS_NN O
, POS_, O
brain POS_NN WORDNET_body_part.n.01 O
computed POS_VBD O
tomography POS_NN O
, POS_, O
IQ POS_NNP O
testing POS_NN O
, POS_, O
and POS_CC O
assessment POS_NN O
with POS_IN O
the POS_DT O
Childhood POS_NNP O
Behavior POS_NNP O
Checklist POS_NNP O
at POS_IN O
baseline POS_NN O
before POS_IN O
methylphenidate POS_NN T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T

Of POS_IN O
the POS_DT O
5 POS_CD O
children POS_NNS O
with POS_IN O
seizures POS_NNS D
, POS_, O
3 POS_CD O
had POS_VBD O
an POS_DT O
increase POS_NN O
in POS_IN O
attacks POS_NNS O
, POS_, O
whereas POS_IN O
the POS_DT O
other POS_JJ O
2 POS_CD O
showed POS_VBD O
no POS_DT O
change POS_NN O
or POS_CC O
a POS_DT O
reduction POS_NN O

Methylphenidate POS_NNP T
benefited POS_VBD O
70 POS_CD O
% POS_NN O
of POS_IN O
children POS_NNS O
according POS_VBG O
to POS_TO O
parental POS_JJ O
report POS_NN O
; POS_: O
methylphenidate POS_NN T
also POS_RB O
enhanced POS_VBD O
performance POS_NN O
on POS_IN O
the POS_DT O
CPT POS_NNP O

The POS_DT O
torsion-angle POS_JJ O
molecular POS_JJ O
dynamics POS_NNS O
algorithm POS_JJ O
starts POS_NNS O
from POS_IN O
an POS_DT O
extended POS_JJ O
strand POS_NN O
conformation POS_NN O
and POS_CC O
proceeds POS_NNS O
in POS_IN O
four POS_CD O
stages POS_NNS O
: POS_: O
high-temperature POS_JJ O
torsion-angle POS_JJ O
molecular POS_JJ O
dynamics POS_NNS O
, POS_, O
slow-cooling POS_JJ O
torsion-angle POS_JJ O
molecular POS_JJ O
dynamics POS_NNS O
, POS_, O
Cartesian POS_JJ O
molecular POS_NN O
dynamics POS_NNS O
, POS_, O
and POS_CC O
minimization POS_NN O

At POS_IN O
293 POS_CD O
sites POS_NNS O
, POS_, O
we POS_PRP O
randomly POS_VBP O
assigned POS_JJ O
8803 POS_CD O
patients POS_NNS O
who POS_WP O
had POS_VBD O
had POS_VBN O
myocardial POS_JJ D
infarction POS_NN D
, POS_, O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
with POS_IN O
160 POS_CD T
mg POS_NNS T
aspirin POS_RB WORDNET_chemical.n.01 T
, POS_, O
3 POS_CD T
mg POS_NN T
warfarin POS_NN T
with POS_IN T
80 POS_CD T
mg POS_NNS T
aspirin POS_RB WORDNET_chemical.n.01 T
, POS_, O
or POS_CC O
1 POS_CD T
mg POS_NNS T
warfarin POS_VBP T
with POS_IN T
80 POS_CD T
mg POS_NNS T
aspirin POS_NN WORDNET_chemical.n.01 T

Patients POS_NNS O
took POS_VBD O
a POS_DT O
single POS_JJ O
tablet POS_NN O
daily POS_RB O
, POS_, O
and POS_CC O
attended POS_VBD O
for POS_IN O
prothrombin POS_JJ WORDNET_chemical.n.01 O
time POS_NN O
( POS_( O
PT POS_NNP O
) POS_) O
measurements POS_NNS O
at POS_IN O
weeks POS_NNS O
1 POS_CD O
, POS_, O
2 POS_CD O
, POS_, O
3 POS_CD O
, POS_, O
4 POS_CD O
, POS_, O
6 POS_CD O
, POS_, O
and POS_CC O
12 POS_CD O
, POS_, O
and POS_CC O
then POS_RB O
every POS_DT O
3 POS_CD O
months POS_NNS O

FINDINGS POS_NNS MESH_TYPE_qualifier MESH_diagnosis O
: POS_: O
The POS_DT O
primary POS_JJ O
event POS_NN O
was POS_VBD O
first POS_JJ O
occurrence POS_NN MESH_TYPE_qualifier MESH_epidemiology O
of POS_IN O
reinfarction POS_NN O
, POS_, O
non-fatal POS_JJ O
ischaemic POS_JJ D
stroke POS_NN D
, POS_, O
or POS_CC O
cardiovascular POS_JJ O
death POS_NN O

For POS_IN O
spontaneous POS_JJ O
major POS_JJ O
haemorrhage POS_NN O
( POS_( O
not POS_RB O
procedure POS_RB O
related POS_VBN O
) POS_) O
, POS_, O
1-year POS_JJ O
life-table POS_JJ O
estimates POS_NNS O
were POS_VBD O
0.74 POS_CD O
% POS_NN O
( POS_( O
0.43-1.1 POS_JJ O
) POS_) O
in POS_IN O
the POS_DT O
160 POS_CD O
mg POS_NN O
aspirin POS_NN WORDNET_chemical.n.01 O
group POS_NN O
and POS_CC O
1.4 POS_CD O
% POS_NN O
( POS_( O
0.94-1.8 POS_JJ O
) POS_) O
in POS_IN O
the POS_DT O
3 POS_CD O
mg POS_NN O
warfarin POS_NN O
with POS_IN O
80 POS_CD O
mg POS_NNS O
aspirin POS_JJ WORDNET_chemical.n.01 O
group POS_NN O
( POS_( O
p POS_JJ O
= POS_NN O
0.014 POS_CD O
log POS_NN O
rank POS_NN O
on POS_IN O
follow-up POS_NN O
) POS_) O

For POS_IN O
the POS_DT O
3382 POS_CD O
patients POS_NNS O
assigned POS_VBD O
3 POS_CD O
mg POS_NNS O
warfarin POS_VBP T
with POS_IN O
80 POS_CD O
mg POS_NNS O
aspirin POS_RB WORDNET_chemical.n.01 T
, POS_, O
the POS_DT O
INR POS_NNP O
results POS_NNS O
were POS_VBD O
: POS_: O
at POS_IN O
week POS_NN O
1 POS_CD O
( POS_( O
n POS_JJ O
= POS_NN O
2985 POS_CD O
) POS_) O
median POS_JJ O
1.51 POS_CD O
( POS_( O
IQR POS_NNP O
1.23-2.13 POS_CD O
) POS_) O
; POS_: O
at POS_IN O
week POS_NN O
4 POS_CD O
( POS_( O
n POS_JJ O
= POS_NN O
2701 POS_CD O
) POS_) O
1.27 POS_CD O
( POS_( O
1.13-1.64 POS_JJ O
) POS_) O
; POS_: O
at POS_IN O
month POS_NN O
6 POS_CD O
( POS_( O
n POS_JJ O
= POS_NN O
2145 POS_CD O
) POS_) O
1.19 POS_CD O
( POS_( O
1.08-1.44 POS_CD O
) POS_) O

BACKGROUND POS_NN O
: POS_: O
There POS_EX O
is POS_VBZ O
serological POS_JJ O
evidence POS_NN O
for POS_IN O
an POS_DT O
association POS_NN O
between POS_IN O
Chlamydia POS_NNP WORDNET_disease.n.01 D
pneumoniae POS_NN D
and POS_CC O
coronary POS_JJ D
heart POS_NN WORDNET_body_part.n.01 D
disease POS_NN D

Patients POS_NNS O
were POS_VBD O
randomly POS_RB O
assigned POS_VBN O
either POS_CC O
roxithromycin POS_JJ T
150 POS_CD O
mg POS_NN O
orally POS_RB O
twice POS_RB O
a POS_DT O
day POS_NN O
( POS_( O
n POS_JJ O
= POS_NNP O
102 POS_CD O
) POS_) O
or POS_CC O
placebo POS_VB O
orally POS_RB O
twice POS_RB O
a POS_DT O
day POS_NN O
( POS_( O
n POS_JJ O
= POS_NNP O
100 POS_CD O
) POS_) O

We POS_PRP O
report POS_VBP O
the POS_DT O
primary POS_JJ O
clinical POS_JJ O
endpoints POS_NNS O
( POS_( O
cardiac POS_JJ D
ischaemic POS_JJ D
death POS_NN D
, POS_, O
myocardial POS_JJ D
infarction POS_NN D
, POS_, O
and POS_CC O
severe POS_JJ O
recurrent POS_NN O
ischaemia POS_NN D
) POS_) O
, POS_, O
assessed POS_VBN O
at POS_IN O
day POS_NN O
31 POS_CD O
, POS_, O
in POS_IN O
202 POS_CD O
patients POS_NNS O
on POS_IN O
an POS_DT O
intention-to-treat POS_JJ O
basis POS_NN O

The POS_DT O
rate POS_NN O
of POS_IN O
severe POS_JJ O
recurrent POS_NN O
ischaemia POS_NN O
, POS_, O
myocardial POS_JJ O
infarction POS_NN O
, POS_, O
and POS_CC O
ischaemic POS_JJ O
death POS_NN O
was POS_VBD O
5.4 POS_CD O
% POS_NN O
, POS_, O
2.2 POS_CD O
% POS_NN O
, POS_, O
and POS_CC O
2.2 POS_CD O
% POS_NN O
in POS_IN O
the POS_DT O
placebo POS_NN O
group POS_NN O
and POS_CC O
1.1 POS_CD O
% POS_NN O
, POS_, O
0 POS_CD O
% POS_NN O
, POS_, O
and POS_CC O
0 POS_CD O
% POS_NN O
, POS_, O
in POS_IN O
the POS_DT O
roxithromycin POS_NN O
group POS_NN O
, POS_, O
respectively POS_RB O

The POS_DT O
primary POS_JJ O
outcome POS_NN O
measures POS_NNS O
were POS_VBD O
5-year POS_JJ O
survival POS_NN MESH_TYPE_qualifier MESH_mortality O
and POS_CC O
the POS_DT O
rate POS_NN O
of POS_IN O
complications POS_NNS MESH_TYPE_qualifier MESH_complications O

The POS_DT O
analysis POS_NN MESH_TYPE_qualifier MESH_analysis O
of POS_IN O
survival POS_NN MESH_TYPE_qualifier MESH_mortality O
and POS_CC O
recurrence POS_NN O
was POS_VBD O
by POS_IN O
intention POS_NN O
to POS_TO O
treat POS_VB O
and POS_CC O
analysis POS_NN MESH_TYPE_qualifier MESH_analysis O
of POS_IN O
complications POS_NNS MESH_TYPE_qualifier MESH_complications O
was POS_VBD O
by POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
delivered POS_VBN O

FINDINGS POS_NNS MESH_TYPE_qualifier MESH_diagnosis O
: POS_: O
170 POS_CD O
patients POS_NNS O
in POS_IN O
the POS_DT O
surgery POS_NN MESH_TYPE_qualifier MESH_surgery O
group POS_NN O
and POS_CC O
167 POS_CD O
in POS_IN O
the POS_DT O
radiotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_radiotherapy O
group POS_NN O
were POS_VBD O
included POS_VBN O
in POS_IN O
the POS_DT O
intention-to-treat POS_JJ O
analysis POS_NN MESH_TYPE_qualifier MESH_analysis O
; POS_: O
scheduled POS_VBN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
was POS_VBD O
delivered POS_VBN O
to POS_TO O
169 POS_CD O
and POS_CC O
158 POS_CD O
women POS_NNS O
, POS_, O
respectively POS_RB O
, POS_, O
62 POS_CD O
of POS_IN O
114 POS_CD O
women POS_NNS O
with POS_IN O
cervical POS_JJ O
diameters POS_NNS O
of POS_IN O
4 POS_CD O
cm POS_NN O
or POS_CC O
smaller POS_JJR O
and POS_CC O
46 POS_CD O
of POS_IN O
55 POS_CD O
with POS_IN O
diameters POS_NNS O
larger POS_JJR O
than POS_IN O
4 POS_CD O
cm POS_NNS O
received POS_VBD O
adjuvant POS_JJ O
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy O

Nursing POS_NN MESH_TYPE_qualifier MESH_nursing O
across POS_IN O
state POS_NN O
lines POS_NNS O
poses POS_NNS O
complications POS_NNS MESH_TYPE_qualifier MESH_complications O
: POS_: O
state-bound POS_JJ O
regulatory POS_JJ O
and POS_CC O
licensure POS_NN O
issues POS_NNS O

RESULTS POS_NN O
: POS_: O
PIBF POS_NNP O
was POS_VBD O
detected POS_VBN O
in POS_IN O
29.5 POS_CD O
% POS_NN O
of POS_IN O
non-pregnant POS_JJ O
women POS_NNS O
and POS_CC O
52.5 POS_CD O
% POS_NN O
of POS_IN O
pregnant POS_JJ O
women POS_NNS O

More POS_RBR O
advanced-stage POS_JJ O
disease POS_NN O
at POS_IN O
diagnosis POS_NN MESH_TYPE_qualifier MESH_diagnosis O
was POS_VBD O
the POS_DT O
primary POS_JJ O
determinant POS_NN O
, POS_, O
accounting POS_VBG O
for POS_IN O
60 POS_CD O
% POS_NN O
of POS_IN O
the POS_DT O
excess POS_JJ O
mortality POS_NN MESH_TYPE_qualifier MESH_mortality O

This POS_DT O
study POS_NN O
examined POS_VBD O
the POS_DT O
aggressiveness POS_NN O
of POS_IN O
colon POS_NN WORDNET_body_part.n.01 D
tumors POS_NNS D
in POS_IN O
blacks POS_NNS O
and POS_CC O
whites POS_NNS O
to POS_TO O
explore POS_VB O
its POS_PRP$ O
role POS_NN O
in POS_IN O
the POS_DT O
racial POS_JJ O
survival POS_NN MESH_TYPE_qualifier MESH_mortality O
differences POS_NNS O

Tumor POS_NNP O
characteristics POS_NNS O
of POS_IN O
703 POS_CD O
cases POS_NNS O
of POS_IN O
newly POS_RB O
diagnosed POS_VBN O
invasive POS_JJ O
colon POS_NN WORDNET_body_part.n.01 O
adenocarcinoma POS_NN WORDNET_disease.n.01 D
were POS_VBD O
centrally POS_RB O
evaluated POS_VBN O
by POS_IN O
a POS_DT O
gastrointestinal POS_JJ O
pathologist POS_NN O
, POS_, O
blinded POS_VBN O
in POS_IN O
regard POS_NN O
to POS_TO O
the POS_DT O
age POS_NN O
, POS_, O
race POS_NN O
, POS_, O
and POS_CC O
sex POS_NN O
of POS_IN O
the POS_DT O
patients POS_NNS O

Comparison POS_NNP O
by POS_IN O
anatomical POS_JJ O
subsite POS_NN O
showed POS_VBD O
that POS_IN O
blacks POS_NNS O
had POS_VBD O
statistically POS_RB O
significantly POS_RB O
better POS_RBR O
differentiated POS_JJ O
tumors POS_NNS D
for POS_IN O
cancers POS_NNS D
of POS_IN O
the POS_DT O
proximal POS_NN O
and POS_CC O
transverse POS_NN WORDNET_body_part.n.01 O
colon POS_NN WORDNET_body_part.n.01 O
but POS_CC O
not POS_RB O
for POS_IN O
the POS_DT O
distal POS_NN O

The POS_DT O
advantages POS_NNS O
and POS_CC O
pitfalls POS_NNS O
of POS_IN O
this POS_DT O
new POS_JJ O
method POS_NN O
are POS_VBP O
discussed POS_VBN O
in POS_IN O
the POS_DT O
light POS_NN O
of POS_IN O
the POS_DT O
results POS_NNS O
obtained POS_VBD O
with POS_IN O
an POS_DT O
infantile POS_JJ O
GSDII POS_NNP O
patient POS_NN O

The POS_DT O
presence POS_NN O
of POS_IN O
clinical POS_JJ O
autonomic POS_JJ D
dysfunction POS_NN MESH_TYPE_qualifier MESH_physiopathology D
in POS_IN O
patients POS_NNS O
with POS_IN O
neurologic POS_JJ D
diseases POS_NNS D
, POS_, O
such POS_JJ O
as POS_IN O
multiple POS_JJ WORDNET_disease.n.01 D
sclerosis POS_NN WORDNET_disease.n.01 D
, POS_, O
Parkinson POS_NNP D
's POS_POS D
disease POS_NN D
, POS_, O
and POS_CC O
cerebrovascular POS_JJ O
accident POS_NN O
, POS_, O
has POS_VBZ O
become POS_VBN O
increasingly POS_RB O
recognized POS_VBN O
in POS_IN O
the POS_DT O
past POS_JJ O
decade POS_NN O

No POS_DT O
significant POS_JJ O
difference POS_NN O
in POS_IN O
frequency POS_NN MESH_TYPE_qualifier MESH_epidemiology O
of POS_IN O
absent POS_JJ O
response POS_NN O
and POS_CC O
asymmetric POS_JJ O
response POS_NN O
was POS_VBD O
also POS_RB O
noted POS_VBN O

Significant POS_JJ O
negative POS_JJ O
correlation POS_NN O
between POS_IN O
heart POS_NN WORDNET_body_part.n.01 O
rate POS_NN O
and POS_CC O
age POS_NN O
was POS_VBD O
noted POS_VBN O
in POS_IN O
the POS_DT O
control POS_NN MESH_TYPE_qualifier MESH_prevention & control O
group POS_NN O
but POS_CC O
was POS_VBD O
not POS_RB O
present POS_JJ O
in POS_IN O
the POS_DT O
study POS_NN O
group POS_NN O

This POS_DT O
study POS_NN O
is POS_VBZ O
designed POS_VBN O
to POS_TO O
investigate POS_VB O
the POS_DT O
immediate POS_JJ O
effectiveness POS_NN O
of POS_IN O
electrotherapy POS_NN WORDNET_treatment.n.01 T
on POS_IN O
myofascial POS_JJ D
trigger POS_NN D
points POS_NNS D
of POS_IN D
upper POS_JJ D
trapezius POS_NN WORDNET_body_part.n.01 D
muscle POS_NN WORDNET_body_part.n.01 D

Sixty POS_CD O
patients POS_NNS O
( POS_( O
25 POS_CD O
males POS_NNS O
and POS_CC O
35 POS_CD O
females POS_NNS O
) POS_) O
who POS_WP O
had POS_VBD O
myofascial POS_JJ D
trigger POS_NN D
points POS_NNS D
in POS_IN O
one POS_CD O
side POS_NN WORDNET_body_part.n.01 O
of POS_IN O
the POS_DT O
upper POS_JJ O
trapezius POS_NN WORDNET_body_part.n.01 O
muscles POS_NNS O
were POS_VBD O
studied POS_VBN O

The POS_DT O
effectiveness POS_NN O
of POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
was POS_VBD O
assessed POS_VBN O
by POS_IN O
conducting POS_VBG O
three POS_CD O
measurements POS_NNS O
on POS_IN O
each POS_DT O
muscle POS_NN WORDNET_body_part.n.01 O
before POS_IN O
and POS_CC O
immediately POS_RB O
after POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
: POS_: O
subjective POS_JJ O
pain POS_NN O
intensity POS_NN O
( POS_( O
( POS_( O
PI POS_NNP O
) POS_) O
with POS_IN O
a POS_DT O
visual POS_JJ O
analog POS_NN O
scale POS_NN O
) POS_) O
, POS_, O
pressure POS_NN O
pain POS_NN O
threshold POS_NN O
( POS_( O
( POS_( O
PT POS_NNP O
) POS_) O
with POS_IN O
algometry POS_NN O
) POS_) O
, POS_, O
and POS_CC O
range POS_NN O
of POS_IN O
motion POS_NN O
( POS_( O
( POS_( O
ROM POS_NNP O
) POS_) O
with POS_IN O
a POS_DT O
goniometer POS_NN O
) POS_) O
of POS_IN O
upper POS_JJ O
trapezius POS_NN WORDNET_body_part.n.01 O
muscle POS_NN WORDNET_body_part.n.01 O
( POS_( O
lateral POS_JJ O
bending POS_NN O
of POS_IN O
cervical POS_JJ O
spine POS_NN WORDNET_body_part.n.01 O
to POS_TO O
the POS_DT O
opposite POS_JJ O
side POS_NN WORDNET_body_part.n.01 O
) POS_) O

When POS_WRB O
the POS_DT O
effectiveness POS_NN O
of POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
was POS_VBD O
compared POS_VBN O
with POS_IN O
that POS_DT O
of POS_IN O
the POS_DT O
placebo POS_NN O
group POS_NN O
( POS_( O
group POS_NN O
A POS_NNP O
) POS_) O
, POS_, O
there POS_EX O
was POS_VBD O
significant POS_JJ O
improvement POS_NN O
in POS_IN O
PI POS_NNP O
and POS_CC O
PT POS_NNP O
in POS_IN O
group POS_NN O
B POS_NNP O
( POS_( O
P POS_NNP O
& POS_CC O
# POS_# O
60 POS_CD O
; POS_: O
0.01 POS_CD O
) POS_) O
but POS_CC O
not POS_RB O
in POS_IN O
group POS_NN O
C POS_NNP O
( POS_( O
P POS_NNP O
> POS_NNP O
0.05 POS_CD O
) POS_) O

When POS_WRB O
each POS_DT O
group POS_NN O
was POS_VBD O
divided POS_VBN O
into POS_IN O
two POS_CD O
additional POS_JJ O
subgroups POS_NNS O
based POS_VBN O
on POS_IN O
the POS_DT O
initial POS_JJ O
PI POS_NNP O
, POS_, O
it POS_PRP O
was POS_VBD O
found POS_VBN O
that POS_IN O
ENS POS_NNP O
could POS_MD O
reduce POS_VB O
PI POS_NNP O
and POS_CC O
increase POS_VB O
PT POS_NNP O
significantly POS_RB O
( POS_( O
P POS_NNP O
& POS_CC O
# POS_# O
60 POS_CD O
; POS_: O
0.05 POS_CD O
) POS_) O
, POS_, O
but POS_CC O
did POS_VBD O
not POS_RB O
significantly POS_RB O
( POS_( O
P POS_NNP O
> POS_NNP O
0.05 POS_CD O
) POS_) O
improve POS_VB O
ROM POS_NNP O
, POS_, O
as POS_IN O
compared POS_VBN O
with POS_IN O
the POS_DT O
placebo POS_NN O
group POS_NN O
for POS_IN O
both POS_DT O
subgroups POS_NNS O

The POS_DT O
mean POS_JJ O
training POS_NN MESH_TYPE_qualifier MESH_education O
time POS_NN O
per POS_IN O
week POS_NN O
was POS_VBD O
3.2 POS_CD O
+/- POS_JJ O
0.8 POS_CD O
h. POS_NN O
In POS_IN O
the POS_DT O
entire POS_JJ O
group POS_NN O
of POS_IN O
female POS_JJ O
dancers POS_NNS O
, POS_, O
no POS_DT O
significant POS_JJ O
effects POS_NNS O
of POS_IN O
dancing POS_VBG O
on POS_IN O
radial POS_NN O
or POS_CC O
lumbar POS_NN O
bone POS_NN WORDNET_body_part.n.01 O
density POS_NN O
could POS_MD O
be POS_VB O
observed POS_VBN O

OBJECTIVES POS_NN O
: POS_: O
To POS_TO O
estimate POS_VB O
the POS_DT O
prevalence POS_NN MESH_TYPE_qualifier MESH_epidemiology O
of POS_IN O
Chlamydia POS_NNP WORDNET_disease.n.01 D
trachomatis POS_NN D
in POS_IN O
asymptomatic POS_JJ O
women POS_NNS O
attending POS_VBG O
general POS_JJ O
practice POS_NN O
: POS_: O
to POS_TO O
assess POS_VB O
the POS_DT O
potential POS_NN O
of POS_IN O
the POS_DT O
ligase POS_NN O
chain POS_NN O
reaction POS_NN O
as POS_IN O
a POS_DT O
screening POS_NN MESH_TYPE_qualifier MESH_diagnosis O
tool POS_NN O
; POS_: O
and POS_CC O
to POS_TO O
evaluate POS_VB O
selective POS_JJ O
screening POS_NN MESH_TYPE_qualifier MESH_diagnosis O
criteria POS_NNS MESH_TYPE_qualifier MESH_standards O

DESIGN POS_NN O
: POS_: O
Cross POS_NNP O
sectional POS_JJ O
survey POS_NN O

MAIN POS_NNP O
OUTCOME POS_NNP O
MEASURES POS_NNP O
: POS_: O
Prevalence POS_NN MESH_TYPE_qualifier MESH_epidemiology O
of POS_IN O
C POS_NNP D
trachomatis POS_NN D
infection POS_NN D
in POS_IN O
women POS_NNS O
aged POS_VBN O
18-35 POS_JJ O
on POS_IN O
the POS_DT O
basis POS_NN O
of POS_IN O
each POS_DT O
test POS_NN O
; POS_: O
sensitivity POS_NN O
and POS_CC O
specificity POS_NN O
of POS_IN O
both POS_DT O
tests POS_NNS O
in POS_IN O
this POS_DT O
population POS_NN O

Recently POS_RB O
, POS_, O
many POS_JJ O
advances POS_NNS O
have POS_VBP O
been POS_VBN O
made POS_VBN O
in POS_IN O
the POS_DT O
study POS_NN O
of POS_IN O
sexual POS_JJ O
differentiation POS_NN O
, POS_, O
including POS_VBG O
the POS_DT O
discoveries POS_NNS O
of POS_IN O
the POS_DT O
gene POS_NN O
for POS_IN O
antim1/4llerian POS_JJ O
hormone POS_NN O
as POS_RB O
well POS_RB O
as POS_IN O
the POS_DT O
gene POS_NN O
for POS_IN O
its POS_PRP$ O
receptor POS_NN WORDNET_body_part.n.01 O

OBJECTIVES POS_NN O
: POS_: O
Obesity POS_NN D
is POS_VBZ O
an POS_DT O
important POS_JJ O
clinical POS_JJ O
problem POS_NN O
, POS_, O
and POS_CC O
the POS_DT O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
dexfenfluramine POS_NN T
hydrochloride POS_NN WORDNET_chemical.n.01 T
for POS_IN O
weight POS_NN O
reduction POS_NN O
has POS_VBZ O
been POS_VBN O
widely POS_RB O
publicized POS_VBN O
since POS_IN O
its POS_PRP$ O
approval POS_NN O
by POS_IN O
the POS_DT O
Food POS_NNP O
and POS_CC O
Drug POS_NNP O
Administration POS_NNP WORDNET_treatment.n.01 O

However POS_RB O
, POS_, O
animal POS_NN O
and POS_CC O
human POS_JJ O
studies POS_NNS O
have POS_VBP O
demonstrated POS_VBN O
toxic POS_JJ O
effects POS_NNS O
of POS_IN O
fenfluramines POS_NNS T
that POS_WDT O
clinicians POS_NNS O
should POS_MD O
be POS_VB O
aware POS_JJ O
of POS_IN O
when POS_WRB O
considering POS_VBG O
prescribing POS_VBG O
the POS_DT O
drugs POS_NNS O

CONCLUSIONS POS_NN O
: POS_: O
Fenfluramine POS_NN T
and POS_CC O
dexfenfluramine POS_NN T
have POS_VBP O
been POS_VBN O
demonstrated POS_VBN O
to POS_TO O
damage POS_VB O
brain POS_NN WORDNET_body_part.n.01 O
serotonin POS_JJ WORDNET_chemical.n.01 O
neurons POS_NNS O
in POS_IN O
animal POS_NN O
studies POS_NNS O

Use POS_NNP MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
fenfluramines POS_NNS T
is POS_VBZ O
associated POS_VBN O
with POS_IN O
an POS_DT O
increased POS_VBN O
risk POS_NN O
of POS_IN O
PPH POS_NNP D

Future POS_JJ O
studies POS_NNS O
should POS_MD O
address POS_VB O
the POS_DT O
long-term POS_JJ O
consequences POS_NNS O
of POS_IN O
prolonged POS_JJ O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
fenfluramines POS_NNS T

Other POS_JJ O
claims POS_NNS O
suggest POS_VBP O
that POS_IN O
it POS_PRP O
causes POS_VBZ MESH_TYPE_qualifier MESH_etiology O
fewer POS_JJR O
unwanted POS_JJ O
effects POS_NNS O
than POS_IN O
older POS_JJR O
centrally-acting POS_NN O
antihypertensive POS_JJ T
drugs POS_NNS T
such POS_JJ O
as POS_IN O
clonidine POS_NN T
and POS_CC O
methyldopa POS_NN T

This POS_DT O
article POS_NN O
discusses POS_VBZ O
dental POS_JJ O
anxiety POS_NN O
and POS_CC O
phobia POS_NN O

The POS_DT O
author POS_NN O
presents POS_VBZ O
background POS_IN O
information POS_NN O
, POS_, O
including POS_VBG O
incidence POS_NN MESH_TYPE_qualifier MESH_epidemiology O
and POS_CC O
etiology POS_NN MESH_TYPE_qualifier MESH_etiology O

The POS_DT O
article POS_NN O
stresses POS_VBZ O
behavioral POS_JJ O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
modalities POS_NNS O
that POS_WDT O
eliminate POS_VBP O
the POS_DT O
debilitating POS_NN O
phobia POS_NN O

We POS_PRP O
now POS_RB O
show POS_VBP O
that POS_IN O
highly POS_RB O
purified POS_JJ O
populations POS_NNS O
of POS_IN O
very POS_RB O
primitive POS_JJ O
neoplastic POS_JJ O
progenitor POS_NN O
cells POS_NNS O
obtained POS_VBN O
directly POS_RB O
from POS_IN O
CML POS_NNP O
patients POS_NNS O
survive POS_JJ O
and POS_CC O
proliferate POS_NN O
in POS_IN O
vitro POS_NN O
for POS_IN O
several POS_JJ O
weeks POS_NNS O
in POS_IN O
the POS_DT O
absence POS_NN O
of POS_IN O
any POS_DT O
added POS_JJ O
growth POS_NN MESH_TYPE_qualifier MESH_growth & development O
factors POS_NNS O
( POS_( O
except POS_IN O
insulin POS_NN O
) POS_) O

The POS_DT O
involvement POS_NN O
of POS_IN O
structures POS_NNS O
in POS_IN O
the POS_DT O
medial POS_JJ O
temporal POS_JJ WORDNET_body_part.n.01 O
lobe POS_NN WORDNET_body_part.n.01 O
during POS_IN O
the POS_DT O
encoding POS_NN O
of POS_IN O
visual POS_JJ O
associations POS_NNS O
was POS_VBD O
studied POS_VBN O
with POS_IN O
functional POS_JJ O
magnetic POS_JJ O
resonance POS_NN O
imaging POS_NN O

In POS_IN O
11 POS_CD O
out POS_IN O
of POS_IN O
12 POS_CD O
normal POS_JJ O
healthy POS_JJ O
volunteers POS_NNS O
this POS_DT O
task POS_NN O
resulted POS_VBD O
in POS_IN O
activation POS_NN O
in POS_IN O
posterior POS_JJ O
portions POS_NNS O
of POS_IN O
the POS_DT O
parahippocampal POS_JJ O
region POS_NN O
, POS_, O
close POS_RB O
to POS_TO O
the POS_DT O
collateral POS_NN O
sulcus POS_NN WORDNET_body_part.n.01 O

The POS_DT O
current POS_JJ O
study POS_NN O
reviews POS_NNS O
evidence POS_NN O
for POS_IN O
Ca2+ POS_NNP O
dysregulation POS_NN O
during POS_IN O
aging POS_VBG O
which POS_WDT O
could POS_MD O
interact POS_VB O
with POS_IN O
Ca POS_NNP O
( POS_( O
2+ POS_CD O
) POS_) O
-dependent POS_NN O
synaptic POS_JJ O
plasticity POS_NN O

The POS_DT O
authors POS_NNS O
suggest POS_VBP O
that POS_IN O
changes POS_NNS O
in POS_IN O
Ca2+ POS_NNP O
regulation POS_NN O
could POS_MD O
adjust POS_VB O
the POS_DT O
thresholds POS_NNS O
for POS_IN O
synaptic POS_JJ O
modification POS_NN O
, POS_, O
favoring POS_VBG O
processes POS_NNS O
for POS_IN O
depression POS_NN O
of POS_IN O
synaptic POS_JJ O
strength POS_NN O
during POS_IN O
aging POS_VBG O

In POS_IN O
order POS_NN O
to POS_TO O
understand POS_VB O
and POS_CC O
model POS_VB O
cochlear POS_JJ O
processes POS_NNS O
involved POS_VBN O
in POS_IN O
TEOAE POS_NNP O
generation POS_NN O
, POS_, O
it POS_PRP O
needs POS_VBZ O
to POS_TO O
be POS_VB O
known POS_VBN O
whether POS_IN O
the POS_DT O
presence POS_NN O
of POS_IN O
normal POS_JJ O
hearing POS_VBG O
leads POS_VBZ O
automatically POS_RB O
to POS_TO O
generation POS_NN O
of POS_IN O
TEOAEs POS_NNP O

The POS_DT O
present POS_JJ O
study POS_NN O
set POS_VBN O
out POS_RP O
to POS_TO O
establish POS_VB O
in POS_IN O
a POS_DT O
large POS_JJ O
sample POS_NN O
if POS_IN O
any POS_DT O
ears POS_NNS O
could POS_MD O
be POS_VB O
found POS_VBN O
that POS_IN O
lacked POS_VBD O
TEOAEs POS_NNP O
despite POS_IN O
normal POS_JJ O
hearing POS_VBG O
threshold POS_NN O
levels POS_NNS O
( POS_( O
HTL POS_NNP O
) POS_) O

The POS_DT O
ability POS_NN O
of POS_IN O
PRL POS_NNP O
to POS_TO O
activate POS_VB O
the POS_DT O
promoter POS_NN O
of POS_IN O
the POS_DT O
beta-casein POS_JJ O
gene POS_NN O
or POS_CC O
the POS_DT O
lactogenic POS_JJ O
hormone POS_NN O
responsive POS_JJ O
element POS_NN O
fused POS_VBN O
to POS_TO O
the POS_DT O
luciferase POS_NN O
reporter POS_NN O
was POS_VBD O
assessed POS_VBN O
in POS_IN O
Chinese POS_JJ O
hamster POS_NN O
ovary POS_JJ WORDNET_body_part.n.01 O
cells POS_NNS O
or POS_CC O
293 POS_CD O
fibroblasts POS_NNS O
transiently POS_RB O
transfected POS_VBN O
with POS_IN O
PRLR POS_NNP O
cDNAs POS_NN O

We POS_PRP O
cotransfected POS_VBD O
Chinese POS_JJ O
hamster POS_NN O
ovary POS_JJ WORDNET_body_part.n.01 O
cells POS_NNS O
with POS_IN O
two POS_CD O
cDNA POS_NN O
constructs POS_NNS O
: POS_: O
a POS_DT O
cytoplasmic POS_NN O
( POS_( O
soluble POS_JJ O
) POS_) O
form POS_NN O
of POS_IN O
the POS_DT O
receptor POS_NN WORDNET_body_part.n.01 O
with POS_IN O
a POS_DT O
deleted POS_JJ O
signal POS_NN O
peptide POS_NN WORDNET_chemical.n.01 O
( POS_( O
delta-19 POS_JJ O
) POS_) O
, POS_, O
which POS_WDT O
is POS_VBZ O
unable POS_JJ O
to POS_TO O
bind POS_VB O
PRL POS_NNP O
, POS_, O
and POS_CC O
a POS_DT O
functionally POS_RB O
inactive POS_JJ O
receptor POS_NN WORDNET_body_part.n.01 O
mutant POS_NN O
( POS_( O
lacking POS_VBG O
box POS_RB O
1 POS_CD O
) POS_) O
, POS_, O
which POS_WDT O
is POS_VBZ O
anchored POS_VBN O
in POS_IN O
the POS_DT O
plasma POS_NN O
membrane POS_NN WORDNET_body_part.n.01 O
and POS_CC O
able POS_JJ O
to POS_TO O
bind POS_VB O
PRL POS_NNP O

This POS_DT O
approach POS_NN O
has POS_VBZ O
allowed POS_VBN O
us POS_PRP O
to POS_TO O
show POS_VB O
that POS_IN O
delta-19 POS_JJ O
, POS_, O
lacking POS_JJ O
expression POS_NN O
at POS_IN O
the POS_DT O
plasma POS_NN O
membrane POS_NN WORDNET_body_part.n.01 O
, POS_, O
can POS_MD O
transduce POS_VB O
the POS_DT O
hormonal POS_JJ O
message POS_NN O
, POS_, O
at POS_IN O
least POS_JJS O
to POS_TO O
a POS_DT O
limited POS_JJ O
extent POS_NN O
( POS_( O
up POS_IN O
to POS_TO O
30 POS_CD O
% POS_NN O
of POS_IN O
wild POS_JJ O
type POS_JJ O
efficiency POS_NN O
) POS_) O
, POS_, O
providing POS_VBG O
that POS_IN O
association/activation POS_NN O
occurs POS_VBZ O
with POS_IN O
a POS_DT O
PRL-PRLR POS_NNP O
complex POS_NN WORDNET_chemical.n.01 O
initiated POS_VBN O
at POS_IN O
the POS_DT O
cell POS_NN O
surface POS_NN O
level POS_NN O
; POS_: O
box POS_CC O
1 POS_CD O
of POS_IN O
the POS_DT O
cytoplasmic POS_JJ O
form POS_NN O
is POS_VBZ O
necessary POS_JJ O
to POS_TO O
rescue POS_VB O
this POS_DT O
partial POS_JJ O
transcriptional POS_JJ O
activity POS_NN O
of POS_IN O
the POS_DT O
inactive POS_JJ O
mutant POS_NN O

Our POS_PRP$ O
results POS_NNS O
provide POS_VB O
evidence POS_NN O
that POS_IN O
heterodimerization POS_NN O
of POS_IN O
receptors POS_NNS O
can POS_MD O
be POS_VB O
implicated POS_VBN O
either POS_DT O
in POS_IN O
the POS_DT O
positive POS_JJ O
or POS_CC O
in POS_IN O
negative POS_JJ O
activation POS_NN O
of POS_IN O
gene POS_NN O
transcription POS_NN O

BACKGROUND POS_NN O
: POS_: O
Inadequate POS_NNP O
dietary POS_JJ O
intake POS_NN O
of POS_IN O
calcium POS_NN O
and POS_CC O
vitamin POS_NN O
D POS_NNP O
may POS_MD O
contribute POS_VB O
to POS_TO O
the POS_DT O
high POS_JJ O
prevalence POS_NN MESH_TYPE_qualifier MESH_epidemiology O
of POS_IN O
osteoporosis POS_NN D
among POS_IN O
older POS_JJR O
persons POS_NNS O

All POS_DT O
hand POS_NN WORDNET_body_part.n.01 O
instruments POS_NNS MESH_TYPE_qualifier MESH_instrumentation O
, POS_, O
handpieces POS_NNS O
and POS_CC O
triplex POS_JJ O
syringes POS_NNS O
were POS_VBD O
autoclaved POS_VBN O
between POS_IN O
patients POS_NNS O

Safety POS_NN O
and POS_CC O
efficacy POS_NN O
are POS_VBP O
crucial POS_JJ O
but POS_CC O
separate POS_JJ O
issues POS_NNS O
for POS_IN O
vitamin POS_NN O
and POS_CC O
mineral POS_JJ O
supplements POS_NNS O

Misinterpretation POS_NN O
of POS_IN O
`` POS_`` O
safe POS_JJ O
and POS_CC O
adequate POS_JJ O
'' POS_'' O
to POS_TO O
mean POS_VB O
`` POS_`` O
safety POS_NN O
limit POS_NN O
'' POS_'' O
would POS_MD O
impose POS_VB O
restrictions POS_NNS O
on POS_IN O
vitamin POS_NN O
and POS_CC O
mineral POS_JJ O
intakes POS_NNS O
that POS_WDT O
are POS_VBP O
not POS_RB O
needed POS_VBN O
to POS_TO O
ensure POS_VB O
safety POS_NN O

Substantial POS_JJ O
evidence POS_NN O
indicates POS_VBZ O
that POS_IN O
intakes POS_NNS O
greater POS_JJR O
than POS_IN O
the POS_DT O
recommended POS_JJ O
dietary POS_JJ O
allowances POS_NNS O
( POS_( O
RDAs POS_NNP O
) POS_) O
of POS_IN O
certain POS_JJ O
vitamins POS_NNS O
and POS_CC O
minerals POS_NNS O
such POS_JJ O
as POS_IN O
calcium POS_NN O
, POS_, O
folic POS_JJ O
acid POS_NN WORDNET_chemical.n.01 O
, POS_, O
vitamin POS_NN O
E POS_NNP O
, POS_, O
selenium POS_NN O
, POS_, O
and POS_CC O
chromium POS_NN O
reduce POS_VB O
the POS_DT O
risk POS_NN O
of POS_IN O
certain POS_JJ O
diseases POS_NNS O
for POS_IN O
some POS_DT O
people POS_NNS O

The POS_DT O
margin POS_NN MESH_TYPE_qualifier MESH_toxicity O
of POS_IN MESH_TYPE_qualifier MESH_toxicity O
safety POS_NN MESH_TYPE_qualifier MESH_toxicity O
between POS_IN O
the POS_DT O
usual POS_JJ O
dietary POS_JJ O
intake POS_NN O
and POS_CC O
the POS_DT O
intake POS_NN O
that POS_WDT O
would POS_MD O
produce POS_VB O
adverse POS_JJ MESH_TYPE_qualifier MESH_adverse effects O
effects POS_NNS MESH_TYPE_qualifier MESH_adverse effects O
varies POS_NNS O
greatly POS_RB O
among POS_IN O
the POS_DT O
different POS_JJ O
nutrients POS_NNS O

Res POS_NN O

Those POS_DT O
data POS_NNS O
show POS_VBP O
that POS_IN O
after POS_IN O
this POS_DT O
time POS_NN O
has POS_VBZ O
elapsed POS_VBN O
, POS_, O
contrary POS_JJ O
to POS_TO O
the POS_DT O
expectation POS_NN O
of POS_IN O
the POS_DT O
LPL POS_NNP O
model POS_NN O
, POS_, O
survival POS_NN MESH_TYPE_qualifier MESH_mortality O
can POS_MD O
be POS_VB O
increased POS_VBN O
by POS_IN O
changing POS_VBG O
the POS_DT O
medium POS_NN O
used POS_VBN O
for POS_IN O
delayed POS_JJ O
plating POS_NN O
from POS_IN O
fresh POS_JJ O
growth POS_NN MESH_TYPE_qualifier MESH_growth & development O
medium POS_NN O
to POS_TO O
conditioned POS_VB O
medium POS_NN O

Only POS_RB O
the POS_DT O
DSB POS_NNP O
model POS_NN O
correctly POS_RB O
predicted POS_VBD O
that POS_IN O
PLD POS_NNP O
( POS_( O
= POS_NNP O
DSBs POS_NNP O
) POS_) O
would POS_MD O
still POS_RB O
be POS_VB O
available POS_JJ O
for POS_IN O
repair POS_NN O
after POS_IN O
that POS_DT O
time POS_NN O

Second POS_JJ O
, POS_, O
data POS_NNS O
for POS_IN O
split-dose POS_JJ O
recovery POS_NN O
are POS_VBP O
used POS_VBN O
to POS_TO O
predict POS_VB O
the POS_DT O
first-order POS_NN O
kinetics POS_NNS O
time POS_NN O
constant POS_JJ O
for POS_IN O
DSB POS_NNP O
repair POS_NN O
( POS_( O
tau POS_NN O
( POS_( O
DSBR POS_NNP O
) POS_) O
) POS_) O
using POS_VBG O
the POS_DT O
DSB POS_NNP O
model POS_NN O
( POS_( O
24 POS_CD O
+/- POS_JJ O
1.5 POS_CD O
min POS_NN O
) POS_) O

The POS_DT O
value POS_NN O
based POS_VBN O
on POS_IN O
PFGE POS_NNP O
is POS_VBZ O
used POS_VBN O
to POS_TO O
calculate POS_VB O
the POS_DT O
value POS_NN O
of POS_IN O
t POS_NN O
( POS_( O
rep POS_NN O
) POS_) O
predicted POS_VBN O
by POS_IN O
the POS_DT O
DSB POS_NNP O
model POS_NN O
( POS_( O
2.6 POS_CD O
+/- POS_JJ O
0.1 POS_CD O
h POS_NN O
) POS_) O
, POS_, O
which POS_WDT O
agrees POS_VBZ O
with POS_IN O
the POS_DT O
value POS_NN O
determined POS_VBD O
experimentally POS_RB O
as POS_IN O
the POS_DT O
time POS_NN O
when POS_WRB O
changing POS_VBG O
the POS_DT O
delayed-plating POS_JJ O
medium POS_NN O
from POS_IN O
growth POS_NN MESH_TYPE_qualifier MESH_growth & development O
medium POS_NN O
to POS_TO O
conditioned POS_VB O
medium POS_NN O
no POS_RB O
longer POS_RBR O
gives POS_VBZ O
the POS_DT O
full POS_JJ O
recovery POS_NN O
seen POS_VBN O
with POS_IN O
delayed POS_JJ O
plating POS_NN O
in POS_IN O
conditioned POS_JJ O
medium POS_NN O
( POS_( O
2.5 POS_CD O
h POS_NN O
) POS_) O

INTERVENTION POS_NN O
: POS_: O
After POS_IN O
random POS_JJ O
assignment POS_NN O
to POS_TO O
1 POS_CD O
of POS_IN O
3 POS_CD O
groups POS_NNS O
, POS_, O
the POS_DT O
adolescents POS_NNS O
listened POS_VBD O
to POS_TO O
a POS_DT O
standardized POS_JJ O
audiotape POS_NN O
depiction POS_NN O
of POS_IN O
an POS_DT O
office POS_NN O
visit POS_NN O
during POS_IN O
which POS_WDT O
they POS_PRP O
heard POS_VBD O
a POS_DT O
physician POS_NN O
who POS_WP O
assured POS_VBD O
unconditional POS_JJ O
confidentiality POS_NN O
, POS_, O
a POS_DT O
physician POS_NN O
who POS_WP O
assured POS_VBD O
conditional POS_JJ O
confidentiality POS_NN O
, POS_, O
or POS_CC O
a POS_DT O
physician POS_NN O
who POS_WP O
did POS_VBD O
not POS_RB O
mention POS_NN O
confidentiality POS_NN O

RESULTS POS_NN O
: POS_: O
Assurances POS_NNS O
of POS_IN O
confidentiality POS_NN O
increased POS_VBD O
the POS_DT O
number POS_NN O
of POS_IN O
adolescents POS_NNS O
willing POS_JJ O
to POS_TO O
disclose POS_VB O
sensitive POS_JJ O
information POS_NN O
about POS_IN O
sexuality POS_NN O
, POS_, O
substance POS_NN O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
, POS_, O
and POS_CC O
mental POS_JJ O
health POS_NN O
from POS_IN O
39 POS_CD O
% POS_NN O
( POS_( O
68/175 POS_CD O
) POS_) O
to POS_TO O
46.5 POS_CD O
% POS_NN O
( POS_( O
178/383 POS_CD O
) POS_) O
( POS_( O
beta=.10 POS_UH O
, POS_, O
P=.02 POS_NNP O
) POS_) O
and POS_CC O
increased POS_VBD O
the POS_DT O
number POS_NN O
willing POS_JJ O
to POS_TO O
seek POS_VB O
future POS_NN O
health POS_NN O
care POS_NN O
from POS_IN O
53 POS_CD O
% POS_NN O
( POS_( O
93/175 POS_CD O
) POS_) O
to POS_TO O
67 POS_CD O
% POS_NN O
( POS_( O
259/386 POS_CD O
) POS_) O
( POS_( O
beta=.17 POS_UH O
, POS_, O
P POS_NNP O
& POS_CC O
# POS_# O
60 POS_CD O
; POS_: O
.001 POS_CD O
) POS_) O

When POS_WRB O
comparing POS_VBG O
the POS_DT O
unconditional POS_JJ O
with POS_IN O
the POS_DT O
conditional POS_JJ O
groups POS_NNS O
, POS_, O
assurances POS_NNS O
of POS_IN O
unconditional POS_JJ O
confidentiality POS_NN O
increased POS_VBD O
the POS_DT O
number POS_NN O
of POS_IN O
adolescents POS_NNS O
willing POS_JJ O
to POS_TO O
return POS_VB O
for POS_IN O
a POS_DT O
future POS_JJ O
visit POS_NN O
by POS_IN O
10 POS_CD O
percentage POS_NN O
points POS_NNS O
, POS_, O
from POS_IN O
62 POS_CD O
% POS_NN O
( POS_( O
122/196 POS_CD O
) POS_) O
to POS_TO O
72 POS_CD O
% POS_NN O
( POS_( O
137/190 POS_CD O
) POS_) O
( POS_( O
beta=.14 POS_UH O
, POS_, O
P=.001 POS_NNP O
) POS_) O

BACKGROUND POS_NN O
: POS_: O
Diabetic POS_JJ O
foot POS_NN WORDNET_body_part.n.01 D
infections POS_NNS D
cause POS_VBP O
substantial POS_JJ O
morbidity POS_NN MESH_TYPE_qualifier MESH_epidemiology O
and POS_CC O
mortality POS_NN MESH_TYPE_qualifier MESH_mortality O

On POS_IN O
admission POS_NN O
, POS_, O
patients POS_NNS O
were POS_VBD O
randomly POS_RB O
assigned POS_VBN O
G-CSF POS_NNP T
( POS_( T
filgrastim POS_NN T
) POS_) T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
( POS_( O
n POS_JJ O
= POS_NNP O
20 POS_CD O
) POS_) O
or POS_CC O
placebo POS_NN O
( POS_( O
n POS_JJ O
= POS_NNP O
20 POS_CD O
) POS_) O
for POS_IN O
7 POS_CD O
days POS_NNS O

Both POS_DT O
groups POS_NNS O
received POS_VBD O
similar POS_JJ O
antibiotic POS_JJ T
and POS_CC T
insulin POS_JJ T
treatment POS_NN MESH_TYPE_qualifier MESH_therapy T

Neutrophils POS_NNS O
from POS_IN O
the POS_DT O
peripheral POS_JJ O
blood POS_NN MESH_TYPE_qualifier MESH_blood O
of POS_IN O
these POS_DT O
participants POS_NNS O
and POS_CC O
from POS_IN O
healthy POS_JJ O
controls POS_NNS O
were POS_VBD O
stimulated POS_VBN O
with POS_IN O
opsonised POS_JJ O
zymosan POS_NN O
, POS_, O
and POS_CC O
superoxide POS_JJ WORDNET_chemical.n.01 O
production POS_NN O
was POS_VBD O
measured POS_VBN O
by POS_IN O
a POS_DT O
spectrophotometric POS_JJ O
assay POS_NN MESH_TYPE_qualifier MESH_analysis O
( POS_( O
reduction POS_NN O
of POS_IN O
ferricytochrome POS_JJ O
C POS_NNP O
) POS_) O

No POS_DT O
G-CSF-treated POS_JJ O
patient POS_NN O
needed POS_VBN O
surgery POS_NN MESH_TYPE_qualifier MESH_surgery T
, POS_, O
whereas POS_VBP O
two POS_CD O
placebo POS_NN O
recipients POS_NNS O
underwent POS_JJ O
to POS_TO O
amputation POS_NN T
and POS_CC O
two POS_CD O
had POS_VBD O
extensive POS_JJ O
debridement POS_NN T
under POS_IN O
anaesthesia POS_NN O

We POS_PRP O
tested POS_VBD O
the POS_DT O
hypothesis POS_NN O
that POS_IN O
double-bolus POS_JJ T
alteplase POS_NN T
is POS_VBZ O
at POS_IN O
least POS_JJS O
as POS_RB O
effective POS_JJ O
as POS_IN O
accelerated POS_JJ O
infusion POS_NN O

METHODS POS_NN MESH_TYPE_qualifier MESH_methods O
: POS_: O
In POS_IN O
398 POS_CD O
hospitals POS_NNS O
, POS_, O
7169 POS_CD O
patients POS_NNS O
with POS_IN O
acute POS_JJ D
myocardial POS_JJ D
infarction POS_NN D
were POS_VBD O
randomly POS_RB O
assigned POS_VBN O
to POS_TO O
weight-adjusted POS_JJ O
, POS_, O
accelerated POS_JJ O
infusion POS_NN O
of POS_IN O
100 POS_CD O
mg POS_NN O
of POS_IN O
alteplase POS_NN T
or POS_CC O
to POS_TO O
a POS_DT O
bolus POS_NN O
of POS_IN O
50 POS_CD O
mg POS_NN O
of POS_IN O
alteplase POS_NN T
over POS_IN O
a POS_DT O
period POS_NN O
of POS_IN O
1 POS_CD O
to POS_TO O
3 POS_CD O
minutes POS_NNS O
followed POS_VBD O
30 POS_CD O
minutes POS_NNS O
later POS_RB O
by POS_IN O
a POS_DT O
second POS_JJ O
bolus POS_NN O
of POS_IN O
50 POS_CD O
mg POS_NN O
( POS_( O
or POS_CC O
40 POS_CD O
mg POS_NNS O
for POS_IN O
patients POS_NNS O
who POS_WP O
weighed POS_VBD O
less POS_JJR O
than POS_IN O
60 POS_CD O
kg POS_NNS O
) POS_) O

The POS_DT O
women POS_NNS O
presented POS_VBN O
with POS_IN O
cardiovascular POS_JJ D
symptoms POS_NNS MESH_TYPE_qualifier MESH_diagnosis D
or POS_CC O
a POS_DT O
heart POS_NN WORDNET_body_part.n.01 D
murmur POS_NN D

As POS_IN O
increasing POS_VBG O
numbers POS_NNS O
of POS_IN O
these POS_DT O
patients POS_NNS O
with POS_IN O
similar POS_JJ O
clinical POS_JJ O
features POS_NNS O
were POS_VBD O
identified POS_VBN O
, POS_, O
there POS_EX O
appeared POS_VBD O
to POS_TO O
be POS_VB O
an POS_DT O
association POS_NN O
between POS_IN O
these POS_DT O
features POS_NNS O
and POS_CC O
fenfluramine-phentermine POS_JJ T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T

Both POS_DT O
right-sided POS_JJ O
and POS_CC O
left-sided POS_JJ O
heart POS_NN WORDNET_body_part.n.01 O
valves POS_NNS O
were POS_VBD O
involved POS_VBN O

To POS_TO O
date POS_NN O
, POS_, O
cardiac POS_JJ T
surgical POS_JJ T
intervention POS_NN T
has POS_VBZ O
been POS_VBN O
required POS_VBN O
in POS_IN O
five POS_CD O
patients POS_NNS O

The POS_DT O
patient POS_NN O
's POS_POS O
ability POS_NN O
to POS_TO O
wear POS_VB O
shoes POS_NNS O
improved POS_VBN O
from POS_IN O
0.87 POS_CD O
to POS_TO O
3.1 POS_CD O

Successful POS_JJ O
arthrodesis POS_NN T
produces POS_VBZ O
a POS_DT O
foot POS_NN WORDNET_body_part.n.01 O
that POS_WDT O
is POS_VBZ O
more POS_JJR O
functional POS_JJ O
and POS_CC O
durable POS_JJ O
than POS_IN O
excisional POS_JJ T
arthroplasty POS_NN T

Although POS_IN O
technically POS_RB O
demanding POS_VBG O
, POS_, O
it POS_PRP O
provides POS_VBZ O
long-term POS_JJ O
stability POS_NN O
to POS_TO O
the POS_DT O
hallux POS_NN O
, POS_, O
restores POS_VBZ O
weightbearing POS_VBG O
, POS_, O
and POS_CC O
allows POS_VBZ O
for POS_IN O
maintenance POS_NN O
of POS_IN O
a POS_DT O
propulsive POS_JJ O
gait POS_NN O

CONCLUSION POS_NN O
: POS_: O
With POS_IN O
a POS_DT O
standardised POS_JJ O
rate POS_NN O
of POS_IN O
68 POS_CD O
per POS_IN O
100000 POS_CD O
and POS_CC O
a POS_DT O
first-week POS_JJ O
mortality POS_NN MESH_TYPE_qualifier MESH_mortality O
rate POS_NN O
of POS_IN O
35 POS_CD O
% POS_NN O
, POS_, O
stroke POS_NN D
must POS_MD O
now POS_RB O
be POS_VB O
considered POS_VBN O
an POS_DT O
important POS_JJ O
cause POS_NN O
of POS_IN O
morbidity POS_NN MESH_TYPE_qualifier MESH_epidemiology O
and POS_CC O
mortality POS_NN MESH_TYPE_qualifier MESH_mortality O
in POS_IN O
the POS_DT O
population POS_NN O

OBJECTIVE POS_NN O
: POS_: O
To POS_TO O
explore POS_VB O
the POS_DT O
long-term POS_JJ O
effect POS_NN O
of POS_IN O
calcium POS_NN T
supplementation POS_NN T
during POS_IN O
pregnancy POS_NN O
on POS_IN O
the POS_DT O
offspring POS_NN O
's POS_POS O
blood POS_NN MESH_TYPE_qualifier MESH_blood O
pressure POS_NN O
during POS_IN O
childhood POS_NN O

The POS_DT O
effect POS_NN O
was POS_VBD O
found POS_VBN O
predominantly POS_RB O
among POS_IN O
children POS_NNS O
whose POS_WP$ O
body POS_NN O
mass POS_NN O
index POS_NN WORDNET_body_part.n.01 O
at POS_IN O
assessment POS_NN O
was POS_VBD O
above POS_IN O
the POS_DT O
median POS_NN O
for POS_IN O
this POS_DT O
population POS_NN O
( POS_( O
mean POS_JJ O
difference POS_NN O
in POS_IN O
systolic POS_JJ O
blood POS_NN MESH_TYPE_qualifier MESH_blood O
pressure POS_NN O
-5.8 POS_NNP O
mm POS_NN O
Hg POS_NNP O
( POS_( O
-9.8 POS_NNP O
mm POS_RB O
Hg POS_NNP O
to POS_TO O
-1.7 POS_VB O
mm POS_JJ O
Hg POS_NNP O
) POS_) O
for POS_IN O
children POS_NNS O
with POS_IN O
an POS_DT O
index POS_NN WORDNET_body_part.n.01 O
> POS_VBD O
17.5 POS_CD O
and POS_CC O
-3.2 POS_NNP O
mm POS_NN O
Hg POS_NNP O
( POS_( O
-6.3 POS_NNP O
mm POS_RB O
Hg POS_NNP O
to POS_TO O
-0.1 POS_VB O
mm POS_JJ O
Hg POS_NNP O
) POS_) O
for POS_IN O
those POS_DT O
with POS_IN O
an POS_DT O
index POS_NN WORDNET_body_part.n.01 O
of POS_IN O
> POS_$ O
15.7 POS_CD O
to POS_TO O
17.5 POS_CD O
) POS_) O

The POS_DT O
risk POS_NN O
of POS_IN O
high POS_JJ O
systolic POS_JJ O
blood POS_NN MESH_TYPE_qualifier MESH_blood O
pressure POS_NN O
was POS_VBD O
also POS_RB O
lower POS_JJR O
in POS_IN O
the POS_DT O
calcium POS_NN O
group POS_NN O
than POS_IN O
in POS_IN O
the POS_DT O
placebo POS_NN O
group POS_NN O
( POS_( O
relative POS_JJ O
risk POS_NN O
0.59 POS_CD O
; POS_: O
0.39 POS_CD O
to POS_TO O
0.90 POS_CD O
) POS_) O
and POS_CC O
particularly POS_RB O
among POS_IN O
children POS_NNS O
in POS_IN O
the POS_DT O
highest POS_JJS O
fourth POS_JJ O
of POS_IN O
body POS_NN O
mass POS_NN O
index POS_NN WORDNET_body_part.n.01 O
( POS_( O
0.43 POS_CD O
; POS_: O
0.26 POS_CD O
to POS_TO O
0.71 POS_CD O
) POS_) O

The POS_DT O
fast POS_JJ O
reaction POS_NN O
of POS_IN O
peroxynitrite POS_NN O
with POS_IN O
CO2 POS_NNP O
and POS_CC O
the POS_DT O
high POS_JJ O
concentration POS_NN O
of POS_IN O
dissolved POS_JJ O
CO2 POS_NNP O
in POS_IN O
vivo POS_NN O
( POS_( O
ca POS_MD O

Even POS_RB O
low POS_JJ O
concentrations POS_NNS O
of POS_IN O
CO2 POS_NNP O
that POS_WDT O
result POS_NN O
from POS_IN O
the POS_DT O
dissolution POS_NN O
of POS_IN O
ambient POS_JJ O
CO2 POS_NNP O
can POS_MD O
have POS_VB O
pronounced POS_VBN O
catalytic POS_JJ O
effects POS_NNS O

The POS_DT O
rabbits POS_NNS O
were POS_VBD O
divided POS_VBN O
into POS_IN O
two POS_CD O
study POS_NN O
groups POS_NNS O
, POS_, O
one POS_CD O
control POS_NN MESH_TYPE_qualifier MESH_prevention & control O
and POS_CC O
the POS_DT O
other POS_JJ O
receiving POS_VBG O
about POS_IN O
16 POS_CD O
mg POS_NNS O
fluoride/rabbit/day POS_RB O
in POS_IN O
their POS_PRP$ O
drinking POS_NN O
water POS_NN WORDNET_chemical.n.01 O

Fluoride POS_NNP WORDNET_chemical.n.01 T
treatment POS_NN MESH_TYPE_qualifier MESH_therapy T
increased POS_VBD O
serum POS_NN O
and POS_CC O
bone POS_NN WORDNET_body_part.n.01 O
fluoride POS_NN WORDNET_chemical.n.01 O
levels POS_NNS O
by POS_IN O
over POS_IN O
an POS_DT O
order POS_NN O
of POS_IN O
magnitude POS_NN O
( POS_( O
P POS_NNP O
& POS_CC O
# POS_# O
60 POS_CD O
; POS_: O
0.001 POS_CD O
) POS_) O
, POS_, O
but POS_CC O
did POS_VBD O
not POS_RB O
affect POS_VB O
body POS_NN O
weight POS_NN O
or POS_CC O
the POS_DT O
following POS_JJ O
serum POS_NN O
biochemical POS_JJ O
variables POS_NNS O
: POS_: O
urea POS_NN WORDNET_chemical.n.01 O
, POS_, O
creatinine POS_NN O
, POS_, O
phosphorus POS_NN O
, POS_, O
total POS_JJ O
protein POS_NN WORDNET_chemical.n.01 O
, POS_, O
albumin POS_NN WORDNET_chemical.n.01 O
, POS_, O
bilirubin POS_NN O
, POS_, O
SGOT POS_NNP O
, POS_, O
or POS_CC O
total POS_JJ O
alkaline POS_JJ O
phosphatase POS_NN WORDNET_chemical.n.01 O

BAP POS_NNP O
was POS_VBD O
increased POS_VBN O
37 POS_CD O
% POS_NN O
( POS_( O
P POS_NNP O
& POS_CC O
# POS_# O
60 POS_CD O
; POS_: O
0.05 POS_CD O
) POS_) O
by POS_IN O
fluoride POS_NN WORDNET_chemical.n.01 O
; POS_: O
serum POS_CC O
TRAP POS_NNP WORDNET_body_part.n.01 O
was POS_VBD O
increased POS_VBN O
42 POS_CD O
% POS_NN O
( POS_( O
P POS_NNP O
& POS_CC O
# POS_# O
60 POS_CD O
; POS_: O
0.05 POS_CD O
) POS_) O
; POS_: O
serum POS_JJ O
IGF-1 POS_NNP O
was POS_VBD O
increased POS_VBN O
40 POS_CD O
% POS_NN O
( POS_( O
P POS_NNP O
& POS_CC O
# POS_# O
60 POS_CD O
; POS_: O
0.05 POS_CD O
) POS_) O

05 POS_CD O
) POS_) O

High-dose POS_JJ O
fluoride POS_NN WORDNET_chemical.n.01 T
treatment POS_NN MESH_TYPE_qualifier MESH_therapy T
did POS_VBD O
not POS_RB O
improve POS_VB O
, POS_, O
but POS_CC O
decreased POS_VBD O
, POS_, O
bone POS_NN WORDNET_body_part.n.01 O
strength POS_NN O
in POS_IN O
rabbits POS_NNS O
, POS_, O
even POS_RB O
in POS_IN O
the POS_DT O
absence POS_NN O
of POS_IN O
impaired POS_JJ O
mineralization POS_NN O

The POS_DT O
posterior POS_JJ O
capsule POS_NN WORDNET_body_part.n.01 O
and POS_CC O
anterior POS_RB O
vitreous POS_JJ O
were POS_VBD O
managed POS_VBN O
in POS_IN O
a POS_DT O
variety POS_NN O
of POS_IN O
ways POS_NNS O
: POS_: O
In POS_IN O
5 POS_CD O
eyes POS_NNS O
, POS_, O
the POS_DT O
posterior POS_JJ O
capsule POS_NN WORDNET_body_part.n.01 O
was POS_VBD O
left POS_VBN WORDNET_body_part.n.01 O
intact POS_JJ O
; POS_: O
in POS_IN O
15 POS_CD O
eyes POS_NNS O
, POS_, O
a POS_DT O
posterior POS_JJ T
continuous POS_JJ T
curvilinear POS_NN T
capsulorhexis POS_NN T
( POS_( T
PCCC POS_NNP T
) POS_) T
was POS_VBD O
performed POS_VBN O
- POS_: O
6 POS_CD O
with POS_IN O
and POS_CC O
9 POS_CD O
without POS_IN O
anterior POS_JJ T
vitrectomy POS_NN T
; POS_: O
in POS_IN O
8 POS_CD O
eyes POS_NNS O
, POS_, O
posterior POS_JJ T
optic POS_JJ T
capture POS_NN T
was POS_VBD O
performed POS_VBN O
- POS_: O
3 POS_CD O
with POS_IN O
and POS_CC O
5 POS_CD O
without POS_IN O
vitrectomy POS_NN T

OBJECTIVE POS_NN O
: POS_: O
To POS_TO O
assess POS_VB O
the POS_DT O
medicalising POS_VBG O
effect POS_NN O
of POS_IN O
prescribing POS_VBG O
antibiotics POS_NNS T
for POS_IN O
sore POS_NN WORDNET_disease.n.01 D
throat POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D

There POS_EX O
was POS_VBD O
no POS_DT O
difference POS_NN O
between POS_IN O
groups POS_NNS O
in POS_IN O
early POS_JJ O
return POS_NN O
( POS_( O
13/238 POS_CD O
( POS_( O
5.5 POS_CD O
% POS_NN O
) POS_) O
v POS_NN O
27/437 POS_CD O
( POS_( O
6 POS_CD O
% POS_NN O
) POS_) O
) POS_) O
, POS_, O
or POS_CC O
complications POS_NNS MESH_TYPE_qualifier MESH_complications O
( POS_( O
2/236 POS_CD O
( POS_( O
0.8 POS_CD O
% POS_NN O
) POS_) O
v POS_NN O
3/434 POS_CD O
( POS_( O
0.7 POS_CD O
% POS_NN O
) POS_) O
) POS_) O

CONCLUSIONS POS_NN O
: POS_: O
Complications POS_NNS MESH_TYPE_qualifier MESH_complications O
and POS_CC O
early POS_JJ O
return POS_NN O
resulting POS_VBG O
from POS_IN O
no POS_DT O
or POS_CC O
delayed POS_VBN O
prescribing POS_NN O
of POS_IN O
antibiotics POS_NNS T
for POS_IN O
sore POS_NN WORDNET_disease.n.01 D
throat POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D
are POS_VBP O
rare POS_JJ O

F POS_NNP O
100 POS_CD O
and POS_CC O
200 POS_CD O
microg POS_NN O
and POS_CC O
S POS_NNP O
20 POS_CD O
and POS_CC O
30 POS_CD O
microg POS_NN O
all POS_DT O
achieved POS_VBN O
VAS POS_NNP O
scores POS_VBZ O
& POS_CC O
# POS_# O
60 POS_CD O
; POS_: O
10 POS_CD O
mm POS_NN O
in POS_IN O
all POS_DT O
women POS_NNS O
with POS_IN O
no POS_DT O
differences POS_NNS O
in POS_IN O
time POS_NN O
to POS_TO O
50 POS_CD O
% POS_NN O
reduction POS_NN O
in POS_IN O
VAS POS_NNP O
( POS_( O
mean POS_JJ O
11-16 POS_JJ O
min POS_NN O
) POS_) O
and POS_CC O
no POS_DT O
differences POS_NNS O
in POS_IN O
duration POS_NN O
of POS_IN O
analgesia POS_NN O
( POS_( O
mean POS_JJ O
117-138 POS_JJ O
min POS_NN O
) POS_) O

Our POS_PRP$ O
data POS_NNS O
suggest POS_VBP O
that POS_IN O
the POS_DT O
relative POS_JJ O
analgesic POS_JJ O
potency POS_NN O
of POS_IN O
epidural POS_JJ O
S POS_NNP O
: POS_: O
F POS_NNP O
is POS_VBZ O
approximately POS_RB O
5 POS_CD O
and POS_CC O
that POS_IN O
there POS_EX O
are POS_VBP O
no POS_DT O
differences POS_NNS O
between POS_IN O
the POS_DT O
opioids POS_NNS O
in POS_IN O
the POS_DT O
onset POS_NN O
, POS_, O
duration POS_NN O
, POS_, O
and POS_CC O
effectiveness POS_NN O
of POS_IN O
analgesia POS_NN O
when POS_WRB O
equianalgesic POS_JJ O
doses POS_NNS O
are POS_VBP O
administered POS_VBN O
postoperatively POS_RB O
after POS_IN O
lidocaine POS_JJ O
anesthesia POS_NN O
for POS_IN O
C/S POS_NNP O

We POS_PRP O
describe POS_VBP O
2 POS_CD O
cases POS_NNS O
in POS_IN O
which POS_WDT O
intraoperative POS_JJ O
transesophageal POS_NN O
echocardiography POS_NN O
detected POS_VBD O
complications POS_NNS MESH_TYPE_qualifier MESH_complications O
related POS_VBN O
to POS_TO O
the POS_DT O
proximal POS_JJ O
coronary POS_JJ O
arteries POS_NNS O
during POS_IN O
homograft POS_NN WORDNET_body_part.n.01 T
aortic POS_JJ WORDNET_body_part.n.01 T
valve POS_NN WORDNET_body_part.n.01 T
and POS_CC T
root POS_NN WORDNET_body_part.n.01 T
replacement POS_NN T

In POS_IN O
both POS_DT O
cases POS_NNS O
, POS_, O
cardiopulmonary POS_JJ T
bypass POS_NN WORDNET_body_part.n.01 T
could POS_MD O
not POS_RB O
be POS_VB O
discontinued POS_VBN O
despite POS_IN O
the POS_DT O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
large POS_JJ O
doses POS_NNS O
of POS_IN O
inotropic POS_NN T
drugs POS_NNS T

It POS_PRP O
resembles POS_VBZ O
Crohn POS_NNP D
's POS_POS D
disease POS_NN D
clinically POS_RB O
and POS_CC O
radiologically POS_RB O
, POS_, O
and POS_CC O
it POS_PRP O
may POS_MD O
be POS_VB O
difficult POS_JJ O
to POS_TO O
differentiate POS_VB O
between POS_IN O
them POS_PRP O
, POS_, O
even POS_RB O
at POS_IN O
laparotomy POS_NN O
or POS_CC O
histology POS_NN MESH_TYPE_qualifier MESH_anatomy & histology O

PURPOSE POS_NN O
: POS_: O
The POS_DT O
American POS_NNP O
Urological POS_NNP O
Association POS_NNP O
convened POS_VBD O
the POS_DT O
Female POS_NNP D
Stress POS_NNP D
Urinary POS_NNP D
Incontinence POS_NNP D
Clinical POS_NNP O
Guidelines POS_NNP MESH_TYPE_qualifier MESH_standards O
Panel POS_NNP O
to POS_TO O
analyze POS_VB O
the POS_DT O
literature POS_NN O
regarding POS_VBG O
surgical POS_JJ T
procedures POS_NNS MESH_TYPE_qualifier MESH_methods T
for POS_IN O
treating POS_VBG O
stress POS_NN D
urinary POS_JJ D
incontinence POS_NN D
in POS_IN O
the POS_DT O
otherwise POS_RB O
healthy POS_JJ O
female POS_NN O
subject POS_NN O
and POS_CC O
to POS_TO O
make POS_VB O
practice POS_NN O
recommendations POS_NNS O
based POS_VBN O
on POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
outcomes POS_VBZ O
data POS_NNS O

MATERIALS POS_NNP O
AND POS_CC O
METHODS POS_NNP MESH_TYPE_qualifier MESH_methods O
: POS_: O
The POS_DT O
panel POS_NN O
searched POS_VBD O
the POS_DT O
MEDLINE POS_NNP O
data POS_NN O
base POS_NN WORDNET_chemical.n.01 O
for POS_IN O
all POS_DT O
articles POS_NNS O
through POS_IN O
1993 POS_CD O
on POS_IN O
surgical POS_JJ T
treatment POS_NN MESH_TYPE_qualifier MESH_therapy T
of POS_IN O
female POS_JJ D
stress POS_NN D
urinary POS_JJ D
incontinence POS_NN D

She POS_PRP O
made POS_VBD O
an POS_DT O
uneventful POS_JJ O
postoperative POS_JJ O
recovery POS_NN O
and POS_CC O
now POS_RB O
leads POS_VBZ O
an POS_DT O
unrestricted POS_JJ O
life POS_NN O

BACKGROUND POS_NN O
: POS_: O
For POS_IN O
more POS_JJR O
than POS_IN O
30 POS_CD O
years POS_NNS O
it POS_PRP O
has POS_VBZ O
been POS_VBN O
known POS_VBN O
that POS_IN O
gastric POS_JJ O
acid POS_JJ WORDNET_chemical.n.01 O
secretion POS_NN MESH_TYPE_qualifier MESH_secretion O
is POS_VBZ O
inversely POS_RB O
related POS_VBN O
to POS_TO O
the POS_DT O
extent POS_NN O
and POS_CC O
severity POS_NN O
of POS_IN O
corpal POS_JJ D
gastritis POS_NN D

We POS_PRP O
hypothesize POS_VBP O
that POS_IN O
there POS_EX O
is POS_VBZ O
a POS_DT O
higher POS_JJR O
incidence POS_NN MESH_TYPE_qualifier MESH_epidemiology O
of POS_IN O
preeclampsia POS_NN D
( POS_( D
proteinuric POS_JJ D
hypertension POS_NN D
) POS_) D
in POS_IN O
women POS_NNS O
conceiving POS_VBG O
by POS_IN O
intrauterine POS_JJ O
insemination POS_NN O
with POS_IN O
donor POS_JJ O
sperm POS_JJ O
versus POS_NN O
intrauterine POS_JJ O
insemination POS_NN O
with POS_IN O
partner POS_NN O
sperm POS_NNS O

STUDY POS_NNP O
DESIGN POS_NNP O
: POS_: O
This POS_DT O
was POS_VBD O
a POS_DT O
retrospective POS_JJ O
cohort POS_NN O
study POS_NN O

By POS_IN O
initially POS_RB O
selecting POS_VBG O
for POS_IN O
proviral POS_JJ O
integrants POS_NNS O
in POS_IN O
hygromycin POS_NN O
followed POS_VBN O
by POS_IN O
shifting POS_VBG O
into POS_IN O
neomycin POS_JJ O
+ POS_NNP O
ganciclovir POS_NN O
to POS_TO O
select POS_VB O
for POS_IN O
S POS_NNP O
sequence-mediated POS_JJ O
deletions POS_NNS O
, POS_, O
switch POS_VB O
recombinations POS_NNS O
can POS_MD O
be POS_VB O
specifically POS_RB O
forestalled POS_VBN O
in POS_IN O
B POS_NNP O
cell POS_NN O
lines POS_NNS O
whilst POS_VBZ O
most POS_RBS O
switch-incompetent POS_JJ O
cells POS_NNS O
do POS_VBP O
not POS_RB O
survive POS_VB O
secondary POS_JJ MESH_TYPE_qualifier MESH_secondary O
selection POS_NN O

A POS_DT O
semi-quantitative POS_JJ O
DC-PCR POS_NNP O
assay POS_NN MESH_TYPE_qualifier MESH_analysis O
detects POS_VBZ O
a POS_DT O
significant POS_JJ O
recombinase POS_NN O
activity POS_NN O
only POS_RB O
in POS_IN O
a POS_DT O
restricted POS_JJ O
set POS_NN O
of POS_IN O
late POS_JJ O
stage POS_NN O
pre-B POS_JJ O
and POS_CC O
mature POS_NN O
B POS_NNP O
cell POS_NN O
lines POS_NNS O

The POS_DT O
SSR POS_NNP O
recombinase POS_NN O
assay POS_NN MESH_TYPE_qualifier MESH_analysis O
can POS_MD O
be POS_VB O
performed POS_VBN O
in POS_IN O
a POS_DT O
transient POS_JJ O
fashion POS_NN O
wherein POS_NN O
extensive POS_JJ O
, POS_, O
B POS_NNP O
cell-specific POS_JJ O
recombination POS_NN O
can POS_MD O
be POS_VB O
visualized POS_VBN O
within POS_IN O
only POS_RB O
a POS_DT O
few POS_JJ O
cell POS_NN O
divisions POS_NNS O
post POS_VBP O
proviral POS_JJ O
integration POS_NN O

Drug POS_NN O
histories POS_NNS O
were POS_VBD O
taken POS_VBN O
and POS_CC O
samples POS_NNS O
were POS_VBD O
tested POS_VBN O
for POS_IN O
alcohol POS_NN O
and POS_CC O
six POS_CD O
of POS_IN O
the POS_DT O
most POS_RBS O
commonly POS_RB O
abused POS_VBD O
drugs POS_NNS O

Prenatal POS_JJ O
diagnosis POS_NN MESH_TYPE_qualifier MESH_diagnosis O
can POS_MD O
be POS_VB O
difficult POS_JJ O
especially POS_RB O
if POS_IN O
they POS_PRP O
present POS_VBP O
in POS_IN O
late POS_JJ O
gestation POS_NN O

PATIENTS POS_NNS O
: POS_: O
36 POS_CD O
patients POS_NNS O
with POS_IN O
cardiac POS_JJ D
amyloid POS_JJ WORDNET_chemical.n.01 D
heart POS_NN WORDNET_body_part.n.01 D
disease POS_NN D
, POS_, O
of POS_IN O
whom POS_WP O
12 POS_CD O
had POS_VBD O
familial POS_JJ O
and POS_CC O
24 POS_CD O
had POS_VBD O
primary POS_JJ O
AL POS_NNP O
amyloidosis POS_NN D

Doppler POS_NNP O
indices POS_NNS O
of POS_IN O
left POS_NN WORDNET_body_part.n.01 O
and POS_CC O
right POS_JJ WORDNET_body_part.n.01 O
ventricular POS_NN O
function POS_NN MESH_TYPE_qualifier MESH_physiology O
, POS_, O
left POS_VBD WORDNET_body_part.n.01 O
ventricular POS_JJ O
volume POS_NN O
, POS_, O
and POS_CC O
ejection POS_NN O
fraction POS_NN WORDNET_chemical.n.01 O
were POS_VBD O
also POS_RB O
similar POS_JJ O

CONCLUSIONS POS_NN O
: POS_: O
Although POS_IN O
cardiac POS_JJ O
involvement POS_NN O
is POS_VBZ O
echocardiographically POS_RB O
indistinguishable POS_JJ O
, POS_, O
cardiac POS_JJ O
mortality POS_NN MESH_TYPE_qualifier MESH_mortality O
is POS_VBZ O
very POS_RB O
different POS_JJ O
between POS_IN O
the POS_DT O
two POS_CD O
forms POS_NNS O
of POS_IN O
amyloidosis POS_NN D

Preservation POS_NN O
of POS_IN O
electrocardiographic POS_JJ O
voltage POS_NN O
in POS_IN O
familial POS_JJ O
amyloidosis POS_NN D
suggests POS_VBZ O
that POS_IN O
the POS_DT O
particular POS_JJ O
biochemical POS_JJ O
characteristics POS_NNS O
of POS_IN O
distinct POS_JJ O
types POS_NNS O
of POS_IN O
amyloid POS_NN WORDNET_chemical.n.01 O
fibril POS_NNS O
have POS_VBP O
different POS_JJ O
pathological POS_JJ O
effects POS_NNS O
on POS_IN O
the POS_DT O
myocardium POS_NN WORDNET_body_part.n.01 O

This POS_DT O
distinction POS_NN O
becomes POS_VBZ O
critical POS_JJ O
in POS_IN O
the POS_DT O
evaluation POS_NN O
, POS_, O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
, POS_, O
and POS_CC O
management POS_NN O
of POS_IN O
patients POS_NNS O
who POS_WP O
have POS_VBP O
a POS_DT O
diagnosis POS_NN MESH_TYPE_qualifier MESH_diagnosis O
within POS_IN O
the POS_DT O
spectrum POS_NN O
of POS_IN O
the POS_DT O
protein POS_NN WORDNET_chemical.n.01 D
deposition POS_NN D
diseases POS_NNS D

Plasma POS_NNP O
PAI-1 POS_NNP O
activity POS_NN O
was POS_VBD O
not POS_RB O
significantly POS_RB O
different POS_JJ O
among POS_IN O
subjects POS_NNS O
with POS_IN O
and POS_CC O
without POS_IN O
retinopathy POS_NN WORDNET_disease.n.01 D
( POS_( O
17.1 POS_CD O
+/- POS_NN O
vs. POS_FW O
19.7 POS_CD O
+/- POS_JJ O
9.1 POS_CD O
arbitrary POS_JJ O
units POS_NNS O
( POS_( O
AU POS_NNP O
) POS_) O
/ml POS_NN O
, POS_, O
P POS_NNP O
= POS_NNP O
0.09 POS_CD O
) POS_) O

The POS_DT O
prevalence POS_NN MESH_TYPE_qualifier MESH_epidemiology O
of POS_IN O
retinopathy POS_NN WORDNET_disease.n.01 D
in POS_IN O
the POS_DT O
three POS_CD O
genotype POS_NN O
groups POS_NNS O
differed POS_VBD O
significantly POS_RB O
( POS_( O
4G/4G POS_CD O
, POS_, O
4G/5G POS_CD O
, POS_, O
and POS_CC O
5G/5G POS_CD O
were POS_VBD O
44 POS_CD O
, POS_, O
49 POS_CD O
, POS_, O
and POS_CC O
24 POS_CD O
% POS_NN O
, POS_, O
respectively POS_RB O
; POS_: O
chi POS_VB O
2 POS_CD O
= POS_JJ O
8.22 POS_CD O
, POS_, O
df POS_NN O
= POS_VBD O
2 POS_CD O
, POS_, O
P POS_NNP O
= POS_NNP O
0.016 POS_CD O
) POS_) O
and POS_CC O
remained POS_VBD O
significant POS_JJ O
after POS_IN O
controlling POS_VBG O
for POS_IN O
age POS_NN O
, POS_, O
sex POS_NN O
, POS_, O
BMI POS_NNP O
, POS_, O
duration POS_NN O
of POS_IN O
diabetes POS_NNS WORDNET_disease.n.01 D
, POS_, O
glycated POS_VBD O
hemoglobin POS_NN WORDNET_chemical.n.01 O
, POS_, O
and POS_CC O
urine POS_JJ MESH_TYPE_qualifier MESH_urine O
albumin-to-creatine POS_JJ O
ratio POS_NN O
in POS_IN O
a POS_DT O
logistic POS_JJ O
regression POS_NN O
analysis POS_NN MESH_TYPE_qualifier MESH_analysis O

The POS_DT O
senior POS_JJ O
surgery POS_NN MESH_TYPE_qualifier MESH_surgery O
resident POS_NN O
correctly POS_RB O
predicted POS_VBD O
the POS_DT O
presence POS_NN O
of POS_IN O
intra-abdominal POS_JJ D
injury POS_NN D
in POS_IN O
36 POS_CD O
( POS_( O
82 POS_CD O
% POS_NN O
) POS_) O
of POS_IN O
the POS_DT O
patients POS_NNS O
( POS_( O
sensitivity POS_NN O
= POS_RB O
90.0 POS_CD O
% POS_NN O
, POS_, O
specificity POS_NN O
= POS_RB O
58.3 POS_CD O
% POS_NN O
, POS_, O
positive POS_JJ O
predictive POS_JJ O
value POS_NN O
= POS_VBD O
85.3 POS_CD O
% POS_NN O
, POS_, O
negative POS_JJ O
predictive POS_JJ O
value POS_NN O
= POS_VBD O
63.6 POS_CD O
% POS_NN O
, POS_, O
phi POS_NN O
= POS_VBD O
0.52 POS_CD O
, POS_, O
P POS_NNP O
& POS_CC O
# POS_# O
60 POS_CD O
; POS_: O
.01 POS_NN O
) POS_) O
in POS_IN O
the POS_DT O
emergency POS_NN O
department POS_NN O
before POS_IN O
DPL POS_NNP O
and POS_CC O
celiotomy POS_NN O
were POS_VBD O
performed POS_VBN O

Diagnostic POS_JJ O
peritoneal POS_NN O
lavage POS_NN WORDNET_treatment.n.01 O
is POS_VBZ O
highly POS_RB O
predictive POS_JJ O
of POS_IN O
the POS_DT O
presence POS_NN O
of POS_IN O
intra-abdominal POS_JJ D
injury POS_NN D

Also POS_RB O
, POS_, O
its POS_PRP$ O
was POS_VBD O
determined POS_VBN O
the POS_DT O
morphology POS_NN MESH_TYPE_qualifier MESH_anatomy & histology O
and POS_CC O
quantification POS_NN O
of POS_IN O
parasites POS_NNS MESH_TYPE_qualifier MESH_parasitology O

In POS_IN O
21 POS_CD O
patients POS_NNS O
B POS_NNP O

We POS_PRP O
did POS_VBD O
not POS_RB O
find POS_VB O
a POS_DT O
statistically POS_RB O
significant POS_JJ O
association POS_NN O
between POS_IN O
the POS_DT O
number POS_NN O
of POS_IN O
B POS_NNP O

The POS_DT O
vacuolar POS_JJ O
form POS_NN O
was POS_VBD O
the POS_DT O
predominant POS_JJ O
morphological POS_JJ O
type POS_NN O

MEASUREMENTS POS_NNS O
: POS_: O
Liver POS_NNP WORDNET_body_part.n.01 O
tissue POS_NN WORDNET_body_part.n.01 O
was POS_VBD O
analyzed POS_VBN O
to POS_TO O
determine POS_VB O
the POS_DT O
activities POS_NNS O
of POS_IN O
two POS_CD O
urea POS_JJ WORDNET_chemical.n.01 O
cycle POS_NN O
enzymes POS_NNS MESH_TYPE_qualifier MESH_enzymology O
and POS_CC O
glutamine POS_NN WORDNET_chemical.n.01 O
synthetase POS_NN O

Breastfed POS_NNP O
infants POS_NNS O
also POS_RB O
showed POS_VBD O
greater POS_JJR O
catch-up POS_JJ O
growth POS_NN MESH_TYPE_qualifier MESH_growth & development O
in POS_IN O
head POS_NN WORDNET_body_part.n.01 O
circumference POS_NN O
( POS_( O
SD POS_NNP O
score POS_NN O
( POS_( O
SDS POS_NNP O
) POS_) O
0.53 POS_CD O
higher POS_JJR O
at POS_IN O
3 POS_CD O
months POS_NNS O
) POS_) O
, POS_, O
and POS_CC O
greater POS_JJR O
body POS_NN O
length POS_JJ O
gain POS_NN O
( POS_( O
SDS POS_NNP O
0.68 POS_CD O
higher POS_JJR O
at POS_IN O
6 POS_CD O
months POS_NNS O
) POS_) O

This POS_DT O
increased POS_VBD O
growth POS_NN MESH_TYPE_qualifier MESH_growth & development O
was POS_VBD O
independent POS_JJ O
of POS_IN O
potentially POS_RB O
confounding POS_VBG O
obstetric POS_JJ O
, POS_, O
social POS_JJ O
and POS_CC O
demographic POS_JJ O
factors POS_NNS O

However POS_RB O
, POS_, O
it POS_PRP O
may POS_MD O
be POS_VB O
even POS_RB O
more POS_RBR O
important POS_JJ O
that POS_IN O
the POS_DT O
nurses POS_NNS O
themselves POS_PRP O
have POS_VBP O
a POS_DT O
healthy POS_JJ O
lifestyle POS_NN O
, POS_, O
thus POS_RB O
serving POS_VBG O
as POS_IN O
role POS_NN O
models POS_NNS O
for POS_IN O
patients POS_NNS O

The POS_DT O
best POS_JJS O
salespersons POS_NNS O
are POS_VBP O
those POS_DT O
who POS_WP O
are POS_VBP O
genuinely POS_RB O
committed POS_VBN O
to POS_TO O
their POS_PRP$ O
product POS_NN WORDNET_chemical.n.01 O
and POS_CC O
model POS_VB O
its POS_PRP$ O
benefits POS_NNS O

Five POS_CD O
themes POS_NNS O
emerged POS_VBN O
from POS_IN O
the POS_DT O
videotaped POS_JJ O
interviews POS_NNS O
: POS_: O
( POS_( O
1 POS_CD O
) POS_) O
Heart-healthy POS_JJ O
practices POS_NNS O
predominated POS_VBD O
the POS_DT O
responses POS_NNS O

( POS_( O
3 POS_CD O
) POS_) O
Critical POS_NNP O
care POS_NN O
nurses POS_NNS O
readily POS_RB O
listed POS_VBD O
barriers POS_NNS O
to POS_TO O
healthy POS_JJ O
living POS_NN O

( POS_( O
5 POS_CD O
) POS_) O
Future POS_NN O
plans POS_NNS O
were POS_VBD O
either POS_RB O
singular POS_JJ O
in POS_IN O
focus POS_NN O
or POS_CC O
limited POS_VBN O
to POS_TO O
maintenance POS_NN O
of POS_IN O
current POS_JJ O
health POS_NN O
habits POS_NNS O

All POS_DT O
patients POS_NNS O
were POS_VBD O
hemodynamically POS_RB O
stable POS_JJ O
( POS_( O
ie POS_JJ O
, POS_, O
without POS_IN O
evidence POS_NN O
of POS_IN O
cardiogenic POS_JJ D
shock POS_NN D
) POS_) O
at POS_IN O
presentation POS_NN O

treatment POS_NN MESH_TYPE_qualifier MESH_therapy T
( POS_( O
within POS_IN O
24 POS_CD O
hours POS_NNS O
of POS_IN O
diagnosis POS_NN MESH_TYPE_qualifier MESH_diagnosis O
) POS_) O
was POS_VBD O
given POS_VBN O
to POS_TO O
169 POS_CD O
patients POS_NNS O
( POS_( O
23.5 POS_CD O
% POS_NN O
) POS_) O
, POS_, O
whereas POS_IN O
the POS_DT O
remaining POS_VBG O
550 POS_CD O
patients POS_NNS O
were POS_VBD O
initially POS_RB O
treated POS_VBN O
with POS_IN O
heparin POS_NN WORDNET_chemical.n.01 T
alone POS_RB O

However POS_RB O
, POS_, O
only POS_RB O
primary POS_JJ D
thrombolysis POS_NN D
was POS_VBD O
found POS_VBN O
by POS_IN O
multivariate POS_NN O
analysis POS_NN MESH_TYPE_qualifier MESH_analysis O
to POS_TO O
be POS_VB O
an POS_DT O
independent POS_JJ O
predictor POS_NN O
of POS_IN O
survival POS_NN MESH_TYPE_qualifier MESH_mortality O
( POS_( O
odds POS_NNS O
ratio POS_NN O
for POS_IN O
in-hospital POS_JJ O
death POS_NN O
, POS_, O
0.46 POS_CD O
; POS_: O
95 POS_CD O
% POS_NN O
confidence POS_NN O
interval POS_NN O
, POS_, O
0.21 POS_CD O
to POS_TO O
1.00 POS_CD O
) POS_) O

< POS_JJ O
TO_SEE POS_NNP O
> POS_NN O
Patients POS_NNPS O
who POS_WP O
underwent POS_VBD O
early POS_JJ O
thrombolytic POS_JJ O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
had POS_VBD O
a POS_DT O
reduced POS_JJ O
rate POS_NN O
of POS_IN O
recurrent POS_NN O
pulmonary POS_JJ O
embolism POS_NN O
( POS_( O
7.7 POS_CD O
versus POS_RB O
18.7 POS_CD O
% POS_NN O
, POS_, O
P POS_NNP O
& POS_CC O
# POS_# O
60 POS_CD O
; POS_: O
.001 POS_NN O
) POS_) O
but POS_CC O
also POS_RB O
a POS_DT O
higher POS_JJR O
frequency POS_NN MESH_TYPE_qualifier MESH_epidemiology O
of POS_IN O
major POS_JJ O
bleeding POS_VBG O
episodes POS_NNS O
( POS_( O
21.9 POS_CD O
% POS_NN O
versus POS_IN O
7.8 POS_CD O
% POS_NN O
, POS_, O
P POS_NNP O
& POS_CC O
# POS_# O
60 POS_CD O
; POS_: O
.001 POS_CD O
) POS_) O

A POS_DT O
66-year-old POS_JJ O
male POS_NN O
engineer POS_NN O
diagnosed POS_VBN O
with POS_IN O
malignant POS_JJ D
pleural POS_JJ D
mesothelioma POS_NN WORDNET_disease.n.01 D
4 POS_CD O
years POS_NNS O
previously POS_RB O
had POS_VBD O
thoracotomy POS_NN T
, POS_, T
radiotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_radiotherapy T
, POS_, T
and POS_CC T
chemotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_drug therapy T

Sequential POS_JJ O
MR POS_NNP O
studies POS_NNS O
were POS_VBD O
obtained POS_VBN O
within POS_IN O
1 POS_CD O
to POS_TO O
3 POS_CD O
days POS_NNS O
postoperatively POS_RB O
and POS_CC O
at POS_IN O
6-month POS_JJ O
follow-up POS_JJ O
examination POS_NN O

Ischemic POS_NNP D
infarction POS_NN D
resulted POS_VBD O
in POS_IN O
mild POS_JJ O
transient POS_JJ O
Broca POS_NNP D
's POS_POS D
aphasia POS_NN D
in POS_IN O
one POS_CD O
patient POS_NN O
, POS_, O
but POS_CC O
there POS_EX O
was POS_VBD O
no POS_DT O
detectable POS_JJ O
neurological POS_JJ O
deficit POS_NN O
in POS_IN O
the POS_DT O
other POS_JJ O
two POS_CD O

METHODS POS_NN MESH_TYPE_qualifier MESH_methods O
: POS_: O
BAEP POS_NNP O
studies POS_NNS O
were POS_VBD O
performed POS_VBN O
before POS_IN O
discharge POS_NN O
in POS_IN O
infants POS_NNS O
treated POS_VBN O
with POS_IN O
extracorporeal POS_JJ T
membrane POS_NN WORDNET_body_part.n.01 T
oxygenation POS_NN T
( POS_( T
ECMO POS_NNP T
) POS_) T
, POS_, O
and POS_CC O
two POS_CD O
specific POS_JJ O
abnormalities POS_NNS MESH_TYPE_qualifier MESH_abnormalities O
were POS_VBD O
analyzed POS_VBN O
: POS_: O
elevated POS_VBN O
threshold POS_NN O
and POS_CC O
delayed POS_JJ O
central POS_JJ O
auditory POS_NN O
conduction POS_NN O

Neonatal POS_JJ O
BAEP POS_NNP O
specificity POS_NN O
for POS_IN O
excluding POS_VBG O
subsequent POS_JJ O
hearing POS_NN D
loss POS_NN D
was POS_VBD O
76 POS_CD O
% POS_NN O

In POS_IN O
contrast POS_NN O
, POS_, O
on POS_IN O
language POS_NN O
development POS_NN MESH_TYPE_qualifier MESH_growth & development O
testing POS_NN O
, POS_, O
19 POS_CD O
children POS_NNS O
demonstrated POS_VBD O
receptive POS_JJ O
language POS_NN O
delay POS_NN O

It POS_PRP O
assumes POS_VBZ O
that POS_IN O
a POS_DT O
single POS_JJ O
pathway POS_NN O
is POS_VBZ O
sufficient POS_JJ O
for POS_IN O
educating POS_VBG O
general POS_JJ O
internists POS_NNS O
and POS_CC O
subspecialty-bound POS_NN O
trainees POS_NNS O

The POS_DT O
average POS_JJ O
age POS_NN O
at POS_IN O
onset POS_NN O
was POS_VBD O
27 POS_CD O
years POS_NNS O

Initially POS_RB O
the POS_DT O
diagnosis POS_NN MESH_TYPE_qualifier MESH_diagnosis O
of POS_IN O
the POS_DT O
syndrome POS_NN O
of POS_IN O
hemorrhagic POS_NN D
shock POS_NN D
and POS_CC O
encephalopathy POS_NN D
was POS_VBD O
made POS_VBN O

It POS_PRP O
is POS_VBZ O
possible POS_JJ O
that POS_IN O
some POS_DT O
cases POS_NNS O
of POS_IN O
syndrome POS_NN O
of POS_IN O
hemorrhagic POS_NN D
shock POS_NN D
and POS_CC O
encephalopathy POS_JJ D
represent POS_NN O
a POS_DT O
variant POS_NN O
of POS_IN O
TSS POS_NNP D
in POS_IN O
small POS_JJ WORDNET_body_part.n.01 O
children POS_NNS O

These POS_DT O
relationships POS_NNS O
were POS_VBD O
preserved POS_VBN O
in POS_IN O
the POS_DT O
subjects POS_NNS O
without POS_IN O
prior POS_JJ O
events POS_NNS O
at POS_IN O
the POS_DT O
time POS_NN O
of POS_IN O
scanning POS_VBG O

Research POS_NN O
into POS_IN O
sexual POS_JJ O
orientation-simplistically POS_RB O
referred POS_VBN O
to POS_TO O
as POS_IN O
`` POS_`` O
gay POS_JJ O
gene POS_NN O
'' POS_'' O
research-is POS_NN O
an POS_DT O
example POS_NN O
of POS_IN O
research POS_NN O
that POS_WDT O
provokes POS_VBZ O
intense POS_JJ O
controversy POS_NN O

Cyclin POS_NNP O
D1 POS_NNP O
, POS_, O
the POS_DT O
regulatory POS_JJ O
subunit POS_NN O
of POS_IN O
certain POS_JJ O
protein POS_NN WORDNET_chemical.n.01 O
kinases POS_NNS O
thought POS_VBD O
to POS_TO O
advance POS_VB O
the POS_DT O
G1 POS_NNP O
phase POS_NN O
of POS_IN O
the POS_DT O
cell POS_NN O
cycle POS_NN O
, POS_, O
is POS_VBZ O
now POS_RB O
established POS_VBN O
as POS_IN O
a POS_DT O
proto-oncogene POS_NN O
, POS_, O
with POS_IN O
evidence POS_NN O
indicating POS_VBG O
that POS_IN O
its POS_PRP$ O
derangement POS_NN O
may POS_MD O
contribute POS_VB O
to POS_TO O
the POS_DT O
uncontrolled POS_JJ O
cell POS_NN O
growth POS_NN MESH_TYPE_qualifier MESH_growth & development O
characteristic POS_NN O
of POS_IN O
tumors POS_NNS D

The POS_DT O
chromosomal POS_JJ O
translocation POS_NN O
t POS_NN O
( POS_( O
11 POS_CD O
; POS_: O
14 POS_CD O
) POS_) O
( POS_( O
q13 POS_NN O
: POS_: O
q32 POS_NN O
) POS_) O
, POS_, O
involving POS_VBG O
rearrangement POS_NN O
of POS_IN O
the POS_DT O
BCL-1 POS_NNP O
locus POS_NN O
, POS_, O
is POS_VBZ O
closely POS_RB O
associated POS_VBN O
with POS_IN O
human POS_JJ D
lymphoid POS_JJ D
neoplasia POS_NN D
affecting POS_VBG O
mantle POS_NN D
cell POS_NN D
lymphomas POS_NN D
( POS_( D
MCL POS_NNP D
) POS_) D

Of POS_IN O
note POS_NN O
, POS_, O
all POS_DT O
of POS_IN O
the POS_DT O
known POS_VBN O
break POS_NN O
points POS_NNS O
leave POS_VBP O
the POS_DT O
cyclin POS_NN O
D1 POS_NNP O
coding POS_VBG O
region POS_NN O
structurally POS_RB O
intact POS_JJ O
and POS_CC O
result POS_NN O
in POS_IN O
increased POS_JJ O
protein POS_NN WORDNET_chemical.n.01 O
expression POS_NN O
, POS_, O
implying POS_VBG O
that POS_IN O
this POS_DT O
may POS_MD O
provide POS_VB O
a POS_DT O
highly POS_RB O
sensitive POS_JJ O
and POS_CC O
specific POS_JJ O
marker POS_NN O
for POS_IN O
MCL POS_NNP D

In POS_IN O
PC12 POS_NNP O
cells POS_NNS O
, POS_, O
a POS_DT O
model POS_NN O
system POS_NN WORDNET_body_part.n.01 O
to POS_TO O
study POS_VB O
neurite POS_JJ O
outgrowth POS_NN O
, POS_, O
SHARP POS_NNP O
genes POS_NNS O
can POS_MD O
be POS_VB O
induced POS_VBN O
by POS_IN O
NGF POS_NNP O
with POS_IN O
the POS_DT O
kinetics POS_NNS O
of POS_IN O
an POS_DT O
immediate-early POS_JJ O
gene POS_NN O

The POS_DT O
subjects POS_NNS O
were POS_VBD O
matched POS_VBN O
for POS_IN O
age POS_NN O
, POS_, O
ethnicity POS_NN MESH_TYPE_qualifier MESH_ethnology O
, POS_, O
parity POS_NN O
, POS_, O
and POS_CC O
gestational POS_JJ O
age POS_NN O

Blood POS_NN MESH_TYPE_qualifier MESH_blood O
samples POS_NNS O
were POS_VBD O
taken POS_VBN O
at POS_IN O
the POS_DT O
time POS_NN O
of POS_IN O
diagnosis POS_NN MESH_TYPE_qualifier MESH_diagnosis O
of POS_IN O
preeclampsia POS_NN D
and POS_CC O
at POS_IN O
comparable POS_JJ O
gestational POS_JJ O
ages POS_NNS O
for POS_IN O
matched POS_VBN O
normal POS_JJ O
controls POS_NNS O

Variables POS_NNS O
differing POS_VBG O
significantly POS_RB O
between POS_IN O
groups POS_NNS O
included POS_VBD O
increases POS_NNS O
in POS_IN O
uric POS_JJ WORDNET_chemical.n.01 O
acid POS_NN WORDNET_chemical.n.01 O
( POS_( O
UA POS_NNP O
) POS_) O
, POS_, O
low-density POS_JJ O
lipoproteins POS_NNS O
( POS_( O
LDL POS_NNP O
) POS_) O
, POS_, O
phosphoglycerate POS_JJ O
kinase POS_NN WORDNET_chemical.n.01 O
( POS_( O
PGK POS_NNP O
) POS_) O
, POS_, O
and POS_CC O
mean POS_JJ O
platelet POS_NN O
volume POS_NN O
( POS_( O
MPV POS_NNP O
) POS_) O
, POS_, O
and POS_CC O
decreases POS_NNS O
in POS_IN O
glyceraldehyde POS_JJ WORDNET_chemical.n.01 O
phosphate POS_NN WORDNET_chemical.n.01 O
dehydrogenase POS_NN O
( POS_( O
G3PD POS_NNP O
) POS_) O
in POS_IN O
preeclamptic POS_JJ O
women POS_NNS O
compared POS_VBN O
to POS_TO O
normal POS_JJ O
controls POS_NNS O

Photolithographic POS_JJ O
patterning POS_NN O
was POS_VBD O
performed POS_VBN O
with POS_IN O
a POS_DT O
positive POS_JJ O
photoresist POS_NN O
with POS_IN O
modified POS_JJ O
bake POS_NN O
temperatures POS_NNS O
and POS_CC O
times POS_NNS O
, POS_, O
selective POS_JJ O
UV POS_NNP O
exposure POS_NN O
with POS_IN O
a POS_DT O
contact POS_NN O
mask POS_NN O
, POS_, O
and POS_CC O
aqueous POS_JJ O
alkaline POS_JJ O
solubilization POS_NN O
of POS_IN O
exposed POS_JJ O
resist POS_NN O

Successful POS_JJ O
patterning POS_NN O
was POS_VBD O
demonstrated POS_VBN O
by POS_IN O
challenging POS_VBG O
surfaces POS_NNS O
with POS_IN O
goat POS_JJ O
anti-mouse POS_NN O
antibody POS_NN WORDNET_chemical.n.01 O
conjugated POS_VBD O
to POS_TO O
tetramethylrhodamine POS_VB O
isothiocyanate POS_NN O

Challenge POS_NN O
with POS_IN O
enzyme POS_NN WORDNET_chemical.n.01 O
linked POS_VBN O
antigen POS_NN O
of POS_IN O
oxygen POS_NN O
plasma POS_NN O
exposed POS_VBD O
antibody POS_NN WORDNET_chemical.n.01 O
layers POS_NNS O
demonstrated POS_VBD O
that POS_IN O
plasma POS_NN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
completely POS_RB O
neutralized POS_VBN O
antibody POS_NN WORDNET_chemical.n.01 O
capture POS_NN O
ability POS_NN O

Fluorescent POS_NNP O
imaging POS_VBG O
demonstrated POS_VBN O
smallest POS_JJS O
line POS_NN O
widths POS_NNS O
of POS_IN O
2-3 POS_JJ O
microns POS_NNS O

We POS_PRP O
have POS_VBP O
been POS_VBN O
investigating POS_VBG O
the POS_DT O
potential POS_NN O
of POS_IN O
exploiting POS_VBG O
the POS_DT O
immunosensing POS_VBG O
detection POS_NN O
abilities POS_NNS O
of POS_IN O
excitable POS_JJ O
immune POS_JJ O
cells POS_NNS O
( POS_( O
i.e POS_NN O
. POS_. O
the POS_DT O
mast POS_NN O
cell POS_NN O
) POS_) O
for POS_IN O
the POS_DT O
development POS_NN MESH_TYPE_qualifier MESH_growth & development O
of POS_IN O
whole POS_JJ O
cell POS_NN O
immunobiosensors POS_NNS O

We POS_PRP O
have POS_VBP O
previously POS_RB O
determined POS_VBN O
that POS_IN O
mast POS_NN O
cell POS_NN O
metabolic POS_JJ O
responses POS_NNS O
can POS_MD O
be POS_VB O
thermally POS_RB O
transduced POS_VBN O
in POS_IN O
real POS_JJ O
time POS_NN O
, POS_, O
thus POS_RB O
indicating POS_VBG O
the POS_DT O
possibility POS_NN O
of POS_IN O
whole POS_JJ O
cell POS_NN O
thermoelectric POS_IN O
immunobiosensing POS_VBG O

An POS_DT O
easy-to-use POS_NN O
technique POS_NN O
for POS_IN O
detection POS_NN O
of POS_IN O
antibodies POS_NNS O
specific POS_JJ O
for POS_IN O
the POS_DT O
parasite POS_JJ O
L. POS_NNP O
donovani POS_NN O
in POS_IN O
human POS_JJ O
serum POS_NN O
sample POS_NN O
has POS_VBZ O
been POS_VBN O
developed POS_VBN O

Tapered POS_VBN O
fibres POS_NNS O
are POS_VBP O
immobilized POS_VBN O
with POS_IN O
the POS_DT O
purified POS_VBN O
cell POS_NN O
surface POS_NN O
protein POS_NN WORDNET_chemical.n.01 O
of POS_IN O
L. POS_NNP O
donovani POS_NN O
by POS_IN O
covalent POS_NN O
bonding POS_NN O

Treated POS_VBN O
fibres POS_NNS O
are POS_VBP O
incubated POS_VBN O
with POS_IN O
the POS_DT O
patient POS_NN O
serum POS_NN O
for POS_IN O
10 POS_CD O
min POS_NN O
followed POS_VBN O
by POS_IN O
incubation POS_NN O
with POS_IN O
goat POS_NN O
anti POS_NN O
human POS_JJ O
IgG POS_NNP O
tagged POS_VBD O
FITC POS_NNP O

These POS_DT O
biosensors POS_NNS O
are POS_VBP O
fabricated POS_VBN O
by POS_IN O
site-selective POS_JJ O
photodeposition POS_NN O
of POS_IN O
analyte-sensitive POS_JJ O
polymer POS_NN WORDNET_chemical.n.01 O
matrices POS_NNS O
on POS_IN O
optical POS_JJ O
imaging POS_NN O
fibres POS_NNS O

Independent POS_JJ O
measurement POS_NN O
of POS_IN O
the POS_DT O
transducing POS_VBG O
analyte POS_NN O
allows POS_VBZ O
penicillin POS_NN T
or POS_CC O
glucose POS_VB WORDNET_chemical.n.01 O
to POS_TO O
be POS_VB O
quantitated POS_VBN O
in POS_IN O
the POS_DT O
presence POS_NN O
of POS_IN O
a POS_DT O
concurrent POS_JJ O
pH POS_NN O
or POS_CC O
O2 POS_NNP O
change POS_NN O
, POS_, O
respectively POS_RB O

Glucose POS_NNP WORDNET_chemical.n.01 O
can POS_MD O
be POS_VB O
measured POS_VBN O
in POS_IN O
the POS_DT O
range POS_NN O
0.6-20.0 POS_JJ O
mM POS_NN O
in POS_IN O
the POS_DT O
O2 POS_NNP O
range POS_VB O
20-100 POS_CD O
% POS_NN O

Reflectometric POS_JJ O
interference POS_NN O
spectroscopy POS_NN O
, POS_, O
an POS_DT O
optical POS_JJ O
transducer POS_NN O
which POS_WDT O
allows POS_VBZ O
the POS_DT O
monitoring POS_NN O
of POS_IN O
a POS_DT O
few POS_JJ O
picograms POS_NNS O
per POS_IN O
square POS_NN O
millimetre POS_NN O
changes POS_NNS O
in POS_IN O
surface POS_NN O
coverage POS_NN O
, POS_, O
was POS_VBD O
used POS_VBN O
to POS_TO O
study POS_VB O
two POS_CD O
model POS_NN O
systems POS_NNS O

The POS_DT O
final POS_JJ O
lactate POS_NN WORDNET_chemical.n.01 O
catheter POS_NN O
is POS_VBZ O
characterized POS_VBN O
by POS_IN O
a POS_DT O
linear POS_JJ O
concentration POS_NN O
range POS_NN O
between POS_IN O
0.5 POS_CD O
and POS_CC O
20 POS_CD O
mmol/l POS_NNS O
lactate POS_VBP WORDNET_chemical.n.01 O
with POS_IN O
a POS_DT O
sensitivity POS_NN O
around POS_IN O
2 POS_CD O
nA POS_JJ O
mmol-1 POS_JJ O
l-1 POS_JJ O
lactate POS_NN WORDNET_chemical.n.01 O

Lactate POS_NNP WORDNET_chemical.n.01 O
values POS_NNS O
obtained POS_VBN O
by POS_IN O
continuous POS_JJ O
catheter POS_NN O
operation POS_NN O
ex POS_FW O
vivo POS_NN O
correlate POS_NN O
well POS_NN O
with POS_IN O
those POS_DT O
obtained POS_VBN O
by POS_IN O
BIOSEN POS_NNP O
Med POS_NNP O
L. POS_NNP O
First POS_NNP O
subcutaneous POS_JJ O
implantation POS_NN O
( POS_( O
dog POS_NN O
) POS_) O
underlines POS_VBZ O
the POS_DT O
characteristics POS_NNS O
obtained POS_VBD O
ex POS_JJ O
vivo POS_NN O
: POS_: O
after POS_IN O
30 POS_CD O
min POS_NN O
hydration POS_NN O
the POS_DT O
lactate POS_NN WORDNET_chemical.n.01 O
catheter POS_NN O
follows POS_VBZ O
the POS_DT O
lactate POS_JJ WORDNET_chemical.n.01 O
concentration POS_NN O
measured POS_VBD O
ex POS_JJ O
vivo POS_NN O
with POS_IN O
samples POS_NNS O
from POS_IN O
the POS_DT O
leg POS_NN WORDNET_body_part.n.01 O
vein POS_NN WORDNET_body_part.n.01 O
by POS_IN O
BIOSEN POS_NNP O
Med POS_NNP O
L. POS_NNP O

The POS_DT O
diffusion-limited POS_JJ O
binding POS_NN O
kinetics POS_NNS O
of POS_IN O
antigen POS_NN O
( POS_( O
or POS_CC O
antibody POS_NN WORDNET_chemical.n.01 O
) POS_) O
in POS_IN O
solution POS_NN O
to POS_TO O
antibody POS_NN WORDNET_chemical.n.01 O
( POS_( O
or POS_CC O
antigen POS_NN O
) POS_) O
immobilized POS_VBN O
on POS_IN O
a POS_DT O
biosensor POS_NN O
and POS_CC O
other POS_JJ O
surfaces POS_NNS O
is POS_VBZ O
analyzed POS_VBN O
within POS_IN O
a POS_DT O
fractal POS_JJ O
framework POS_NN O

In POS_IN O
some POS_DT O
cases POS_NNS O
, POS_, O
the POS_DT O
binding POS_NN O
curve POS_NN O
exhibits POS_VBZ O
complexities POS_NNS O

This POS_DT O
indicates POS_VBZ O
a POS_DT O
change POS_NN O
in POS_IN O
the POS_DT O
reaction POS_NN O
mechanism POS_NN O
on POS_IN O
the POS_DT O
surface POS_NN O

The POS_DT O
different POS_JJ O
examples POS_NNS O
analyzed POS_VBN O
and POS_CC O
presented POS_VBN O
together POS_RB O
provide POS_VB O
a POS_DT O
means POS_NN O
by POS_IN O
which POS_WDT O
the POS_DT O
antigen-antibody POS_NN O
reactions POS_NNS O
may POS_MD O
be POS_VB O
better POS_JJR O
controlled POS_VBN O
by POS_IN O
noting POS_VBG O
the POS_DT O
magnitude POS_NN O
of POS_IN O
the POS_DT O
changes POS_NNS O
in POS_IN O
the POS_DT O
fractal POS_JJ O
dimension POS_NN O
and POS_CC O
in POS_IN O
the POS_DT O
binding POS_NN O
rate POS_NN O
coefficient POS_NN O
as POS_IN O
the POS_DT O
reaction POS_NN O
progresses POS_VBZ O
on POS_IN O
the POS_DT O
biosensor POS_NN O
surface POS_NN O

This POS_DT O
may POS_MD O
be POS_VB O
one POS_CD O
method POS_NN O
to POS_TO O
help POS_VB O
manipulate POS_VB O
or POS_CC O
control POS_VB MESH_TYPE_qualifier MESH_prevention & control O
the POS_DT O
binding POS_NN O
rate POS_NN O
coefficients POS_NNS O
on POS_IN O
the POS_DT O
reaction POS_NN O
surface POS_NN O

The POS_DT O
ability POS_NN O
to POS_TO O
detect POS_VB O
UTI POS_NNP D
by POS_IN O
dipstick POS_NN O
only POS_RB O
and POS_CC O
by POS_IN O
complete POS_JJ O
urinalysis POS_NN O
was POS_VBD O
the POS_DT O
same POS_JJ O
, POS_, O
however POS_RB O
microscopic POS_JJ O
evaluation POS_NN O
added POS_VBD O
many POS_JJ O
false-positive POS_JJ O
results POS_NNS O
without POS_IN O
detecting POS_VBG O
additional POS_JJ O
UTIs POS_NN D

Because POS_IN O
the POS_DT O
ability POS_NN O
to POS_TO O
detect POS_VB O
UTI POS_NNP D
( POS_( O
sensitivity POS_NN O
) POS_) O
is POS_VBZ O
maintained POS_VBN O
, POS_, O
we POS_PRP O
now POS_RB O
offer POS_VBP O
a POS_DT O
dipstick POS_NN O
only POS_RB O
urinalysis POS_NN O
to POS_TO O
our POS_PRP$ O
emergency POS_NN O
room POS_NN O
for POS_IN O
children POS_NNS O
2 POS_CD O
years POS_NNS O
of POS_IN O
age POS_NN O
or POS_CC O
older POS_JJR O
, POS_, O
with POS_IN O
a POS_DT O
microscopic POS_NN O
analysis POS_NN MESH_TYPE_qualifier MESH_analysis O
performed POS_VBN O
automatically POS_RB O
if POS_IN O
dipstick POS_JJ O
results POS_NNS O
are POS_VBP O
positive POS_JJ O

$ POS_$ O
12 POS_CD O

We POS_PRP O
varied POS_VBD O
the POS_DT O
composition POS_NN O
and POS_CC O
the POS_DT O
osmolarity POS_NN O
of POS_IN O
the POS_DT O
culture POS_NN MESH_TYPE_qualifier MESH_ethnology O
solution POS_NN O
as POS_RB O
well POS_RB O
as POS_IN O
the POS_DT O
electrical POS_JJ O
charge POS_NN WORDNET_chemical.n.01 O
and POS_CC O
the POS_DT O
molecular POS_JJ O
mass POS_NN O
of POS_IN O
the POS_DT O
microinjected POS_JJ O
fluorescent POS_NN O
probe POS_NN O

In POS_IN O
all POS_DT O
simple POS_JJ O
salines POS_NNS O
, POS_, O
irrespective POS_NN O
of POS_IN O
their POS_PRP$ O
osmolarity POS_NN O
, POS_, O
Lucifer POS_NNP O
Yellow POS_NNP O
CH POS_NNP O
was POS_VBD O
found POS_VBN O
to POS_TO O
preferentially POS_RB O
migrate POS_VB O
in POS_IN O
the POS_DT O
posterior POS_JJ O
direction POS_NN O
and POS_CC O
to POS_TO O
accumulate POS_VB O
in POS_IN O
the POS_DT O
oocyte POS_NN O
due POS_JJ O
to POS_TO O
progressive POS_VB O
binding POS_NN O
to POS_TO O
yolk POS_VB O
spheres POS_NNS O

A POS_DT O
set POS_NN O
of POS_IN O
recombinant POS_JJ O
phage POS_NN O
carrying POS_VBG O
genomic POS_JJ O
fragments POS_NNS O
for POS_IN O
the POS_DT O
coding POS_JJ O
region POS_NN O
and POS_CC O
flanking POS_VBG O
sequences POS_NNS O
of POS_IN O
the POS_DT O
AF-4 POS_NNP O
gene POS_NN O
were POS_VBD O
isolated POS_VBN O

The POS_DT O
AF-4 POS_NNP O
gene POS_NN O
is POS_VBZ O
a POS_DT O
member POS_NN O
of POS_IN O
the POS_DT O
AF-4 POS_NNP O
, POS_, O
LAF-4 POS_NNP O
and POS_CC O
FMR-2 POS_NNP O
gene POS_NN O
family POS_NN O

In POS_IN O
addition POS_NN O
, POS_, O
we POS_PRP O
demonstrate POS_VBP O
using POS_VBG O
a POS_DT O
fusion POS_NN WORDNET_treatment.n.01 O
protein POS_NN WORDNET_chemical.n.01 O
expressed POS_VBN O
in POS_IN O
eukaryotic POS_JJ O
cells POS_NNS O
that POS_WDT O
chLAMP POS_VBP O
has POS_VBZ O
homophilic POS_JJ O
binding POS_NN O
activity POS_NN O

The POS_DT O
protein POS_NN WORDNET_chemical.n.01 O
was POS_VBD O
found POS_VBN O
on POS_IN O
a POS_DT O
subset POS_NN O
of POS_IN O
axons POS_NNS O
in POS_IN O
the POS_DT O
central POS_JJ O
and POS_CC O
peripheral POS_JJ WORDNET_body_part.n.01 O
nervous POS_JJ WORDNET_body_part.n.01 O
system POS_NN WORDNET_body_part.n.01 O
and POS_CC O
is POS_VBZ O
likely POS_JJ O
to POS_TO O
be POS_VB O
involved POS_VBN O
in POS_IN O
specific POS_JJ O
cell-cell POS_JJ O
interactions POS_NNS O
in POS_IN O
neurohistogenesis POS_NN O

Two POS_CD O
novel POS_JJ O
cDNAs POS_NNS O
, POS_, O
DNAS1L2 POS_NNP O
and POS_CC O
DNAS1L3 POS_NNP O
, POS_, O
are POS_VBP O
predicted POS_VBN O
to POS_TO O
encode POS_VB O
proteins POS_NNS O
of POS_IN O
299 POS_CD O
and POS_CC O
305 POS_CD O
amino POS_NN O
acids POS_NNS O
with POS_IN O
56 POS_CD O
and POS_CC O
46 POS_CD O
% POS_NN O
residue POS_JJ O
identity POS_NN O
( POS_( O
71 POS_CD O
and POS_CC O
63 POS_CD O
% POS_NN O
similarity POS_NN O
) POS_) O
, POS_, O
respectively POS_RB O
, POS_, O
to POS_TO O
deoxyribonuclease POS_VB O
I POS_PRP O
( POS_( O
DNase POS_NNP O
I POS_PRP O
) POS_) O

Thus POS_RB O
, POS_, O
to POS_TO O
date POS_NN O
, POS_, O
four POS_CD O
DNase POS_NNP O
I-like POS_NNP O
genes POS_NNS O
that POS_WDT O
show POS_VBP O
different POS_JJ O
tissue POS_NN WORDNET_body_part.n.01 O
expression POS_NN O
patterns POS_NNS O
are POS_VBP O
known POS_VBN O

A POS_DT O
comparison POS_NN O
of POS_IN O
DNAS1L1 POS_NNP O
, POS_, O
DNAS1L2 POS_NNP O
, POS_, O
and POS_CC O
DNAS1L3 POS_NNP O
with POS_IN O
the POS_DT O
well-characterized POS_JJ O
DNase POS_NNP O
I POS_PRP O
suggests POS_VBZ O
that POS_IN O
the POS_DT O
DNAS1L POS_NNP O
proteins POS_NNS O
are POS_VBP O
unlikely POS_JJ O
to POS_TO O
be POS_VB O
glycosylated POS_VBN O
or POS_CC O
bind POS_VB O
actin POS_NN WORDNET_chemical.n.01 O
; POS_: O
however POS_RB O
, POS_, O
catalytic POS_JJ O
and POS_CC O
calcium- POS_JJ O
and POS_CC O
DNA-binding POS_JJ O
residues POS_NNS O
are POS_VBP O
conserved POS_VBN O
, POS_, O
and POS_CC O
potentially POS_RB O
cleavable POS_JJ O
signal POS_JJ O
peptides POS_NNS O
are POS_VBP O
present POS_JJ O
among POS_IN O
all POS_PDT O
these POS_DT O
proteins POS_NNS O

This POS_DT O
was POS_VBD O
associated POS_VBN O
with POS_IN O
the POS_DT O
emergence POS_NN O
of POS_IN O
drug-resistant POS_JJ O
variants POS_NNS O

In POS_IN O
the POS_DT O
six POS_CD O
patients POS_NNS O
in POS_IN O
this POS_DT O
group POS_NN O
, POS_, O
there POS_EX O
was POS_VBD O
also POS_RB O
an POS_DT O
identical POS_JJ O
mutation POS_NN O
in POS_IN O
the POS_DT O
gag POS_NN O
p7/p1 POS_NN O
gag POS_NN O
protease POS_NN WORDNET_chemical.n.01 O
cleavage POS_NN WORDNET_body_part.n.01 O
site POS_NN O

In POS_IN O
three POS_CD O
of POS_IN O
the POS_DT O
patients POS_NNS O
, POS_, O
this POS_DT O
change POS_NN O
was POS_VBD O
seen POS_VBN O
as POS_RB O
early POS_JJ O
as POS_IN O
6 POS_CD O
to POS_TO O
10 POS_CD O
weeks POS_NNS O
after POS_IN O
the POS_DT O
start POS_NN O
of POS_IN O
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy O

A POS_DT O
cDNA POS_NN O
was POS_VBD O
isolated POS_VBN O
from POS_IN O
a POS_DT O
lambdagt11 POS_NN O
protoscolex POS_JJ O
expression POS_NN O
library POS_NN O
and POS_CC O
the POS_DT O
deduced POS_JJ O
amino POS_NN WORDNET_chemical.n.01 O
acid POS_NN WORDNET_chemical.n.01 O
sequence POS_NN O
has POS_VBZ O
at POS_IN O
least POS_JJS O
fifteen POS_JJ O
sequentially POS_RB O
repeated POS_VBN O
twelve-residue POS_JJ O
repeats POS_NNS O
that POS_WDT O
resemble POS_VBP O
the POS_DT O
calcium-binding POS_JJ O
loop POS_NN O
of POS_IN O
EF-hands POS_NNP O
; POS_: O
however POS_RB O
, POS_, O
the POS_DT O
dodecamer POS_NN O
motif POS_NN O
has POS_VBZ O
no POS_DT O
flanking POS_NN O
helices POS_NNS O

In POS_IN O
this POS_DT O
report POS_NN O
, POS_, O
we POS_PRP O
demonstrated POS_VBD O
that POS_IN O
Raf-1 POS_NNP O
protein POS_JJ WORDNET_chemical.n.01 O
kinase POS_NN WORDNET_chemical.n.01 O
activity POS_NN O
in POS_IN O
the POS_DT O
mouse POS_NN O
parotid POS_NN O
glands POS_NNS O
was POS_VBD O
induced POS_VBN O
by POS_IN O
chronic POS_JJ O
isoproterenol POS_JJ O
administration POS_NN WORDNET_treatment.n.01 O
in POS_IN O
whole POS_JJ O
animals POS_NNS O

To POS_TO O
investigate POS_VB O
the POS_DT O
molecular POS_JJ O
nature POS_NN O
underlying POS_VBG O
cellular POS_JJ O
responses POS_NNS O
to POS_TO O
Raf-1 POS_NNP O
activation POS_NN O
, POS_, O
we POS_PRP O
have POS_VBP O
stably POS_RB O
transfected POS_VBN O
rat POS_NN O
salivary POS_JJ O
epithelial POS_JJ O
Pa-4 POS_NNP O
cells POS_NNS O
with POS_IN O
human POS_JJ O
Raf-1-estrogen POS_NNP O
receptor POS_NN WORDNET_body_part.n.01 O
fusion POS_NN WORDNET_treatment.n.01 O
gene POS_NN O
( POS_( O
DeltaRaf-1 POS_JJ O
: POS_: O
ER POS_NN O
) POS_) O
and POS_CC O
used POS_VBN O
mRNA POS_JJ O
differential POS_JJ O
display POS_NN O
in POS_IN O
search POS_NN O
of POS_IN O
messages POS_NNS O
induced POS_VBN O
by POS_IN O
DeltaRaf-1 POS_NNP O
: POS_: O
ER POS_CD O
activation POS_NN O

Activation POS_NN O
of POS_IN O
Raf-1 POS_NNP O
kinase POS_NN WORDNET_chemical.n.01 O
resulted POS_VBD O
in POS_IN O
a POS_DT O
delayed POS_NN O
and POS_CC O
sustained POS_JJ O
increase POS_NN O
of POS_IN O
HMGI-C POS_NNP O
expression POS_NN O
in POS_IN O
the POS_DT O
Pa-4 POS_NNP O
cells POS_NNS O

The POS_DT O
role POS_NN O
of POS_IN O
the POS_DT O
extracellular POS_JJ O
signal-related POS_JJ O
kinase POS_NN WORDNET_chemical.n.01 O
( POS_( O
ERK POS_NNP O
) POS_) O
signaling POS_VBG O
pathway POS_NN O
in POS_IN O
the POS_DT O
HMGI-C POS_NNP O
induction POS_NN O
was POS_VBD O
highlighted POS_VBN O
by POS_IN O
the POS_DT O
result POS_NN O
that POS_IN O
the POS_DT O
MAP POS_NNP O
kinase POS_NN WORDNET_chemical.n.01 O
kinase POS_NN WORDNET_chemical.n.01 O
( POS_( O
MEK POS_NNP O
) POS_) O
inhibitor POS_NN O
, POS_, O
PD POS_NNP O
98059 POS_CD O
, POS_, O
blocked POS_VBD O
DeltaRaf-1 POS_JJ O
: POS_: O
ER- POS_JJ O
and POS_CC O
12-O-tetradecanoylphorbol-13-acetate-stimulated POS_JJ O
HMGI-C POS_NNP O
induction POS_NN O

By POS_IN O
some POS_DT O
estimates POS_NNS O
, POS_, O
the POS_DT O
disorder POS_NN O
may POS_MD O
account POS_VB O
for POS_IN O
upwards POS_NNS O
of POS_IN O
10 POS_CD O
% POS_NN O
of POS_IN O
hereditary POS_JJ D
deafness POS_NN D

Using POS_VBG O
a POS_DT O
positional POS_JJ O
cloning POS_NN O
strategy POS_NN O
, POS_, O
we POS_PRP O
have POS_VBP O
identified POS_VBN O
the POS_DT O
gene POS_NN O
( POS_( O
PDS POS_NNP O
) POS_) O
mutated POS_VBD O
in POS_IN O
Pendred POS_NNP D
syndrome POS_NN D
and POS_CC O
found POS_VBD O
three POS_CD O
apparently POS_RB O
deleterious POS_JJ O
mutations POS_NNS O
, POS_, O
each POS_DT O
segregating POS_VBG O
with POS_IN O
the POS_DT O
disease POS_NN O
in POS_IN O
the POS_DT O
respective POS_JJ O
families POS_NNS O
in POS_IN O
which POS_WDT O
they POS_PRP O
occur POS_VBP O

These POS_DT O
studies POS_NNS O
provide POS_VBP O
compelling POS_VBG O
evidence POS_NN O
that POS_WDT O
defects POS_VBZ MESH_TYPE_qualifier MESH_abnormalities O
in POS_IN O
pendrin POS_NN O
cause POS_NN O
Pendred POS_VBD D
syndrome POS_JJ D
thereby POS_RB O
launching POS_VBG O
a POS_DT O
new POS_JJ O
area POS_NN WORDNET_body_part.n.01 O
of POS_IN O
investigation POS_NN O
into POS_IN O
thyroid POS_JJ O
physiology POS_NN MESH_TYPE_qualifier MESH_physiology O
, POS_, O
the POS_DT O
pathogenesis POS_NN MESH_TYPE_qualifier MESH_etiology O
of POS_IN O
congenital POS_JJ MESH_TYPE_qualifier MESH_congenital D
deafness POS_NN D
and POS_CC O
the POS_DT O
role POS_NN O
of POS_IN O
altered POS_JJ O
sulphate POS_NN O
transport POS_NN O
in POS_IN O
human POS_JJ O
disease POS_NN O

By POS_IN O
in POS_IN O
situ POS_JJ O
hybridization POS_NN O
analysis POS_NN MESH_TYPE_qualifier MESH_analysis O
, POS_, O
we POS_PRP O
show POS_VBP O
that POS_IN O
the POS_DT O
Meis2 POS_NNP O
gene POS_NN O
displays POS_NNS O
spatially POS_RB O
restricted POS_VBN O
expression POS_NN O
patterns POS_NNS O
in POS_IN O
the POS_DT O
developing POS_VBG O
nervous POS_JJ WORDNET_body_part.n.01 O
system POS_NN WORDNET_body_part.n.01 O
, POS_, O
limbs POS_NNS O
, POS_, O
face POS_NN WORDNET_body_part.n.01 O
, POS_, O
and POS_CC O
in POS_IN O
various POS_JJ O
viscera POS_NN WORDNET_body_part.n.01 O

We POS_PRP O
speculate POS_VBP O
that POS_IN O
regional POS_JJ O
hot POS_JJ O
spots POS_NNS O
of POS_IN O
the POS_DT O
viverrid POS_JJ D
rabies POS_NNS WORDNET_disease.n.01 D
biotype POS_VBP O
reflect POS_JJ O
population POS_NN O
density POS_NN O
differences POS_NNS O
in POS_IN O
the POS_DT O
yellow POS_NN O
mongoose POS_NN O
that POS_WDT O
are POS_VBP O
not POS_RB O
underscored POS_VBN O
by POS_IN O
genetic POS_JJ O
partitioning POS_NN O
, POS_, O
at POS_IN O
least POS_JJS O
at POS_IN O
the POS_DT O
level POS_NN O
of POS_IN O
resolution POS_NN O
provided POS_VBN O
by POS_IN O
our POS_PRP$ O
analyses POS_NNS O

The POS_DT O
search POS_NN O
of POS_IN O
solutions POS_NNS O
needs POS_NNS O
multiple POS_JJ O
competences POS_NNS O
from POS_IN O
the POS_DT O
physician POS_NN O
, POS_, O
who POS_WP O
has POS_VBZ O
to POS_TO O
play POS_VB O
an POS_DT O
essential POS_JJ O
role POS_NN O

< POS_JJ O
TO_SEE POS_NNP O
> POS_NNP O
Despite POS_IN O
Beta-blockade POS_NNP T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
has POS_VBZ O
been POS_VBN O
considered POS_VBN O
as POS_IN O
an POS_DT O
absolute POS_JJ O
contraindication POS_NN O
in POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
heart POS_NN WORDNET_body_part.n.01 D
failure POS_NN D
, POS_, O
it POS_PRP O
has POS_VBZ O
been POS_VBN O
shown POS_VBN O
that POS_IN O
they POS_PRP O
could POS_MD O
have POS_VB O
a POS_DT O
beneficial POS_JJ O
effect POS_NN O
, POS_, O
provided POS_VBD O
that POS_IN O
they POS_PRP O
were POS_VBD O
introduced POS_VBN O
at POS_IN O
very POS_RB O
low POS_JJ O
dose POS_NN O
, POS_, O
and POS_CC O
very POS_RB O
progressively POS_RB O
in POS_IN O
addition POS_NN O
of POS_IN O
the POS_DT O
traditional POS_JJ O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O

Calcium POS_NN T
antagonists POS_NNS MESH_TYPE_qualifier MESH_antagonists & inhibitors T
have POS_VBP O
been POS_VBN O
used POS_VBN O
for POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
cardiovascular POS_JJ D
diseases POS_NNS D
for POS_IN O
more POS_JJR O
than POS_IN O
25 POS_CD O
years POS_NNS O

< POS_JJ O
TO_SEE POS_NNP O
> POS_NNP O
There POS_EX O
is POS_VBZ O
therefore POS_RB O
no POS_DT O
reason POS_NN O
to POS_TO O
believe POS_VB O
that POS_IN O
the POS_DT O
questionable POS_JJ O
results POS_NNS O
derived POS_VBD O
from POS_IN O
retrospective POS_JJ O
studies POS_NNS O
of POS_IN O
the POS_DT O
effects POS_NNS O
of POS_IN O
short-acting POS_JJ O
calcium POS_NN O
antagonists POS_NNS MESH_TYPE_qualifier MESH_antagonists & inhibitors O
on POS_IN O
cardiac POS_NN O
and POS_CC O
noncardiac POS_JJ O
events POS_NNS O
may POS_MD O
apply POS_VB O
to POS_TO O
the POS_DT O
newer POS_JJR O
generation POS_NN O
of POS_IN O
long-acting POS_JJ O
calcium POS_NN O
antagonists POS_NNS MESH_TYPE_qualifier MESH_antagonists & inhibitors O

Fiercer POS_NNP O
competition POS_NN O
between POS_IN O
athletes POS_NNS O
and POS_CC O
a POS_DT O
wider POS_NN O
knowledge POS_NN O
of POS_IN O
optimal POS_JJ O
training POS_NN MESH_TYPE_qualifier MESH_education O
regimens POS_NNS O
dramatically POS_RB O
influence POS_VBP O
current POS_JJ O
training POS_NN MESH_TYPE_qualifier MESH_education O
methods POS_NNS MESH_TYPE_qualifier MESH_methods O

However POS_RB O
, POS_, O
psychological POS_JJ O
testing POS_NN O
may POS_MD O
reveal POS_VB O
early-warning POS_JJ O
signs POS_NNS MESH_TYPE_qualifier MESH_diagnosis O
more POS_RBR O
readily POS_RB O
than POS_IN O
the POS_DT O
various POS_JJ O
physiological POS_JJ O
or POS_CC O
immunological POS_JJ O
markers POS_NNS O

One POS_CD O
such POS_JJ O
framework POS_NN O
for POS_IN O
this POS_DT O
is POS_VBZ O
referred POS_VBN O
to POS_TO O
as POS_IN O
the POS_DT O
total POS_JJ O
quality POS_NN O
recovery POS_NN O
( POS_( O
TQR POS_NNP O
) POS_) O
process POS_NN WORDNET_body_part.n.01 O

By POS_IN O
using POS_VBG O
a POS_DT O
TQR POS_NNP O
scale POS_NN O
, POS_, O
structured POS_VBN O
around POS_IN O
the POS_DT O
scale POS_NN O
developed POS_VBD O
for POS_IN O
ratings POS_NNS O
of POS_IN O
perceived POS_JJ O
exertion POS_NN O
( POS_( O
RPE POS_NNP O
) POS_) O
, POS_, O
the POS_DT O
recovery POS_NN O
process POS_NN WORDNET_body_part.n.01 O
can POS_MD O
be POS_VB O
monitored POS_VBN O
and POS_CC O
matched POS_VBN O
against POS_IN O
the POS_DT O
breakdown POS_NN O
( POS_( O
training POS_VBG MESH_TYPE_qualifier MESH_education O
) POS_) O
process POS_NN WORDNET_body_part.n.01 O
( POS_( O
TQR POS_NNP O
versus POS_NNP O
RPE POS_NNP O
) POS_) O

A POS_DT O
knowledge POS_NN O
of POS_IN O
the POS_DT O
neural POS_JJ O
control POS_NN MESH_TYPE_qualifier MESH_prevention & control O
of POS_IN O
salivary POS_JJ O
secretion POS_NN MESH_TYPE_qualifier MESH_secretion O
is POS_VBZ O
especially POS_RB O
important POS_JJ O
for POS_IN O
the POS_DT O
understanding POS_NN O
of POS_IN O
the POS_DT O
effects POS_NNS O
of POS_IN O
exertion POS_NN O
on POS_IN O
salivary POS_JJ O
secretion POS_NN MESH_TYPE_qualifier MESH_secretion O

However POS_RB O
, POS_, O
an POS_DT O
exercise POS_NN O
intensity POS_NN O
of POS_IN O
65 POS_CD O
% POS_NN O
VO2max POS_NNP O
results POS_NNS O
in POS_IN O
a POS_DT O
slight POS_JJ O
decrease POS_NN O
in POS_IN O
the POS_DT O
amount POS_NN O
of POS_IN O
plasma POS_NN O
FFA POS_NNP O
uptake POS_NN O
by POS_IN O
muscle POS_NN WORDNET_body_part.n.01 O
tissue POS_NN WORDNET_body_part.n.01 O

Other POS_JJ O
studies POS_NNS O
have POS_VBP O
found POS_VBN O
that POS_IN O
during POS_IN O
prolonged POS_JJ O
exercise POS_NN O
, POS_, O
muscle POS_NN WORDNET_body_part.n.01 O
TGs POS_NNP O
become POS_VBD O
the POS_DT O
predominant POS_JJ O
source POS_NN O
of POS_IN O
energy POS_NN O
obtained POS_VBN O
from POS_IN O
fat POS_NN WORDNET_chemical.n.01 O

Although POS_IN O
it POS_PRP O
was POS_VBD O
many POS_JJ O
years POS_NNS O
before POS_IN O
it POS_PRP O
was POS_VBD O
fully POS_RB O
demonstrated POS_VBN O
, POS_, O
fat POS_EX WORDNET_chemical.n.01 O
is POS_VBZ O
now POS_RB O
known POS_VBN O
to POS_TO O
be POS_VB O
transported POS_VBN O
in POS_IN O
the POS_DT O
blood POS_NN MESH_TYPE_qualifier MESH_blood O
as POS_IN O
FFA POS_NNP O
bound POS_NN O
to POS_TO O
the POS_DT O
protein POS_NN WORDNET_chemical.n.01 O
carrier POS_NN WORDNET_chemical.n.01 O
albumin POS_NN WORDNET_chemical.n.01 O

The POS_DT O
recommendation POS_NN O
of POS_IN O
the POS_DT O
Japan POS_NNP O
Diabetes POS_NNP WORDNET_disease.n.01 O
Society POS_NNP O
to POS_TO O
measure POS_VB O
only POS_RB O
the POS_DT O
stable POS_JJ O
GHb POS_NNP O
component POS_NN O
and POS_CC O
to POS_TO O
correct POS_VB O
the POS_DT O
GHb POS_NNP O
percentage POS_NN O
by POS_IN O
two-point POS_JJ O
calibration POS_NN O
with POS_IN O
assigned POS_JJ O
values POS_NNS O
, POS_, O
was POS_VBD O
effective POS_JJ O
but POS_CC O
not POS_RB O
sufficient POS_JJ O

Some POS_DT O
alternative POS_JJ O
measurement POS_NN O
system POS_NN WORDNET_body_part.n.01 O
with POS_IN O
comparability POS_NN O
, POS_, O
commutability POS_NN O
and POS_CC O
precision POS_NN O
should POS_MD O
be POS_VB O
established POS_VBN O

Scientists POS_NNS O
at POS_IN O
major POS_JJ O
and POS_CC O
minor POS_JJ O
universities POS_NNS O
: POS_: O
a POS_DT O
study POS_NN O
of POS_IN O
productivity POS_NN O
and POS_CC O
recognition POS_NN O

A POS_DT O
comment POS_NN O
on POS_IN O
`` POS_`` O
anomy POS_NN O
'' POS_'' O

Potential POS_JJ O
ethological POS_JJ O
isolating POS_NN O
mechanisms POS_NNS O
and POS_CC O
assortative POS_JJ O
mating POS_NN O
in POS_IN O
the POS_DT O
domestic POS_JJ O
fowl POS_NN O

The POS_DT O
transport POS_NN O
of POS_IN O
prey POS_NN O
by POS_IN O
ants POS_NNS O

Courtship POS_NNP O
behaviour POS_NN O
in POS_IN O
the POS_DT O
Drosophila POS_NNP O
obscura POS_NN O
group POS_NN O

Vision POS_NNP O
versus POS_NN O
touch POS_NN O
in POS_IN O
form POS_NN O
discrimination POS_NN O

Persisting POS_VBG O
odours POS_PRP O
as POS_IN O
a POS_DT O
biasing POS_NN O
factor POS_NN O
in POS_IN O
open-field POS_JJ O
research POS_NN O
with POS_IN O
mice POS_NNS O

Review POS_NN O
and POS_CC O
personal POS_JJ O
cases POS_NNS O

Dextran POS_NNP O
of POS_IN O
low POS_JJ O
molecular POS_JJ O
weight POS_NN O
in POS_IN O
peripheral POS_JJ D
arterial POS_JJ D
insufficiency POS_NN D

On POS_IN O
the POS_DT O
significance POS_NN O
of POS_IN O
histologic POS_JJ O
findings POS_NNS MESH_TYPE_qualifier MESH_diagnosis O
in POS_IN O
neoplasms POS_NNS D
of POS_IN O
the POS_DT O
trophoblast POS_NN WORDNET_body_part.n.01 O
( POS_( O
case POS_NN O
contributions POS_NNS O
) POS_) O

Epidemiology POS_NN WORDNET_medicine.n.01 MESH_TYPE_qualifier MESH_epidemiology O
of POS_IN O
hypertension POS_NN D

The POS_DT O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
radioactive POS_JJ O
isotopes POS_NNS O
in POS_IN O
the POS_DT O
diagnosis POS_NN MESH_TYPE_qualifier MESH_diagnosis O
of POS_IN O
hypertension POS_NN D

The POS_DT O
angiogram POS_NN O
in POS_IN O
the POS_DT O
study POS_NN O
of POS_IN O
hypertension POS_NN D

Hepatocerebral POS_JJ D
degeneration POS_NN D
( POS_( D
portal POS_JJ D
systemic POS_JJ D
encephalopathy POS_NN D
) POS_) D

Conflict POS_NNP O
and POS_CC O
conditioned POS_VBD O
aversive POS_JJ O
stimuli POS_NNS O
in POS_IN O
the POS_DT O
development POS_NN MESH_TYPE_qualifier MESH_growth & development O
of POS_IN O
experimental POS_JJ O
neuroses POS_NNS O

Treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
a POS_DT D
disorder POS_NN D
of POS_IN D
perception POS_NN D
and POS_CC D
concept POS_NN D
formation POS_NN D
in POS_IN O
a POS_DT O
case POS_NN O
of POS_IN O
school POS_NN O
failure POS_NN O

Long POS_JJ O
term POS_NN O
results POS_NNS O
in POS_IN O
the POS_DT O
300 POS_CD O
most POS_JJS O
grave POS_VBP O
cases POS_NNS O
out POS_IN O
of POS_IN O
4000 POS_CD O
hyperthyroid POS_NN D
patients POS_NNS D
treated POS_VBN O
with POS_IN O
iodine POS_JJ T
I-131 POS_NNP T
at POS_IN O
the POS_DT O
center POS_NN WORDNET_body_part.n.01 O
of POS_IN O
Ancona POS_NNP O

Lymphatics POS_NNS O
of POS_IN O
the POS_DT O
mouth POS_NN WORDNET_body_part.n.01 O
and POS_CC O
neck POS_NN WORDNET_body_part.n.01 O

Skilled POS_JJ O
workers POS_NNS MESH_TYPE_qualifier MESH_manpower O
are POS_VBP O
vital POS_JJ O
to POS_TO O
maintenance POS_VB O
cost POS_NN MESH_TYPE_qualifier MESH_economics O
cuts POS_NNS O

Tumours POS_NNS D
of POS_IN O
the POS_DT O
uterus POS_NN WORDNET_body_part.n.01 O

Strucutre POS_NNP O
of POS_IN O
the POS_DT O
influenza POS_NN WORDNET_disease.n.01 D
virus POS_NN D

Treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
childhood POS_NN D
schizophrenia POS_NN D

The POS_DT O
metabolism POS_NN MESH_TYPE_qualifier MESH_metabolism O
of POS_IN O
intravenously POS_RB O
injected POS_VBN O
isotopic POS_NN O
cholic POS_JJ WORDNET_chemical.n.01 O
acid POS_NN WORDNET_chemical.n.01 O
in POS_IN O
Laennec POS_NNP D
's POS_POS D
cirrhosis POS_NN WORDNET_disease.n.01 D

The POS_DT O
effect POS_NN O
of POS_IN O
epinephrine POS_NN WORDNET_chemical.n.01 O
on POS_IN O
immunoreactive POS_JJ O
insulin POS_NN O
levels POS_NNS O
in POS_IN O
man POS_NN O

Etiology POS_NN MESH_TYPE_qualifier MESH_etiology O
and POS_CC O
incidence POS_NN MESH_TYPE_qualifier MESH_epidemiology O
of POS_IN O
renal POS_JJ D
stones POS_NNS D

Diagnosis POS_NN MESH_TYPE_qualifier MESH_diagnosis O
of POS_IN O
stone POS_NN D
disease POS_NN D

Surgical POS_JJ T
treatment POS_NN MESH_TYPE_qualifier MESH_therapy T
of POS_IN O
urinary POS_JJ D
stones POS_NNS D

Prevention POS_NN MESH_TYPE_qualifier MESH_prevention & control O
of POS_IN O
stone POS_NN D
formation POS_NN D

Effects POS_NNS O
of POS_IN O
tryptophan POS_JJ WORDNET_chemical.n.01 O
mustard POS_NN O
on POS_IN O
incorporation POS_NN MESH_TYPE_qualifier MESH_metabolism O
of POS_IN O
amino POS_JJ O
acids POS_NNS O
into POS_IN O
proteins POS_NNS O
in POS_IN O
tumor-bearing POS_JJ O
rats POS_NNS O

An POS_DT O
electron POS_NN O
microscope POS_NN O
study POS_NN O
of POS_IN O
plant POS_NN D
neoplasia POS_NN D
induced POS_VBN O
by POS_IN O
wound POS_JJ D
tumor POS_NN D
virus POS_NN D

Origin POS_NN O
of POS_IN O
milk POS_NN O
cholesterol POS_NN WORDNET_chemical.n.01 O
in POS_IN O
the POS_DT O
rat POS_NN O
: POS_: O
dietary POS_JJ O
versus POS_NN O
endogenous POS_JJ O
sources POS_NNS O

Studies POS_NNS O
in POS_IN O
infantile POS_JJ D
malnutrition POS_NN WORDNET_disease.n.01 D

Bony POS_NNP O
proliferation POS_NN O
of POS_IN O
neural POS_JJ O
arches POS_NNS O
with POS_IN O
cord POS_NN O
compression POS_NN O

`` POS_`` O
Return POS_VB O
the POS_DT O
joy POS_NN O
of POS_IN O
home POS_NN O
delivery POS_NN O
'' POS_'' O
with POS_IN O
fathers POS_NNS O
in POS_IN O
the POS_DT O
delivery POS_NN O
room POS_NN O

Doctors POS_NNS O
-- POS_: O
we POS_PRP O
need POS_VBP O
you POS_PRP O

Aromatization POS_NN O
of POS_IN O
7-alpha-hydroxydehydroepiandrosterone POS_CD O
and POS_CC O
of POS_IN O
its POS_PRP$ O
3-sulphate POS_JJ O
by POS_IN O
ovarian POS_JJ O
and POS_CC O
placental POS_JJ O
tissue POS_NN WORDNET_body_part.n.01 O
cultures POS_NNS O

Comparison POS_NNP O
of POS_IN O
neutral POS_JJ O
fat POS_NN WORDNET_chemical.n.01 O
and POS_CC O
free POS_JJ O
fatty POS_JJ O
acids POS_NNS O
in POS_IN O
high POS_JJ O
lipid-low POS_JJ O
carbohydrate POS_NN WORDNET_chemical.n.01 O
diets POS_NNS O
for POS_IN O
the POS_DT O
growing POS_VBG O
chicken POS_NN O

Breast POS_NNP WORDNET_body_part.n.01 O
engorgement POS_NN O
and POS_CC O
postpartum POS_NN D
fever POS_NN D

Evolution POS_NN O
of POS_IN O
a POS_DT O
placenta POS_NN WORDNET_body_part.n.01 O
circumvallata POS_NN O

On POS_IN O
the POS_DT O
influence POS_NN O
of POS_IN O
cytostatic POS_JJ O
agents POS_NNS O
and POS_CC O
immune POS_JJ O
bodies POS_NNS O
on POS_IN O
choriocarcinoma POS_NN O
cells POS_NNS O
in POS_IN O
tissue POS_NN WORDNET_body_part.n.01 O
culture POS_NN MESH_TYPE_qualifier MESH_ethnology O

Reconstructive POS_JJ O
tubal POS_NN T
surgery POS_NN MESH_TYPE_qualifier MESH_surgery T

II POS_NN O

3 POS_CD O

I POS_PRP O
. POS_. O
Effects POS_NNS O
of POS_IN O
radiation POS_NN WORDNET_body_part.n.01 O
on POS_IN O
physical POS_JJ O
and POS_CC O
chemical POS_JJ MESH_TYPE_qualifier MESH_chemistry O
properties POS_NNS MESH_TYPE_qualifier MESH_chemistry O
of POS_IN O
injection POS_NN WORDNET_treatment.n.01 O
needles POS_NNS O

Correlation POS_NN O
between POS_IN O
the POS_DT O
concentration POS_NN O
of POS_IN O
various POS_JJ O
kinds POS_NNS O
of POS_IN O
pollutants POS_NNS O
in POS_IN O
atmosphere POS_NN O
and POS_CC O
wind POS_VB O
direction POS_NN O
and POS_CC O
velocity POS_NN O
at POS_IN O
Kasumigaseki POS_NNP O
, POS_, O
central POS_JJ O
district POS_NN O
of POS_IN O
Tokyo POS_NNP O

Some POS_DT O
knowledges POS_NNS O
on POS_IN O
the POS_DT O
potency POS_NN O
of POS_IN O
heparin POS_JJ WORDNET_chemical.n.01 O
fractions POS_NNS O
obtained POS_VBN O
by POS_IN O
gel POS_JJ O
filtration POS_NN O

On POS_IN O
the POS_DT O
peripheral POS_JJ O
effects POS_NNS O
of POS_IN O
endotoxin POS_NN O
and POS_CC O
leucocyte POS_NN O
pyrogen POS_NN O
in POS_IN O
rabbit POS_NN O

Analysis POS_NN MESH_TYPE_qualifier MESH_analysis O
of POS_IN O
steroids POS_NNS O

3 POS_CD O

Colorimetric POS_NNP O
assay POS_NN MESH_TYPE_qualifier MESH_analysis O
of POS_IN O
thiomesterone POS_NN O

I POS_PRP O
. POS_. O
The POS_DT O
production POS_NN O
and POS_CC O
detection POS_NN O
of POS_IN O
anti-insulin POS_JJ O
serum POS_NN O
and POS_CC O
anti-guinea-pig POS_JJ O
globulin POS_NN WORDNET_chemical.n.01 O
rabbit POS_NN O
serum POS_NN O

Undergraduate POS_NNP O
research POS_NN O
assistants POS_NNS O
in POS_IN O
the POS_DT O
Faculty POS_NN O
of POS_IN O
Medicine POS_NNP O

Clinical POS_JJ O
physiopathology POS_NN MESH_TYPE_qualifier MESH_physiopathology O
of POS_IN O
the POS_DT O
patency POS_NN O
of POS_IN O
the POS_DT O
interatrial POS_JJ O
septum POS_NN WORDNET_body_part.n.01 O

Defects POS_NNS MESH_TYPE_qualifier MESH_abnormalities O
of POS_IN O
the POS_DT O
interventricular POS_JJ O
septum POS_NN WORDNET_body_part.n.01 O
not POS_RB O
associated POS_VBN O
with POS_IN O
other POS_JJ O
malformations POS_NNS MESH_TYPE_qualifier MESH_abnormalities O

Rhinitis POS_NN D
in POS_IN O
herds POS_NNS O
with POS_IN O
piglet POS_NN D
influenza POS_NN WORDNET_disease.n.01 D

Some POS_DT O
functional POS_JJ O
and POS_CC O
morphological POS_JJ O
alterations POS_NNS O
occurring POS_VBG O
during POS_IN O
and POS_CC O
after POS_IN O
the POS_DT O
adaptation POS_NN O
of POS_IN O
BHK POS_NNP O
21 POS_CD O
clone POS_NN O
13 POS_CD O
cells POS_NNS O
to POS_TO O
suspension POS_VB O
culture POS_NN MESH_TYPE_qualifier MESH_ethnology O

Technoogy POS_NNP O
, POS_, O
automation POS_NN O
and POS_CC O
human POS_JJ O
welfare POS_NN O

Differential POS_JJ O
expression POS_NN O
of POS_IN O
fibroblast POS_JJ O
growth POS_NN MESH_TYPE_qualifier MESH_growth & development O
factor-2 POS_JJ O
and POS_CC O
receptor POS_NN WORDNET_body_part.n.01 O
by POS_IN O
glial POS_JJ O
cells POS_NNS O
in POS_IN O
experimental POS_JJ O
autoimmune POS_NN D
encephalomelitis POS_NN D
( POS_( D
EAE POS_NNP D
) POS_) D

Increase POS_NN O
in POS_IN O
ambient POS_JJ O
temperature POS_NN O
may POS_MD O
explain POS_VB O
decrease POS_NN O
in POS_IN O
amniotic POS_JJ O
fluid POS_NN O
index POS_NN WORDNET_body_part.n.01 O

Thermal POS_JJ O
equipment POS_NN MESH_TYPE_qualifier MESH_instrumentation O
usage POS_NN O
patterns POS_NNS O
in POS_IN O
neonatal POS_JJ O
intensive POS_JJ WORDNET_treatment.n.01 O
care POS_NN WORDNET_treatment.n.01 O
units POS_NNS O
: POS_: O
interunit POS_NN O
variability POS_NN O
and POS_CC O
intraunit POS_NN O
consistency POS_NN O

Fetal POS_JJ O
breathing POS_NN O
movements POS_NNS O
within POS_IN O
24 POS_CD O
hours POS_NNS O
of POS_IN O
delivery POS_NN O
in POS_IN O
prematurity POS_NN O
are POS_VBP O
related POS_VBN O
to POS_TO O
histologic POS_VB O
and POS_CC O
clinical POS_JJ O
evidence POS_NN O
of POS_IN O
amnionitis POS_NN D

Technical POS_JJ O
Working POS_NNP O
Group POS_NNP O
, POS_, O
World POS_NNP O
Health POS_NNP O
Organization POS_NNP MESH_TYPE_qualifier MESH_organization & administration O

Epidurals POS_NNS T
and POS_CC O
breastfeeding POS_VBG O

Concerns POS_NNS O
about POS_IN O
the POS_DT O
institutionalization POS_NN O
of POS_IN O
childbirth POS_NN O
education POS_NN MESH_TYPE_qualifier MESH_education O

Quality POS_NNP O
framework POS_NN O
for POS_IN O
force POS_NN O
plate POS_NN WORDNET_body_part.n.01 O
testing POS_NN O

Treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
cavernous POS_JJ D
hemangiomas POS_NN D
with POS_IN O
the POS_DT O
neodymium POS_NN T
: POS_: T
YAG POS_NNP T
laser POS_NN T

Detection POS_NN O
of POS_IN O
differentially POS_RB O
expressed POS_VBN O
genes POS_NNS O
in POS_IN O
head-neck POS_NN D
carcinomas POS_NN D

Genomic POS_NNP O
medicine POS_NN O

A POS_DT O
position POS_NN O
paper POS_NN O
of POS_IN O
the POS_DT O
National POS_NNP O
Society POS_NNP O
of POS_IN O
Genetic POS_NNP O
Counselors POS_NNS O

> POS_NN O
From POS_IN O
the POS_DT O
Centers POS_NNPS O
for POS_IN O
Disease POS_NNP O
Control POS_NNP MESH_TYPE_qualifier MESH_prevention & control O
and POS_CC O
Prevention POS_NNP MESH_TYPE_qualifier MESH_prevention & control O

> POS_NN O
From POS_IN O
the POS_DT O
Centers POS_NNPS O
for POS_IN O
Disease POS_NNP O
Control POS_NNP MESH_TYPE_qualifier MESH_prevention & control O
and POS_CC O
Prevention POS_NNP MESH_TYPE_qualifier MESH_prevention & control O

Evidence POS_NN O
for POS_IN O
a POS_DT O
new POS_JJ O
locus POS_NN O
on POS_IN O
chromosome POS_NN O
12 POS_CD O

Characteristics POS_NNS O
of POS_IN O
prostate POS_NN WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D
in POS_IN O
families POS_NNS O
potentially POS_RB O
linked POS_VBN O
to POS_TO O
the POS_DT O
hereditary POS_JJ O
prostate POS_NN WORDNET_disease.n.01 O
cancer POS_NN WORDNET_disease.n.01 O
1 POS_CD O
( POS_( O
HPC1 POS_NNP O
) POS_) O
locus POS_NN O

Radiation POS_NNP WORDNET_body_part.n.01 O
dose POS_NN O
and POS_CC O
sarcoma POS_NN WORDNET_disease.n.01 O
risk POS_NN O

Homology POS_NNP O
modeling POS_NN O
of POS_IN O
adenylosuccinate POS_JJ O
synthetase POS_NN O
from POS_IN O
Saccharomyces POS_NNP O
cerevisiae POS_NN O
reveals POS_VBZ O
a POS_DT O
possible POS_JJ O
binding POS_NN O
region POS_NN O
for POS_IN O
single-stranded POS_JJ O
ARS POS_NNP O
sequences POS_NNS O

IV POS_NN O

The POS_DT O
search POS_NN O

1981 POS_CD O

Legislative POS_JJ O
and POS_CC O
legal POS_JJ O
vigilance POS_NN O

Osteopathic POS_NNP O
manifesto POS_NN O

VI POS_NN O

Electrophysiological POS_JJ O
evidence POS_NN O
on POS_IN O
the POS_DT O
time POS_NN O
course POS_NN O
of POS_IN O
semantic POS_JJ O
and POS_CC O
phonological POS_JJ O
processes POS_NNS O
in POS_IN O
speech POS_NN O
production POS_NN O

Investigation POS_NN O
of POS_IN O
uncertainties POS_NNS O
in POS_IN O
relaxation POS_NN O
analysis POS_NN MESH_TYPE_qualifier MESH_analysis O
of POS_IN O
2D POS_CD O
NOE POS_NNP O
which POS_WDT O
arise POS_VBP O
from POS_IN O
spectral POS_JJ O
noise POS_NN O

IX POS_NN O

1981 POS_CD O

The POS_DT O
practical POS_JJ O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
PCR POS_NNP O
for POS_IN O
rapid POS_JJ O
detection POS_NN O
of POS_IN O
methicillin POS_JJ T
resistance POS_NN O
among POS_IN O
staphylococcal POS_JJ O
clinical POS_JJ O
isolates POS_NNS O
from POS_IN O
Turkish POS_JJ O
hospitals POS_NNS O

Randomised POS_VBN O
trial POS_NN O
of POS_IN O
roxithromycin POS_NN T
in POS_IN O
non-Q-wave POS_JJ D
coronary POS_JJ D
syndromes POS_NNS D
: POS_: O
ROXIS POS_NNP O
Pilot POS_NNP O
Study POS_NNP O

Association POS_NNP O
between POS_IN O
5-HT2A POS_JJ O
gene POS_NN O
promoter POS_NN O
polymorphism POS_NN O
and POS_CC O
anorexia POS_NN D
nervosa POS_NN D

Randomised POS_VBN O
study POS_NN O
of POS_IN O
radical POS_JJ T
surgery POS_NN MESH_TYPE_qualifier MESH_surgery T
versus POS_NN T
radiotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_radiotherapy T
for POS_IN O
stage POS_NN D
Ib-IIa POS_JJ D
cervical POS_JJ D
cancer POS_NN WORDNET_disease.n.01 D

State POS_NN O
regulation POS_NN O
in POS_IN O
a POS_DT O
world POS_NN O
of POS_IN O
`` POS_`` O
boundary-less POS_JJ O
'' POS_'' O
technology POS_NN O

Screening POS_VBG MESH_TYPE_qualifier MESH_diagnosis O
for POS_IN O
Chlamydia POS_NNP WORDNET_disease.n.01 D
trachomatis POS_NN D
? POS_. O

Common POS_JJ O
nutritional POS_JJ O
issues POS_NNS O
in POS_IN O
pediatric POS_JJ O
and POS_CC O
adult POS_JJ O
critical POS_JJ O
care POS_NN O
medicine POS_NN O

Clinical POS_JJ O
problem-solving POS_NN O
-- POS_: O
where POS_WRB O
did POS_VBD O
good POS_JJ O
old POS_JJ O
clinical POS_JJ O
diagnosis POS_NN MESH_TYPE_qualifier MESH_diagnosis O
go POS_VB O
? POS_. O

Heterologous POS_JJ O
vaccines POS_NNS T
: POS_: O
proponent POS_NN O
sparks POS_VBZ O
some POS_DT O
interest POS_NN O

Patient-centered POS_JJ O
ethics POS_NNS MESH_TYPE_qualifier MESH_ethics O
reclaiming POS_VBG O
center POS_NN WORDNET_body_part.n.01 O
stage POS_NN O

Connecting POS_VBG O
peptide POS_NN WORDNET_chemical.n.01 O
, POS_, O
correcting POS_VBG O
peptide POS_NN WORDNET_chemical.n.01 O
? POS_. O

Classification POS_NN MESH_TYPE_qualifier MESH_classification O
of POS_IN O
malignant POS_JJ D
lymphomas POS_NN D
: POS_: O
the POS_DT O
updated POS_JJ O
Kiel POS_NNP O
classification POS_NN MESH_TYPE_qualifier MESH_classification O

The POS_DT O
case POS_NN O
of POS_IN O
the POS_DT O
missing POS_VBG O
methylphenidate POS_NN T

< POS_JJ O
TO_SEE POS_NNP O
> POS_NNP O
Intensive POS_NNP T
insulin POS_NN T
treatment POS_NN MESH_TYPE_qualifier MESH_therapy T
after POS_IN O
acute POS_JJ D
myocardial POS_JJ D
infarction POS_NN D
in POS_IN O
diabetes POS_NNS WORDNET_disease.n.01 D
mellitus POS_VBP WORDNET_disease.n.01 D

Intensive POS_JJ O
insulin POS_NN O
regimens POS_NNS O
in POS_IN O
primary POS_JJ O
prevention POS_NN MESH_TYPE_qualifier MESH_prevention & control O
should POS_MD O
be POS_VB O
assessed POS_VBN O

Research POS_NN O
into POS_IN O
long POS_JJ O
term POS_NN O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
is POS_VBZ O
needed POS_VBN O

Search POS_NN O
for POS_IN O
studies POS_NNS O
was POS_VBD O
limited POS_JJ O

System POS_NNP WORDNET_body_part.n.01 O
acknowledging POS_VBG O
roles POS_NNS O
of POS_IN O
contributors POS_NNS O
is POS_VBZ O
best POS_JJS O

Producing POS_VBG O
consistent POS_JJ O
estimates POS_NNS O
of POS_IN O
the POS_DT O
power POS_NN O
spectral POS_JJ O
density POS_NN O
of POS_IN O
NN POS_NNP O
sequences POS_NNS O

The POS_DT O
pruning POS_NN O
of POS_IN O
Doctor POS_NNP O
McDonough POS_NNP O
and POS_CC O
the POS_DT O
`` POS_`` O
humanizing POS_NN O
'' POS_'' O
of POS_IN O
statistics POS_NNS O

Extracorporeal POS_JJ O
photopheresis POS_NN O
in POS_IN O
S POS_NNP O
( POS_( O
c POS_NN O
) POS_) O
zary POS_VBZ O
syndrome POS_NN O

Attacks POS_NNS O
on POS_IN O
tobacco POS_NN O
industry POS_NN O

Does POS_NNP O
blinding POS_NN O
of POS_IN O
readers POS_NNS O
affect POS_VBP O
results POS_NNS O
of POS_IN O
meta-analyses POS_NNS O
? POS_. O

Cyclosporiasis POS_NN D
and POS_CC O
raspberries POS_NNS O

Protean POS_JJ O
agonists POS_NNS MESH_TYPE_qualifier MESH_agonists O

Keys POS_NNS O
to POS_TO O
receptor POS_VB WORDNET_body_part.n.01 O
active POS_JJ O
states POS_NNS O
? POS_. O

Verona POS_NNP O
, POS_, O
Italy POS_NNP O
, POS_, O
September POS_NNP O
21-22 POS_CD O
, POS_, O
1995 POS_CD O

The POS_DT O
US POS_NNP O
attack POS_NN O
on POS_IN O
Cuba POS_NNP O
's POS_POS O
health POS_NN O

Battling POS_VBG O
HI POS_NNP D
on POS_IN O
many POS_JJ O
fronts POS_NNS O

Medical POS_JJ O
Injury POS_NNP O
Compensation POS_NNP O
Reform POS_NNP O
Act POS_NNP O
: POS_: O
good POS_JJ O
or POS_CC O
bad POS_JJ O
? POS_. O

Moxonidine POS_NNP T
for POS_IN O
hypertension POS_NN D

Assessment POS_NN O
of POS_IN O
fetal POS_JJ O
nuchal POS_JJ O
translucency POS_NN O
test POS_NN O
for POS_IN O
Down POS_NNP D
's POS_POS D
syndrome POS_NN D

Addressing POS_VBG O
needle-stick POS_JJ O
concerns POS_NNS O

Patient POS_JJ O
consent POS_NN O
for POS_IN O
publication POS_NN O

Meta-analyses POS_NNS O
and POS_CC O
large POS_JJ O
randomized POS_VBN O
, POS_, O
controlled POS_VBN O
trials POS_NNS O

Are POS_NNP O
normal POS_JJ O
hearing POS_VBG O
thresholds POS_NNS O
a POS_DT O
sufficient POS_JJ O
condition POS_NN O
for POS_IN O
click-evoked POS_JJ O
otoacoustic POS_JJ O
emissions POS_NNS O
? POS_. O

ATP-dependent POS_JJ O
transport POS_NN O
of POS_IN O
lipophilic POS_JJ O
cytotoxic POS_NN O
drugs POS_NNS O
by POS_IN O
membrane POS_NN WORDNET_body_part.n.01 O
vesicles POS_NNS O
prepared POS_VBN O
from POS_IN O
MRP-overexpressing POS_NNP O
HL60/ADR POS_NNP O
cells POS_NNS O

Cellular POS_JJ O
and POS_CC O
in POS_IN O
vitro POS_JJ O
transport POS_NN O
of POS_IN O
glutathione POS_NN O
conjugates POS_NNS O
by POS_IN O
MRP POS_NNP O

Infection POS_NNP O
control POS_NN MESH_TYPE_qualifier MESH_prevention & control O
and POS_CC O
contaminated POS_VBN O
waste POS_NN O
disposal POS_NN O
practices POS_NNS O
in POS_IN O
Southern POS_NNP O
Sydney POS_NNP O
Area POS_NNP WORDNET_body_part.n.01 O
Health POS_NNP O
Service POS_NNP O
Dental POS_NNP O
Clinics POS_NNP O

Vitamins POS_NNS O
and POS_CC O
minerals POS_NNS O
: POS_: O
efficacy POS_NN O
and POS_CC O
safety POS_NN O

Mental POS_NNP O
health POS_NN O
and POS_CC O
the POS_DT O
law POS_NN O

Female POS_NNP O
embryonic POS_JJ O
lethality POS_NN O
in POS_IN O
mice POS_NNS O
nullizygous POS_JJ O
for POS_IN O
both POS_DT O
Msh2 POS_NNP O
and POS_CC O
p53 POS_NN O

A POS_DT O
randomized POS_VBN O
controlled POS_VBN O
trial POS_NN O

Atrial POS_JJ D
fibrillation POS_NN D
begets POS_NNS O
trouble POS_NN O

The POS_DT O
ethics POS_NNS MESH_TYPE_qualifier MESH_ethics O
industry POS_NN O

Structure-activity POS_NN O
and POS_CC O
mechanism POS_NN O
studies POS_NNS O
on POS_IN O
silicon POS_NN O
phthalocyanines POS_NNS O
with POS_IN O
Plasmodium POS_NNP O
falciparum POS_NN O
in POS_IN O
the POS_DT O
dark POS_NN O
and POS_CC O
under POS_IN O
red POS_JJ O
light POS_NN O

Research POS_NN O
in POS_IN O
Copenhagen POS_NNP O
hospitals POS_NNS O
-- POS_: O
a POS_DT O
bibliometric POS_JJ O
evaluation POS_NN O

More POS_RBR O
on POS_IN O
infertility POS_NN D

Mutual POS_JJ O
relationships POS_NNS O
based POS_VBN O
on POS_IN O
equality POS_NN O

Taking POS_VBG O
issue POS_NN O
with POS_IN O
UK POS_NNP O
funding POS_NN MESH_TYPE_qualifier MESH_economics O
priorities POS_NNS O

Female POS_NNP O
genital POS_JJ O
mutilation POS_NN O
: POS_: O
a POS_DT O
contemporary POS_JJ O
issue POS_NN O
, POS_, O
and POS_CC O
a POS_DT O
Victorian POS_JJ O
obsession POS_NN O

Serotonin POS_NNP WORDNET_chemical.n.01 O
as POS_IN O
a POS_DT O
regulator POS_NN O
of POS_IN O
hypothalamic-pituitary-interrenal POS_JJ O
activity POS_NN O
in POS_IN O
teleost POS_NN O
fish POS_NN O

A POS_DT O
drop POS_NN O
in POS_IN O
pediatric POS_JJ O
subject POS_JJ O
examination POS_NN O
scores POS_NNS O
after POS_IN O
curriculum POS_NN MESH_TYPE_qualifier MESH_education O
changes POS_NNS O
that POS_WDT O
emphasize POS_VBP O
general POS_JJ O
pediatric POS_NN O
topics POS_NNS O

The POS_DT O
diabetes POS_NNS WORDNET_disease.n.01 D
audit POS_NN O
and POS_CC O
research POS_NN O
in POS_IN O
Tayside POS_NNP O
Scotland POS_NNP O
( POS_( O
DARTS POS_NNP O
) POS_) O
study POS_NN O
: POS_: O
electronic POS_JJ O
record POS_NN O
linkage POS_NN O
to POS_TO O
create POS_VB O
a POS_DT O
diabetes POS_NNS WORDNET_disease.n.01 O
register POS_NN O

Should POS_MD O
we POS_PRP O
screen POS_VB O
for POS_IN O
gestational POS_JJ D
diabetes POS_NNS WORDNET_disease.n.01 D
? POS_. O

Practice POS_NNP O
parameters POS_NNS O
for POS_IN O
the POS_DT O
assessment POS_NN O
and POS_CC O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
children POS_NNS O
and POS_CC O
adolescents POS_NNS O
with POS_IN O
schizophrenia POS_NN D

Practice POS_NNP O
parameters POS_NNS O
for POS_IN O
the POS_DT O
psychiatric POS_JJ O
assessment POS_NN O
of POS_IN O
children POS_NNS O
and POS_CC O
adolescents POS_NNS O

Adequacy POS_NN O
of POS_IN O
SMAC POS_NNP O
's POS_POS O
statement POS_NN O
should POS_MD O
be POS_VB O
judged POS_VBN O
by POS_IN O
clinicians POS_NNS O
, POS_, O
not POS_RB O
health POS_NN O
economists POS_NNS O

Pure POS_NNP D
alexia POS_NN D
could POS_MD O
not POS_RB O
be POS_VB O
a POS_DT O
disconnection POS_NN O
syndrome POS_NN O

Case POS_NNP O
records POS_NNS O
of POS_IN O
the POS_DT O
Massachusetts POS_NNP O
General POS_NNP O
Hospital POS_NNP O

Pediatric POS_NNP D
cervical POS_JJ D
spine POS_NN WORDNET_body_part.n.01 D
injury POS_NN D
sustained POS_VBN O
in POS_IN O
falls POS_NNS O
from POS_IN O
low POS_JJ O
heights POS_NNS O

EU POS_NNP O
directive POS_NN O
on POS_IN O
bovine POS_NN D
spongiform POS_NN D
encephalopathy POS_NN D
will POS_MD O
not POS_RB O
affect POS_VB O
drugs POS_NNS O

Who POS_WP O
should POS_MD O
care POS_VB O
? POS_. O

Automation POS_NN O
in POS_IN O
cervical POS_JJ O
cytology POS_NN MESH_TYPE_qualifier MESH_cytology O
: POS_: O
whose POS_WP$ O
cost POS_NN MESH_TYPE_qualifier MESH_economics O
and POS_CC O
whose POS_WP$ O
benefit POS_NN O
? POS_. O

Losing POS_VBG O
weight POS_NN O
-- POS_: O
an POS_DT O
ill-fated POS_JJ O
New POS_NNP O
Year POS_NNP O
's POS_POS O
resolution POS_NN O

Randomised POS_VBN O
controlled POS_JJ O
trial POS_NN O
of POS_IN O
magnetic-resonance POS_NN T
pelvimetry POS_NN T
in POS_IN O
breech POS_JJ D
presentation POS_NN D
at POS_IN D
term POS_NN D

Lung POS_NNP WORDNET_body_part.n.01 WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D
, POS_, O
tobacco POS_NN O
smoking POS_NN O
and POS_CC O
environmental POS_JJ O
factors POS_NNS O
in POS_IN O
Denmark POS_NNP O

Anesthesiology POS_NN WORDNET_medicine.n.01 O

Systematic POS_JJ O
review POS_NN O
of POS_IN O
prophylactic POS_JJ O
vs POS_NN O
rescue POS_NN O
surfactant POS_NN O

schizophrenia POS_NN D
as POS_IN O
failure POS_NN O
of POS_IN O
hemispheric POS_JJ O
dominance POS_NN O
for POS_IN O
language POS_NN O

Diabetic POS_NNP WORDNET_disease.n.01 O
retinopathy POS_NN WORDNET_disease.n.01 O
, POS_, O
promoter POS_NN O
( POS_( O
4G/5G POS_CD O
) POS_) O
polymorphism POS_NN O
of POS_IN O
PAI-1 POS_NNP O
gene POS_NN O
, POS_, O
and POS_CC O
PAI-1 POS_NNP O
activity POS_NN O
in POS_IN O
Pima POS_NNP O
Indians POS_NNPS O
with POS_IN O
type POS_JJ O
2 POS_CD O
diabetes POS_NNS WORDNET_disease.n.01 D

A POS_DT O
randomised POS_JJ O
comparison POS_NN O
of POS_IN O
the POS_DT O
EuroQol POS_NNP O
and POS_CC O
Short POS_NNP O
Form-36 POS_NNP O
after POS_IN O
stroke POS_NN D

HIV POS_NNP O
and POS_CC O
AIDS POS_NNP WORDNET_disease.n.01 D
awareness POS_NN O
: POS_: O
an POS_DT O
evaluation POS_NN O
of POS_IN O
a POS_DT O
short POS_JJ O
training POS_NN MESH_TYPE_qualifier MESH_education O
programme POS_NN O
for POS_IN O
midwives POS_NNS O

Double-blind POS_NNP O
study POS_NN O
of POS_IN O
pulsing POS_VBG T
magnetic POS_JJ T
field POS_NN T
effects POS_NNS O
on POS_IN O
multiple POS_JJ WORDNET_disease.n.01 D
sclerosis POS_NN WORDNET_disease.n.01 D
. POS_. O

CDA POS_NNP O
opposes POS_NNS O
proposed POS_VBD O
HBV POS_NNP O
recommendations POS_NNS O

Clinical POS_JJ O
problem-solving POS_NN O

A POS_DT O
comparison POS_NN O
of POS_IN O
the POS_DT O
early POS_JJ O
outcome POS_NN O
of POS_IN O
acute POS_JJ O
myocardial POS_JJ D
infarction POS_NN D
in POS_IN O
women POS_NNS O
and POS_CC O
men POS_NNS O

Removal POS_NN O
of POS_IN O
a POS_DT O
broken POS_JJ O
solid-core POS_NN O
intramedullary POS_JJ O
femoral POS_JJ O
nail POS_NN WORDNET_body_part.n.01 O
using POS_VBG O
both POS_DT O
antegrade POS_NN O
and POS_CC O
retrograde POS_VB O
starting POS_VBG O
points POS_NNS O

Do POS_VB O
no POS_DT O
harm POS_NN O

Thalidomide POS_NNP T
, POS_, O
laser POS_NN O
cavity POS_NN WORDNET_body_part.n.01 O
preparation POS_NN O
and POS_CC O
oral POS_JJ O
hydrogen POS_NN O
peroxide POS_NN WORDNET_chemical.n.01 O

First POS_RB O
the POS_DT O
bad POS_JJ O
news POS_NN O
... POS_: O

Does POS_NNP O
hyperglycemia POS_VBD D
really POS_RB O
cause POS_JJ O
coronary POS_JJ D
heart POS_NN WORDNET_body_part.n.01 D
disease POS_NN D
? POS_. O

Consensus POS_NN O
of POS_IN O
the POS_DT O
Surgical POS_NNP O
Working POS_NNP O
Group POS_NNP O
for POS_IN O
Oncology POS_NNP WORDNET_medicine.n.01 O
, POS_, O
the POS_DT O
Working POS_NNP O
Group POS_NNP O
for POS_IN O
Medical POS_NNP O
Oncology POS_NNP WORDNET_medicine.n.01 O
and POS_CC O
the POS_DT O
Working POS_NNP O
Group POS_NNP O
for POS_IN O
Radiologic POS_NNP O
Oncology POS_NNP WORDNET_medicine.n.01 O

A POS_DT O
case-control POS_NN O
study POS_NN O
of POS_IN O
cytochrome POS_JJ WORDNET_chemical.n.01 O
P450 POS_NNP O
1A1 POS_CD O
, POS_, O
glutathione POS_CD O
S-transferase POS_JJ O
M1 POS_NNP O
, POS_, O
cigarette POS_NN O
smoking POS_NN O
and POS_CC O
lung POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 O
cancer POS_NN WORDNET_disease.n.01 O
susceptibility POS_NN O
( POS_( O
Massachusetts POS_NNP O
, POS_, O
United POS_NNP O
States POS_NNPS O
) POS_) O

Fulminant POS_NNP O
hepatic POS_JJ D
failure POS_NN D
in POS_IN O
murine POS_NN D
hepatitis POS_NN WORDNET_disease.n.01 D
virus POS_NN D
strain POS_VBP D
3 POS_CD D
infection POS_NN D
: POS_: O
tissue-specific POS_JJ O
expression POS_NN O
of POS_IN O
a POS_DT O
novel POS_JJ O
fgl2 POS_NN O
prothrombinase POS_NN WORDNET_chemical.n.01 O

Implementation POS_NN O
of POS_IN O
pharmaceutical POS_JJ O
practice POS_NN O
guidelines POS_NNS MESH_TYPE_qualifier MESH_standards O

Predicting POS_VBG O
changes POS_NNS O
in POS_IN O
the POS_DT O
distribution POS_NN MESH_TYPE_qualifier MESH_supply & distribution O
of POS_IN O
sweating POS_VBG D
following POS_VBG O
thoracoscopic POS_JJ T
sympathectomy POS_NN T
. POS_. O

Human POS_NNP O
fetal POS_JJ O
pituitary POS_JJ WORDNET_body_part.n.01 O
expresses POS_NNS O
functional POS_JJ O
growth POS_NN MESH_TYPE_qualifier MESH_growth & development O
hormone-releasing POS_JJ O
peptide POS_NN WORDNET_chemical.n.01 O
receptors POS_NNS O

Leaders POS_NNS O
or POS_CC O
lemmings POS_NNS O
? POS_. O

Shark POS_NNP T
cartilage POS_NN WORDNET_body_part.n.01 T
for POS_IN O
cancer POS_NN WORDNET_disease.n.01 D
? POS_. O

Photorepair POS_NNP O
mutants POS_NNS O
of POS_IN O
Arabidopsis POS_NN O

Toxic POS_NNP D
shock POS_NN D
syndrome POS_NN D
without POS_IN O
rash POS_NN D
in POS_IN O
a POS_DT O
young POS_JJ O
child POS_NN O
: POS_: O
link POS_NN O
with POS_IN O
syndrome POS_NN O
of POS_IN O
hemorrhagic POS_NN D
shock POS_NN D
and POS_CC O
encephalopathy POS_NN D
? POS_. O

Fibromyalgia POS_NN D
: POS_: O
La POS_NNP O
Maladie POS_NNP O
est POS_JJS O
Morte POS_NN O

Testicular POS_JJ T
sperm POS_NN T
retrieval POS_NN T
by POS_IN T
percutaneous POS_JJ T
fine POS_JJ T
needle POS_JJ T
sperm POS_NN T
aspiration POS_NN T
compared POS_VBN O
with POS_IN O
testicular POS_JJ T
sperm POS_NNS T
extraction POS_NN T
by POS_IN T
open POS_JJ T
biopsy POS_NN MESH_TYPE_qualifier MESH_pathology T
in POS_IN O
men POS_NNS O
with POS_IN O
non-obstructive POS_JJ D
azoospermia POS_NN D

Ion POS_NNP O
channels POS_NNS O

Analgesic POS_NNP D
nephropathy POS_NN D

Factors POS_NNS O
affecting POS_VBG O
uptake POS_NN O
of POS_IN O
antenatal POS_JJ O
HIV POS_NNP O
testing POS_NN O
in POS_IN O
London POS_NNP O
: POS_: O
results POS_NNS O
of POS_IN O
a POS_DT O
multicentre POS_NN O
study POS_NN O

Patterning POS_VBG O
of POS_IN O
immobilized POS_VBN O
antibody POS_NN WORDNET_chemical.n.01 O
layers POS_NNS O
via POS_IN O
photolithography POS_NN O
and POS_CC O
oxygen POS_NN O
plasma POS_NN O
exposure POS_NN O

Evanescent POS_JJ O
wave POS_NN O
fibre POS_VBN O
optic POS_JJ O
sensor POS_NN O
for POS_IN O
detection POS_NN O
of POS_IN O
L. POS_NNP O
donovani POS_NNP O
specific POS_JJ O
antibodies POS_NNS O
in POS_IN O
sera POS_NN O
of POS_IN O
kala POS_NN O
azar POS_NN O
patients POS_NNS O

Multianalyte POS_NNP O
biosensors POS_NNS O
on POS_IN O
optical POS_JJ O
imaging POS_NN O
bundles POS_NNS O

Cytoplasmic POS_NNP O
transport POS_NN O
in POS_IN O
Drosophila POS_NNP O
ovarian POS_JJ O
follicles POS_NNS O
: POS_: O
the POS_DT O
migration POS_NN O
of POS_IN O
microinjected POS_JJ O
fluorescent POS_NN O
probes POS_NNS O
through POS_IN O
intercellular POS_JJ O
bridges POS_NNS O
depends POS_VBZ O
neither POS_DT O
on POS_IN O
electrical POS_JJ O
charge POS_NN WORDNET_chemical.n.01 O
nor POS_CC O
on POS_IN O
external POS_JJ O
osmolarity POS_NN O

Zoonotic POS_JJ O
and POS_CC O
viral POS_JJ D
infection POS_NN D
in POS_IN O
fetal POS_JJ O
loss POS_NN O
after POS_IN O
12 POS_CD O
weeks POS_NNS O

An POS_DT O
informational POS_JJ O
note POS_NN O

Hazards POS_NNS O
of POS_IN O
running POS_VBG O
a POS_DT O
marathon POS_NN O

19 POS_CD O
September POS_NNP O
1996 POS_CD O

The POS_DT O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
implantable POS_JJ O
venous POS_JJ O
access POS_NN O
devices POS_NNS MESH_TYPE_qualifier MESH_instrumentation O
( POS_( O
IVADs POS_NNP O
) POS_) O
in POS_IN O
children POS_NNS O
with POS_IN O
hemophilia POS_NN D

Nephrotic POS_JJ D
syndrome POS_NN D
associated POS_VBN O
with POS_IN O
hypocomplementemia POS_NN D
in POS_IN O
a POS_DT O
4-year-old POS_JJ O
boy POS_NN O
with POS_IN O
hemophilia POS_NN D
B POS_NNP D

Growth POS_NNP MESH_TYPE_qualifier MESH_growth & development O
hormone POS_CD O
secretion POS_NN MESH_TYPE_qualifier MESH_secretion O
in POS_IN O
HIV-positive POS_JJ O
versus POS_NN O
HIV-negative POS_NNP O
hemophilic POS_NN O
males POS_NNS O
with POS_IN O
abnormal POS_JJ O
growth POS_NN MESH_TYPE_qualifier MESH_growth & development O
and POS_CC O
pubertal POS_NN O
development POS_NN MESH_TYPE_qualifier MESH_growth & development O

Angiogenesis POS_NN O
in POS_IN O
inflammatory POS_JJ WORDNET_disease.n.01 D
disease POS_NN WORDNET_disease.n.01 D

Malignancies POS_NNS O

Current POS_JJ O
progress POS_NN O
in POS_IN O
early POS_JJ O
pregnancy POS_NN O
investigation POS_NN O

hordei POS_JJ O
glyceraldehyde-3-phosphate POS_JJ O
dehydrogenase POS_NN O
gene POS_NN O

Neuropeptides POS_NNS O
in POS_IN O
Development POS_NNP MESH_TYPE_qualifier MESH_growth & development O
and POS_CC O
Aging POS_NNP O

Proceedings POS_NNS O
of POS_IN O
a POS_DT O
conference POS_NN O

Proceedings POS_NNS O
of POS_IN O
a POS_DT O
conference POS_NN O

Psychobiology POS_NN O
of POS_IN O
Postraumatic POS_NNP D
Stress POS_NNP D
Disorder POS_NNP D

Adolescent POS_NNP O
Gynecology POS_NNP WORDNET_medicine.n.01 O
and POS_CC O
Endocrinology POS_NNP WORDNET_medicine.n.01 O
: POS_: O
Basic POS_JJ O
and POS_CC O
Clinical POS_JJ O
Aspects POS_NNS O

Drug POS_NN O
resistance POS_NN O
during POS_IN O
indinavir POS_JJ T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
is POS_VBZ O
caused POS_VBN O
by POS_IN O
mutations POS_NNS O
in POS_IN O
the POS_DT O
protease POS_NN WORDNET_chemical.n.01 O
gene POS_NN O
and POS_CC O
in POS_IN O
its POS_PRP$ O
Gag POS_NNP O
substrate POS_NN O
cleavage POS_NN WORDNET_body_part.n.01 O
sites POS_NNS O

A POS_DT O
protein POS_NN WORDNET_chemical.n.01 O
with POS_IN O
a POS_DT O
novel POS_JJ O
calcium-binding POS_NN O
domain POS_NN O
associated POS_VBN O
with POS_IN O
calcareous POS_JJ O
corpuscles POS_NNS O
in POS_IN O
Echinococcus POS_NNP D
granulosus POS_NN D

Meis2 POS_NNP O
, POS_, O
a POS_DT O
novel POS_JJ O
mouse POS_NN O
Pbx-related POS_NNP O
homeobox POS_NN O
gene POS_NN O
induced POS_VBN O
by POS_IN O
retinoic POS_JJ O
acid POS_NN WORDNET_chemical.n.01 O
during POS_IN O
differentiation POS_NN O
of POS_IN O
P19 POS_NNP O
embryonal POS_JJ WORDNET_disease.n.01 O
carcinoma POS_NN WORDNET_disease.n.01 O
cells POS_NNS O

Xenopus POS_JJ O
Pax-2 POS_NNP O
displays POS_NNS O
multiple POS_JJ O
splice POS_NN O
forms POS_NNS O
during POS_IN O
embryogenesis POS_NN O
and POS_CC O
pronephric POS_JJ O
kidney POS_NN WORDNET_body_part.n.01 O
development POS_NN MESH_TYPE_qualifier MESH_growth & development O

International POS_NNP O
Workshop POS_NNP O
on POS_IN O
Bone POS_NNP WORDNET_body_part.n.01 O
Research POS_NNP O
in POS_IN O
Space POS_NNP O

Proceedings POS_NNS O

Joint POS_JJ WORDNET_body_part.n.01 O
meeting POS_NN O
of POS_IN O
the POS_DT O
Benelux POS_NNP O
Society POS_NNP O
for POS_IN O
Microcirculation POS_NNP O
and POS_CC O
the POS_DT O
Gesellschaft POS_NNP O
f1/4r POS_NN O
Mikrozirkulation POS_NNP O
e.V POS_NN O

Mainz POS_NNP O
, POS_, O
Germany POS_NNP O
, POS_, O
October POS_NNP O
23-25 POS_CD O
, POS_, O
1997 POS_CD O

3rd POS_CD O
Congress POS_NNP O
of POS_IN O
the POS_DT O
French POS_JJ O
Society POS_NNP O
of POS_IN O
Blood POS_NNP MESH_TYPE_qualifier MESH_blood T
Transfusion POS_NNP T

Marseille POS_NNP O
, POS_, O
France POS_NNP O
, POS_, O
28-30 POS_JJ O
April POS_NNP O
1998 POS_CD O

Rapallo POS_NNP O
, POS_, O
Italy POS_NNP O
, POS_, O
14-15 POS_CD O
March POS_NNP O
1997 POS_CD O

New POS_NNP O
names POS_NNS O

Nagrestipen POS_VB O

The POS_DT O
Seventh POS_NNP O
International POS_NNP O
Meeting POS_NNP O
on POS_IN O
Ciliate POS_NNP O
Molecular POS_NNP O
Biology POS_NNP O
Genetics POS_NNP MESH_TYPE_qualifier MESH_genetics O
Nomenclature POS_NN O

Joint POS_JJ WORDNET_body_part.n.01 O
annual POS_JJ O
session POS_NN O
of POS_IN O
the POS_DT O
North POS_JJ O
German POS_JJ O
Society POS_NN O
of POS_IN O
Radiology POS_NNP O
and POS_CC O
the POS_DT O
Radiology POS_NNP O
Society POS_NNP O
of POS_IN O
Lower POS_NNP O
Saxony POS_NNP O
and POS_CC O
Sachsen POS_NNP O
Anhalt POS_NNP O

Neurone POS_NNP O
development POS_NN MESH_TYPE_qualifier MESH_growth & development O
and POS_CC O
death POS_NN O
, POS_, O
from POS_IN O
a POS_DT O
cell POS_NN O
biologist POS_NN O
's POS_POS O
perspective POS_NN O

Bethesda POS_NNP O
, POS_, O
Maryland POS_NNP O
, POS_, O
USA POS_NNP O

Strasbourg POS_NNP O
, POS_, O
France POS_NNP O
, POS_, O
3-6 POS_JJ O
September POS_NNP O
1997 POS_CD O

Copenhagen POS_NN O
, POS_, O
23-26 POS_JJ O
October POS_NNP O
1997 POS_CD O

December POS_NNP O
5 POS_CD O
, POS_, O
1997 POS_CD O

Onset POS_NNP O
of POS_IN O
the POS_DT O
preovulatory POS_NN O
luteinizing POS_VBG O
hormone POS_NN O
surge POS_NN O
: POS_: O
diurnal POS_JJ O
timing POS_NN O
and POS_CC O
critical POS_JJ O
follicular POS_NN O
prerequisites POS_NNS O

Brandon/Hill POS_NNP O
selected POS_VBD O
list POS_NN O
of POS_IN O
nursing POS_NN MESH_TYPE_qualifier MESH_nursing O
books POS_NNS O
and POS_CC O
journals POS_NNS O

Retraction POS_NN O

Influence POS_NN O
of POS_IN O
environmental POS_JJ O
factors POS_NNS O
on POS_IN O
fertility POS_NN O
: POS_: O
example POS_NN O
of POS_IN O
the POS_DT O
diminution POS_NN O
of POS_IN O
sperm POS_JJ O
quality POS_NN O

Prevention POS_NN MESH_TYPE_qualifier MESH_prevention & control O
of POS_IN O
ankle POS_NN WORDNET_body_part.n.01 D
injuries POS_NNS MESH_TYPE_qualifier MESH_injuries D

Factor POS_NNP D
VII POS_NNP D
deficiency POS_NN MESH_TYPE_qualifier MESH_deficiency D

Surgical POS_JJ O
aspects POS_NNS O
in POS_IN O
the POS_DT O
multidisciplinary POS_JJ O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
soft POS_JJ D
tissue POS_NN WORDNET_body_part.n.01 D
sarcomas POS_NN D

Radiotherapy POS_NNP WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_radiotherapy T
of POS_IN O
soft POS_JJ D
tissue POS_NN WORDNET_body_part.n.01 D
sarcomas POS_NN D

Cytokines POS_NNS O
and POS_CC O
peripheral POS_JJ O
neuropathies POS_NNS O

Study POS_NNP O
of POS_IN O
cortical POS_JJ D
atrophy POS_NN D
with POS_IN O
magnetic POS_JJ O
resonance POS_NN O
imaging POS_NN O
in POS_IN O
corticobasal POS_NN D
degeneration POS_NN D

Autosomal POS_NNP O
dominant POS_JJ O
nocturnal POS_JJ O
frontal POS_NN WORDNET_body_part.n.01 O
lobe POS_NN WORDNET_body_part.n.01 O
epilepsy POS_NN D

Current POS_JJ O
status POS_NN O
of POS_IN O
mitochondrial POS_JJ D
diseases POS_NNS D

Epilepsy POS_NN D
and POS_CC O
psychiatric POS_JJ D
disorders POS_NNS D
: POS_: O
epidemiological POS_JJ O
data POS_NNS O

p53 POS_NN O
mutations POS_NNS O
in POS_IN O
BRCA1-associated POS_NNP O
familial POS_JJ O
breast POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D

The POS_DT O
Preterm POS_NNP O
Prediction POS_NNP O
Study POS_NNP O
: POS_: O
association POS_NN O
of POS_IN O
cesarean POS_JJ T
delivery POS_NN T
with POS_IN O
increases POS_NNS O
in POS_IN O
maternal POS_JJ O
weight POS_NN O
and POS_CC O
body POS_NN O
mass POS_NN O
index POS_NN WORDNET_body_part.n.01 O

Structure POS_NN WORDNET_body_part.n.01 O
and POS_CC O
function POS_NN MESH_TYPE_qualifier MESH_physiology O
of POS_IN O
the POS_DT O
long POS_JJ O
terminal POS_JJ O
repeats POS_NNS O
of POS_IN O
feline POS_NN O
leukemia POS_NN WORDNET_disease.n.01 O
viruses POS_NNS MESH_TYPE_qualifier MESH_virology O
derived POS_VBN O
from POS_IN O
naturally POS_RB O
occurring POS_VBG O
acute POS_JJ D
myeloid POS_NN D
leukemias POS_NN D
in POS_IN O
cats POS_NNS O

Satellite POS_NNP O
DNA POS_NNP O
repeat POS_NN O
sequence POS_NN O
variation POS_NN O
is POS_VBZ O
low POS_JJ O
in POS_IN O
three POS_CD O
species POS_NNS O
of POS_IN O
burying POS_VBG O
beetles POS_NNS O
in POS_IN O
the POS_DT O
genus POS_NN O
Nicrophorus POS_NNP O
( POS_( O
Coleoptera POS_NNP O
: POS_: O
Silphidae POS_NN O
) POS_) O

The POS_DT O
importance POS_NN O
of POS_IN O
patient POS_JJ O
registration POS_NN O
and POS_CC O
processing POS_NN O

Why POS_WRB O
Oedipus POS_NNP O
and POS_CC O
not POS_RB O
Christ POS_NNP O
? POS_. O
: POS_: O
a POS_DT O
psychoanalytic POS_JJ O
inquiry POS_NN O
into POS_IN O
innocence POS_NN O
, POS_, O
human POS_JJ O
sacrifice POS_NN O
, POS_, O
and POS_CC O
the POS_DT O
sacred POS_VBN O
-- POS_: O
Part POS_NN O
I POS_PRP O
: POS_: O
Innocence POS_NN O
, POS_, O
spirituality POS_NN O
, POS_, O
and POS_CC O
human POS_JJ O
sacrifice POS_NN O

< POS_JJ O
TO_SEE POS_NNP O
> POS_NNP O
Respiratory POS_NNP O
arrest POS_NN O
following POS_VBG O
peribulbar POS_NN O
anesthesia POS_NN O
for POS_IN O
cataract POS_NN WORDNET_disease.n.01 O
surgery POS_NN MESH_TYPE_qualifier MESH_surgery O
: POS_: O
case POS_NN O
report POS_NN O
and POS_CC O
review POS_NN O
of POS_IN O
the POS_DT O
literature POS_NN O

Mouse POS_NNP O
LIM-kinase POS_NNP O
2 POS_CD O
gene POS_NN O
: POS_: O
cDNA POS_NN O
cloning POS_NN O
, POS_, O
genomic POS_JJ O
organization POS_NN MESH_TYPE_qualifier MESH_organization & administration O
, POS_, O
and POS_CC O
tissue-specific POS_JJ O
expression POS_NN O
of POS_IN O
two POS_CD O
alternatively POS_RB O
initiated POS_JJ O
transcripts POS_NNS O

A POS_DT O
gross POS_JJ O
and POS_CC O
microscopic POS_JJ O
study POS_NN O
of POS_IN O
cerebral POS_JJ D
injuries POS_NNS MESH_TYPE_qualifier MESH_injuries D
accompanying POS_VBG O
maxillofacial POS_JJ O
high-velocity POS_NN O
projectile POS_NN D
wounding POS_VBG D
in POS_IN O
dogs POS_NNS O

Does POS_VBZ O
this POS_DT O
patient POS_NN O
have POS_VBP O
a POS_DT O
mole POS_NN O
or POS_CC O
a POS_DT O
melanoma POS_NN WORDNET_disease.n.01 D
? POS_. O

Genetic POS_JJ O
variation POS_NN O
in POS_IN O
the POS_DT O
dimorphic POS_JJ O
regions POS_NNS O
of POS_IN O
RAP-1 POS_NNP O
genes POS_NNS O
and POS_CC O
rap-1 POS_JJ O
loci POS_NN O
of POS_IN O
Babesia POS_NNP D
bigemina POS_NN D

A POS_DT O
national POS_JJ O
survey POS_NN O
of POS_IN O
physician-assisted POS_JJ O
suicide POS_NN O
and POS_CC O
euthanasia POS_NN O
in POS_IN O
the POS_DT O
United POS_NNP O
States POS_NNPS O

Spontaneous POS_JJ D
ovarian POS_JJ D
hyperstimulation POS_NN D
syndrome POS_NN D
with POS_IN O
pregnancy POS_NN O

Modulation POS_NN O
of POS_IN O
ultraviolet POS_JJ O
light-induced POS_JJ O
epidermal POS_JJ D
damage POS_NN D
: POS_: O
beneficial POS_JJ O
effects POS_NNS O
of POS_IN O
tocopherol POS_NN T

Renal POS_JJ O
ultrasonography POS_NN MESH_TYPE_qualifier MESH_diagnostic imaging O
: POS_: O
a POS_DT O
procedure POS_NN O
for POS_IN O
nephrologists POS_NNS O

Management POS_NN O
of POS_IN O
vaginal POS_JJ D
vault POS_NN D
prolapse POS_NN D

Death POS_NNP O
rates POS_NNS O
of POS_IN O
characters POS_NNS O
in POS_IN O
soap POS_NN WORDNET_chemical.n.01 O
operas POS_NNS O
on POS_IN O
British POS_JJ O
television POS_NN O
: POS_: O
is POS_VBZ O
a POS_DT O
government POS_NN O
health POS_NN O
warning POS_NN O
required POS_VBN O
? POS_. O

Big POS_JJ O
city POS_NN O
health POS_NN O

WHO POS_WP O
decides POS_VBZ O
: POS_: O
food POS_NN O
irradiation POS_NN O
safe POS_JJ O
at POS_IN O
any POS_DT O
level POS_NN O

Genetic POS_JJ O
sampling POS_NN O
: POS_: O
big POS_JJ O
brother POS_NN O
or POS_CC O
big POS_JJ O
science POS_NN O
? POS_. O

Laying POS_VBG O
the POS_DT O
foundation POS_NN O
for POS_IN O
Healthy POS_NNP O
People POS_NNP O
2010 POS_CD O

Is POS_VBZ O
dietary POS_JJ O
fat POS_NN WORDNET_chemical.n.01 O
a POS_DT O
major POS_JJ O
determinant POS_NN O
of POS_IN O
body POS_NN O
fat POS_NN WORDNET_chemical.n.01 O
? POS_. O

Factors POS_NNS O
involved POS_VBN O
in POS_IN O
the POS_DT O
rate POS_NN O
of POS_IN O
fall POS_NN O
of POS_IN O
thyroid POS_JJ O
stimulating POS_VBG O
hormone POS_NN O
in POS_IN O
treated POS_JJ O
hypothyroidism POS_NN D

Imaging POS_VBG O
pulmonary POS_JJ D
embolism POS_NN D

Use POS_NNP MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
a POS_DT O
Foley POS_NNP O
catheter POS_NN O
in POS_IN O
the POS_DT O
removal POS_NN O
of POS_IN O
a POS_DT O
substernal POS_JJ D
goiter POS_NN WORDNET_disease.n.01 D

Re POS_NN O
: POS_: O
Intermediate POS_JJ WORDNET_chemical.n.01 O
term POS_NN O
assessment POS_NN O
of POS_IN O
the POS_DT O
reliability POS_NN O
, POS_, O
function POS_NN MESH_TYPE_qualifier MESH_physiology O
and POS_CC O
patient POS_JJ O
satisfaction POS_NN O
with POS_IN O
the POS_DT O
AMS700 POS_NNP O
ultrex POS_JJ O
penile POS_NN O
prosthesis POS_NN O

Reduced POS_NNP O
ratio POS_NN O
of POS_IN O
male POS_NN O
to POS_TO O
female POS_JJ O
births POS_NNS O
in POS_IN O
several POS_JJ O
industrial POS_JJ O
countries POS_NNS O
: POS_: O
a POS_DT O
sentinel POS_NN O
health POS_NN O
indicator POS_NN O
? POS_. O

Bolus POS_NNP T
thrombolytic POS_JJ T
infusions POS_NNS T
during POS_IN O
CPR POS_NNP O
for POS_IN O
patients POS_NNS O
with POS_IN O
refractory POS_JJ D
arrest POS_NN D
rhythms POS_NN D
: POS_: O
outcome POS_NN O
of POS_IN O
a POS_DT O
case POS_NN O
series POS_NN O

Joint POS_NNP WORDNET_body_part.n.01 O
International POS_NNP O
Symposium POS_NNP O
of POS_IN O
the POS_DT O
Danish POS_JJ O
Cancer POS_NNP WORDNET_disease.n.01 O
Society POS_NNP O
, POS_, O
European POS_JJ O
Cancer POS_NNP WORDNET_disease.n.01 O
Prevention POS_NNP MESH_TYPE_qualifier MESH_prevention & control O
Organization POS_NNP MESH_TYPE_qualifier MESH_organization & administration O
and POS_CC O
National POS_NNP O
Food POS_NNP O
Agency POS_NNP O
of POS_IN O
Denmark POS_NNP O

Munchausen POS_NNP D
's POS_POS D
syndrome POS_NN D

Development POS_NNP MESH_TYPE_qualifier MESH_growth & development O
of POS_IN O
neurosurgery POS_NN T
in POS_IN O
Greece POS_NNP O
: POS_: O
past POS_NN O
, POS_, O
present POS_NN O
, POS_, O
and POS_CC O
future POS_NN O

Inferences POS_NNS O
from POS_IN O
symphysiotomy POS_JJ T
experience POS_NN O

Mouth POS_NNP WORDNET_body_part.n.01 O
care POS_NN O
and POS_CC O
skin POS_NN WORDNET_body_part.n.01 O
care POS_NN O
in POS_IN O
palliative POS_JJ O
medicine POS_NN O

Simple POS_NNP O
antiseptic POS_JJ T
mouthwashes POS_NNS T
are POS_VBP O
best POS_JJS O
for POS_IN O
infection POS_NN D

Platelet POS_NNP O
Receptor POS_NNP WORDNET_body_part.n.01 O
Inhibition POS_NNP O
in POS_IN O
Ischemic POS_NNP O
Syndrome POS_NNP O
Management POS_NNP O
( POS_( O
PRISM POS_NNP O
) POS_) O
Study POS_NNP O
Investigators POS_NNS O

Something POS_VBG O
from POS_IN O
nothing POS_NN O
: POS_: O
the POS_DT O
evolution POS_NN O
and POS_CC O
utility POS_NN O
of POS_IN O
satellite POS_NN O
repeats POS_NNS O

Chemotherapy POS_NNP WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_drug therapy T
alone POS_RB T
compared POS_VBN O
with POS_IN O
chemotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_drug therapy T
plus POS_CC T
radiotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_radiotherapy T
for POS_IN O
localized POS_JJ O
intermediate- POS_JJ O
and POS_CC O
high-grade POS_JJ O
non-Hodgkin POS_NN D
's POS_POS D
lymphoma POS_NN WORDNET_disease.n.01 D

Classification POS_NN MESH_TYPE_qualifier MESH_classification O
of POS_IN O
primary POS_JJ O
gastric POS_JJ D
lymphomas POS_NN D
according POS_VBG O
to POS_TO O
histologic POS_NN O
features POS_NNS O

Molecular POS_JJ O
analysis POS_NN MESH_TYPE_qualifier MESH_analysis O
of POS_IN O
cellulose POS_JJ WORDNET_chemical.n.01 O
biosynthesis POS_NN MESH_TYPE_qualifier MESH_biosynthesis O
in POS_IN O
Arabidopsis POS_NNP O

Users POS_NNS O
' POS_POS O
guides POS_NNS O
to POS_TO O
the POS_DT O
medical POS_JJ O
literature POS_NN O
: POS_: O
XIV POS_NN O

Anterior POS_NNP D
glenohumeral POS_JJ D
dislocations POS_NNS D
: POS_: O
what POS_WP O
to POS_TO O
do POS_VB O
and POS_CC O
how POS_WRB O
to POS_TO O
do POS_VB O
it POS_PRP O

The POS_DT O
Gram POS_NNP O
stain POS_NN O

New POS_NNP O
Zealand POS_NNP O
Cot POS_NNP O
Death POS_NNP O
Study POS_NNP O
Group POS_NNP O

Interleukin-8 POS_JJ O
participates POS_NNS O
in POS_IN O
angiogenesis POS_NN O
in POS_IN O
non-small POS_JJ O
cell POS_NN O
, POS_, O
but POS_CC O
not POS_RB O
small POS_JJ WORDNET_body_part.n.01 O
cell POS_NN O
carcinoma POS_NN WORDNET_disease.n.01 D
of POS_IN O
the POS_DT O
lung POS_NN WORDNET_body_part.n.01 O

Immunogenicity POS_NN O
of POS_IN O
hepatitis POS_NN WORDNET_disease.n.01 D
B POS_NNP WORDNET_disease.n.01 D
vaccine POS_NN T
in POS_IN O
term POS_NN O
and POS_CC O
preterm POS_NN O
infants POS_NNS O

137 POS_CD O

Online POS_NN O

Online POS_NN O

Online POS_NN O

Mutations POS_NNS O
in POS_IN O
brief POS_NN O
no POS_DT O

141 POS_CD O

Online POS_NN O

Novel POS_NNP O
acceptor POS_NN WORDNET_chemical.n.01 O
splice POS_NN O
site POS_NN O
mutation POS_NN O
in POS_IN O
the POS_DT O
invariant POS_JJ O
AG POS_NNP O
of POS_IN O
intron POS_NN WORDNET_chemical.n.01 O
6 POS_CD O
of POS_IN O
alpha-galactosidase POS_NN O
A POS_NNP O
gene POS_NN O
, POS_, O
causing POS_VBG O
Fabry POS_NNP D
disease POS_NN D

146 POS_CD O

Meta-analysis POS_NN O
of POS_IN O
trials POS_NNS O
comparing POS_VBG O
antidepressants POS_NNS T
with POS_IN O
active POS_JJ O
placebos POS_NNS O

Chelation POS_NNP T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
for POS_IN O
peripheral POS_JJ D
arterial POS_JJ D
occlusive POS_JJ D
disease POS_NN D
: POS_: O
a POS_DT O
systematic POS_JJ O
review POS_NN O

Endoscopic POS_NNP T
ultrasound POS_JJ MESH_TYPE_qualifier MESH_diagnostic imaging T
miniprobe-guided POS_JJ T
steroid POS_NN WORDNET_chemical.n.01 T
injection POS_NN WORDNET_treatment.n.01 T
for POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
refractory POS_JJ D
esophageal POS_NN D
strictures POS_NNS D

Current POS_JJ O
management POS_NN O
of POS_IN O
corneal POS_JJ D
abrasions POS_NNS D
: POS_: O
evidence POS_NN O
based POS_VBN O
practice POS_NN O
? POS_. O

Requirements POS_NNS O
for POS_IN O
training POS_VBG MESH_TYPE_qualifier MESH_education O
to POS_TO O
ensure POS_VB O
competence POS_NN O
of POS_IN O
endoscopists POS_NNS O
performing POS_VBG O
invasive POS_JJ MESH_TYPE_qualifier MESH_surgery O
procedures POS_NNS MESH_TYPE_qualifier MESH_methods MESH_surgery O
in POS_IN O
children POS_NNS O

117 POS_CD O

Identification POS_NN O
of POS_IN O
five POS_CD O
new POS_JJ O
mutations POS_NNS O
and POS_CC O
three POS_CD O
novel POS_JJ O
polymorphisms POS_NNS O
in POS_IN O
the POS_DT O
muscle POS_NN WORDNET_body_part.n.01 O
chloride POS_NN WORDNET_chemical.n.01 O
channel POS_NN O
gene POS_NN O
( POS_( O
CLCN1 POS_NNP O
) POS_) O
in POS_IN O
20 POS_CD O
Italian POS_JJ O
patients POS_NNS O
with POS_IN O
dominant POS_JJ O
and POS_CC O
recessive POS_JJ O
myotonia POS_NN D
congenita POS_NN D

Mutations POS_NNS O
in POS_IN O
brief POS_NN O
no POS_DT O

Online POS_NN O

Independent POS_JJ O
occurrence POS_NN MESH_TYPE_qualifier MESH_epidemiology O
of POS_IN O
the POS_DT O
novel POS_JJ O
Arg2163 POS_NNP O
to POS_TO O
His POS_PRP$ O
mutation POS_NN O
in POS_IN O
the POS_DT O
factor POS_NN O
VIII POS_NNP O
gene POS_NN O
in POS_IN O
three POS_CD O
unrelated POS_JJ O
families POS_NNS O
with POS_IN O
haemophila POS_PDT D
A POS_DT D
with POS_IN O
different POS_JJ O
phenotypes POS_NNS O

Mutations POS_NNS O
in POS_IN O
brief POS_NN O
no POS_DT O

126 POS_CD O

Inhalation POS_NN O
of POS_IN O
ammonium POS_NN WORDNET_chemical.n.01 O
nitrate POS_NN WORDNET_chemical.n.01 O
fuel POS_NN WORDNET_chemical.n.01 O
oil POS_NN WORDNET_chemical.n.01 O
explosive POS_NN WORDNET_chemical.n.01 O
( POS_( O
ANFO POS_NNP O
) POS_) O

Ventilatory POS_JJ O
responses POS_NNS O
to POS_TO O
acute POS_VB O
and POS_CC O
sustained POS_JJ O
hypoxia POS_NN O
during POS_IN O
isoflurane POS_NN O
anesthesia POS_NN O

Risk POS_NN O
factors POS_NNS O
for POS_IN O
hemiretinal POS_JJ D
vein POS_NN WORDNET_body_part.n.01 D
occlusion POS_NN D
: POS_: O
comparison POS_NN O
with POS_IN O
risk POS_NN O
factors POS_NNS O
for POS_IN O
central POS_JJ D
and POS_CC D
branch POS_JJ D
retinal POS_JJ D
vein POS_NN WORDNET_body_part.n.01 D
occlusion POS_NN D
: POS_: O
the POS_DT O
eye POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 O
disease POS_NN WORDNET_disease.n.01 O
case-control POS_NN O
study POS_NN O

Clinical POS_JJ T
management POS_NN T
and POS_CC O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
outcomes POS_NNS O
of POS_IN O
Merkel POS_NNP D
cell POS_NN D
carcinoma POS_NN WORDNET_disease.n.01 D

Relatives POS_NNS O
in POS_IN O
the POS_DT O
resuscitation POS_NN O
room POS_NN O
: POS_: O
their POS_PRP$ O
point POS_NN O
of POS_IN O
view POS_NN O

Autonomy POS_NN O
in POS_IN O
the POS_DT O
face POS_NN WORDNET_body_part.n.01 O
of POS_IN O
a POS_DT O
devastating POS_JJ O
diagnosis POS_NN MESH_TYPE_qualifier MESH_diagnosis O

Nonanesthetic POS_JJ O
volatile POS_JJ O
drugs POS_NNS O
obey POS_IN O
the POS_DT O
Meyer-Overton POS_NNP O
correlation POS_NN O
in POS_IN O
two POS_CD O
molecular POS_JJ O
protein POS_NNS WORDNET_chemical.n.01 O
site POS_NN O
models POS_NNS O

Inhaled POS_JJ T
sodium POS_NN T
cromoglycate POS_NN T
in POS_IN O
young POS_JJ O
children POS_NNS O
with POS_IN O
moderate POS_JJ O
asthma POS_NNS WORDNET_disease.n.01 D

Directly POS_RB O
observed POS_VBN O
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy O
and POS_CC O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
completion POS_NN O
for POS_IN O
tuberculosis POS_NN WORDNET_disease.n.01 D
in POS_IN O
the POS_DT O
United POS_NNP O
States POS_NNPS O
: POS_: O
is POS_VBZ O
universal POS_JJ O
supervised POS_JJ O
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy O
necessary POS_JJ O
? POS_. O

Adolescent POS_JJ O
pregnancy POS_NN O
and POS_CC O
sexual POS_JJ O
abuse POS_NN O

considering POS_VBG O
that POS_IN O
hamsters POS_NNS O
had POS_VBD O
a POS_DT O
lung POS_JJ WORDNET_body_part.n.01 O
metastasis POS_NN O
rate POS_NN O
of POS_IN O
50 POS_CD O
% POS_NN O
before POS_IN O
mdp-lys POS_JJ O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
, POS_, O
liposomal POS_JJ T
mdp-lys POS_JJ T
given POS_VBN O
at POS_IN O
a POS_DT O
dose POS_NN O
of POS_IN O
20 POS_CD O
microg POS_NNS O
twice/week POS_NN O
was POS_VBD O
effective POS_JJ O
for POS_IN O
inhibiting POS_VBG O
lung POS_NN WORDNET_body_part.n.01 D
metastasis POS_NN D
at POS_IN O
a POS_DT O
far POS_RB O
lower POS_JJR O
dose POS_NN O
of POS_IN O
mdp-lys POS_NN O
than POS_IN O
that POS_DT O
given POS_VBN O
as POS_IN O
a POS_DT O
solution POS_NN O
( POS_( O
40 POS_CD O
microg POS_NN O
vs. POS_FW O
350 POS_CD O
microg POS_NNS O
per POS_IN O
week POS_NN O
) POS_) O

despite POS_IN O
the POS_DT O
marked POS_JJ O
toxicity POS_NN MESH_TYPE_qualifier MESH_toxicity O
of POS_IN O
the POS_DT O
initial POS_JJ O
intensive POS_JJ T
chemotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_drug therapy T
, POS_, O
the POS_DT O
treatments POS_NNS O
are POS_VBP O
tolerable POS_JJ O
and POS_CC O
effective POS_JJ O
in POS_IN O
the POS_DT O
control POS_NN MESH_TYPE_qualifier MESH_prevention & control O
of POS_IN O
extra-thoracic POS_JJ D
micrometastases POS_NNS D
, POS_, O
whereas POS_IN O
they POS_PRP O
are POS_VBP O
less POS_RBR O
effective POS_JJ O
for POS_IN O
thoracic POS_JJ O
primary POS_JJ O
tumor POS_NN O

the POS_DT O
only POS_JJ O
specific POS_JJ O
antidote POS_NN O
for POS_IN O
dosage-dependent POS_JJ D
hepatotoxicity POS_NN D
is POS_VBZ O
n-acetylcysteine POS_JJ T
( POS_( T
and POS_CC T
some POS_DT T
other POS_JJ T
sulfhydryl POS_JJ T
donors POS_NNS T
) POS_) T
, POS_, O
which POS_WDT O
is POS_VBZ O
highly POS_RB O
effective POS_JJ O
for POS_IN O
the POS_DT O
prevention POS_NN MESH_TYPE_qualifier MESH_prevention & control O
of POS_IN O
significant POS_JJ O
hepatotoxicity POS_NN O
after POS_IN O
acetaminophen POS_NN O
overdose POS_NN O

corticosteroids POS_NNS T
can POS_MD O
be POS_VB O
considered POS_VBN O
for POS_IN O
cases POS_NNS O
of POS_IN O
drug-induced POS_JJ D
hepatitis POS_NN WORDNET_disease.n.01 D
, POS_, O
especially POS_RB O
those POS_DT O
with POS_IN O
evidence POS_NN O
of POS_IN O
immune POS_JJ O
hypersensitivity POS_NN O
, POS_, O
if POS_IN O
no POS_DT O
improvement POS_NN O
is POS_VBZ O
seen POS_VBN O
in POS_IN O
8 POS_CD O
to POS_TO O
12 POS_CD O
weeks POS_NNS O

this POS_DT O
conjugated POS_VBD T
vaccine POS_NN T
against POS_IN O
pneumococcus POS_NN D
uses POS_VBZ O
the POS_DT O
same POS_JJ O
technology POS_NN O
as POS_IN O
the POS_DT O
successful POS_JJ O
vaccine POS_NN T
against POS_IN O
haemophilus POS_JJ D
influenzae POS_JJ D
type POS_NN D
b POS_NN D

only POS_RB O
the POS_DT O
combination POS_NN T
of POS_IN T
a POS_DT T
cell POS_NN T
wall-active POS_JJ T
antibiotic POS_NN T
to POS_TO T
which POS_WDT T
the POS_DT T
enterococcus POS_NN T
is POS_VBZ T
susceptible POS_JJ T
( POS_( T
ie POS_JJ T
, POS_, T
certain POS_JJ T
beta-lactams POS_NNS T
or POS_CC T
vancomycin POS_NN T
) POS_) T
plus POS_CC T
an POS_DT T
aminoglycoside POS_NN T
( POS_( T
ie POS_JJ T
, POS_, T
gentamicin POS_NN T
or POS_CC T
streptomycin POS_NN T
) POS_) T
is POS_VBZ O
bactericidal POS_JJ O
, POS_, O
and POS_CC O
is POS_VBZ O
required POS_VBN O
for POS_IN O
cure POS_NN O
of POS_IN O
endocarditis POS_NN D
, POS_, D
meningitis POS_NN WORDNET_disease.n.01 D
and POS_CC D
probably POS_RB D
infection POS_NN D
in POS_IN D
neutropenic POS_JJ D
patients POS_NNS D
; POS_: O
bacteriostatic POS_JJ O
activity POS_NN O
is POS_VBZ O
sufficient POS_JJ O
to POS_TO O
treat POS_VB O
most POS_RBS O
other POS_JJ O
infections POS_NNS O

stages POS_NNS O
of POS_IN O
non-small POS_JJ D
cell POS_NN D
lung POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D
( POS_( D
nsclc POS_CC D
) POS_) D
that POS_WDT O
are POS_VBP O
potential POS_JJ O
candidates POS_NNS O
for POS_IN O
surgical POS_JJ T
resection POS_NN T
have POS_VBP O
been POS_VBN O
treated POS_VBN O
in POS_IN O
several POS_JJ O
ways POS_NNS O
: POS_: O
surgery POS_NN MESH_TYPE_qualifier MESH_surgery T
alone POS_RB O
is POS_VBZ O
curative POS_JJ O
in POS_IN O
only POS_JJ O
two-thirds POS_NNS O
of POS_IN O
cases POS_NNS O
and POS_CC O
post-operative POS_JJ T
radiotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_radiotherapy T
( POS_( T
rt POS_NN T
) POS_) T
provides POS_VBZ O
only POS_RB O
weak POS_JJ O
control POS_NN MESH_TYPE_qualifier MESH_prevention & control O
of POS_IN O
advanced-stage POS_JJ O
disease POS_NN O

whether POS_IN O
the POS_DT O
era POS_NN O
of POS_IN O
platinum-based POS_JJ T
chemotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_drug therapy T
in POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
nsclc POS_NN D
should POS_MD O
continue POS_VB O
or POS_CC O
not POS_RB O
must POS_MD O
be POS_VB O
determined POS_VBN O
by POS_IN O
phase POS_NN O
iii POS_NN O
trials POS_NNS O
, POS_, O
evaluating POS_VBG O
the POS_DT O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
a POS_DT O
platinum POS_NN O
agent POS_NN O
with POS_IN O
one POS_CD O
of POS_IN O
the POS_DT O
new POS_JJ O
agent POS_NN O
combinations POS_NNS O

conclusions POS_NNS O
: POS_: O
this POS_DT O
constitutes POS_VBZ O
one POS_CD O
of POS_IN O
the POS_DT O
largest POS_JJS O
single-institution POS_NN O
reports POS_NNS O
on POS_IN O
carinal POS_JJ T
resection POS_NN T
for POS_IN O
bronchogenic POS_JJ D
carcinoma POS_NN WORDNET_disease.n.01 D
involving POS_VBG D
the POS_DT D
carina POS_NN WORDNET_body_part.n.01 D

in POS_IN O
three POS_CD O
patients POS_NNS O
with POS_IN O
bos POS_NNS D
and POS_CC D
concurrent POS_JJ D
acute POS_NN D
rejection POS_NN D
, POS_, O
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
with POS_IN T
extracorporeal POS_JJ T
photopheresis POS_NN T
led POS_VBD O
to POS_TO O
the POS_DT O
resolution POS_NN O
of POS_IN O
the POS_DT O
acute POS_JJ O
rejection POS_NN O
episode POS_NN O

conclusion POS_NN O
: POS_: O
extracorporeal POS_JJ T
photopheresis POS_NN T
appears POS_VBZ O
to POS_TO O
be POS_VB O
a POS_DT O
promising POS_JJ O
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy O
for POS_IN O
patients POS_NNS O
with POS_IN O
early POS_JJ D
bos POS_NN D

< POS_JJ O
TO_SEE POS_NNP O
> POS_NNP O
purpose POS_NN O
: POS_: O
the POS_DT O
benefit POS_NN O
of POS_IN O
whole-lung POS_JJ T
irradiation POS_NN T
( POS_( T
wli POS_NN T
) POS_) T
for POS_IN O
patients POS_NNS O
who POS_WP O
have POS_VBP O
pulmonary POS_JJ D
metastases POS_NNS D
( POS_( D
pm POS_NN D
) POS_) D
of POS_IN D
ewing POS_VBG D
sarcoma POS_JJ WORDNET_disease.n.01 D
family POS_NN D
tumors POS_NNS D
( POS_( D
esft POS_NN D
) POS_) D
is POS_VBZ O
unclear POS_JJ O

< POS_JJ O
TO_SEE POS_NNP O
> POS_NNP O
tracheal POS_JJ O
stent POS_JJ O
insertion POS_NN O
is POS_VBZ O
a POS_DT O
useful POS_JJ O
method POS_NN O
for POS_IN O
patients POS_NNS O
with POS_IN O
malignant POS_JJ O
tracheal POS_NN O
stenosis POS_NN O

thus POS_RB O
, POS_, O
we POS_PRP O
should POS_MD O
recognize POS_VB O
this POS_DT O
immanent POS_NN O
risk POS_NN O
and POS_CC O
perform POS_VB O
peri- POS_NN T
and POS_CC T
postoperative POS_JJ T
management POS_NN T
for POS_IN O
patients POS_NNS O
with POS_IN O
gh-producing POS_JJ D
tumors POS_NNS D

background POS_NN O
: POS_: O
at POS_IN O
present POS_JJ O
the POS_DT O
addition POS_NN T
of POS_IN T
thoracic POS_JJ T
irradiation POS_NN T
to POS_TO T
combination POS_NN T
chemotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_drug therapy T
is POS_VBZ O
a POS_DT O
standard POS_JJ O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
for POS_IN O
limited POS_JJ D
staged POS_VBD D
small POS_JJ WORDNET_body_part.n.01 D
cell POS_NN D
lung POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D

methods POS_NNS MESH_TYPE_qualifier MESH_methods O
: POS_: O
forty-four POS_JJ O
patients POS_NNS O
with POS_IN O
limited POS_JJ D
small POS_JJ WORDNET_body_part.n.01 D
cell POS_NN D
lung POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D
were POS_VBD O
treated POS_VBN O
with POS_IN O
etoposide-ifosfamide-cisplatin POS_JJ T
and POS_CC T
concurrent POS_JJ T
thoracic POS_NN T
irradiation POS_NN T

inhaled POS_VBN T
corticosteroid POS_JJ T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
is POS_VBZ O
recommended POS_VBN O
for POS_IN O
patients POS_NNS O
with POS_IN O
persistent POS_JJ D
disease POS_NN D
, POS_, O
and POS_CC O
careful POS_JJ O
instruction POS_NN O
in POS_IN O
the POS_DT O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
metered-dose POS_JJ O
inhalers POS_NNS O
is POS_VBZ O
particularly POS_RB O
important POS_JJ O
for POS_IN O
the POS_DT O
elderly POS_JJ O

in POS_IN O
contrast POS_NN O
, POS_, O
the POS_DT O
introduction POS_NN O
and POS_CC O
improvement POS_NN O
of POS_IN O
chemotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_drug therapy T
since POS_IN O
the POS_DT O
1970s POS_CD O
gave POS_VBD O
rise POS_NN O
to POS_TO O
an POS_DT O
improvement POS_NN O
in POS_IN O
- POS_: O
only POS_RB O
short-term POS_JJ O
( POS_( O
< POS_JJ O
2 POS_CD O
years POS_NNS O
) POS_) O
- POS_: O
survival POS_NN MESH_TYPE_qualifier MESH_mortality O
for POS_IN O
patients POS_NNS O
with POS_IN O
small-cell POS_JJ D
lung POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D

patients POS_NNS O
: POS_: O
during POS_IN O
this POS_DT O
period POS_NN O
, POS_, O
a POS_DT O
total POS_NN O
of POS_IN O
77 POS_CD O
patients POS_NNS O
underwent POS_JJ O
lung POS_JJ WORDNET_body_part.n.01 T
resection POS_NN T
for POS_IN O
the POS_DT O
following POS_JJ O
neuroendocrine POS_JJ D
neoplasms POS_NNS D
: POS_: O
typical POS_JJ D
carcinoid POS_NN D
( POS_( D
tc POS_NN D
) POS_) D
, POS_, O
50 POS_CD O
patients POS_NNS O
; POS_: O
atypical POS_JJ D
carcinoid POS_NN D
( POS_( D
ac POS_NN D
) POS_) D
, POS_, O
5 POS_CD O
patients POS_NNS O
; POS_: O
large POS_JJ D
cell POS_NN D
neuroendocrine POS_NN D
carcinoma POS_NN WORDNET_disease.n.01 D
( POS_( D
lcnec POS_NN D
) POS_) D
, POS_, O
9 POS_CD O
patients POS_NNS O
; POS_: O
mixed POS_JJ D
large-small POS_JJ D
cell POS_NN D
neuroendocrine POS_NN D
carcinoma POS_NN WORDNET_disease.n.01 D
( POS_( D
lsnec POS_NN D
) POS_) D
, POS_, O
4 POS_CD O
patients POS_NNS O
; POS_: O
or POS_CC O
small POS_JJ WORDNET_body_part.n.01 D
cell POS_NN D
neuroendocrine POS_JJ D
carcinoma POS_NN WORDNET_disease.n.01 D
( POS_( D
scc POS_NN D
) POS_) D
, POS_, O
9 POS_CD O
patients POS_NNS O

because POS_IN O
placement POS_NN O
of POS_IN O
stents POS_NNS O
in POS_IN O
both POS_DT O
the POS_DT O
esophagus POS_NN WORDNET_body_part.n.01 O
and POS_CC O
tracheobronchus POS_NN O
has POS_VBZ O
a POS_DT O
high POS_JJ O
risk POS_NN O
of POS_IN O
enlargement POS_NN O
of POS_IN O
the POS_DT O
fistula POS_NN WORDNET_body_part.n.01 O
, POS_, O
a POS_DT O
covered POS_JJ T
metallic POS_JJ T
stent POS_NN T
is POS_VBZ O
preferable POS_JJ O
for POS_IN O
esophageal POS_JJ D
cancer POS_NN WORDNET_disease.n.01 D
involving POS_VBG D
the POS_DT D
tracheobronchus POS_NN D

objective POS_NN O
: POS_: O
to POS_TO O
examine POS_VB O
the POS_DT O
effectiveness POS_NN O
of POS_IN O
ninjin POS_JJ T
yoei POS_NN T
to POS_TO T
( POS_( T
nyt POS_JJ T
; POS_: T
ren-shen-yang-rong-tang POS_JJ T
in POS_IN T
chinese POS_JJ T
medicine POS_NN T
; POS_: T
kotaro POS_NNP T
pharmaceutical POS_NNP T
co. POS_NN T
, POS_, T
ltd. POS_NN T
, POS_, T
osaka POS_NN T
, POS_, T
japan POS_NN T
) POS_) T
, POS_, T
one POS_CD T
of POS_IN T
the POS_DT T
traditional POS_JJ T
herbal POS_JJ T
medicines POS_NNS T
, POS_, O
against POS_IN O
lung POS_NN WORDNET_body_part.n.01 D
carcinoma POS_NN WORDNET_disease.n.01 D

setting POS_NN O
: POS_: O
the POS_DT O
nursing POS_NN MESH_TYPE_qualifier MESH_nursing O
center POS_NN WORDNET_body_part.n.01 O
himawari POS_NN O
design POS_NN O
, POS_, O
patient POS_NN O
, POS_, O
and POS_CC O
preparation POS_NN O
: POS_: O
the POS_DT O
regular POS_JJ O
dosage POS_NN O
of POS_IN O
nyt POS_NN T
( POS_( O
15 POS_CD O
g/d POS_NN O
) POS_) O
was POS_VBD O
prescribed POS_VBN O
for POS_IN O
7 POS_CD O
weeks POS_NNS O
to POS_TO O
one POS_CD O
elderly POS_JJ O
patient POS_NN O
with POS_IN O
lung POS_NN WORDNET_body_part.n.01 D
carcinoma POS_NN WORDNET_disease.n.01 D

object POS_NN O
: POS_: O
the POS_DT O
purpose POS_NN O
of POS_IN O
this POS_DT O
retrospective POS_JJ O
study POS_NN O
was POS_VBD O
to POS_TO O
compare POS_VB O
the POS_DT O
effectiveness POS_NN O
of POS_IN O
gamma POS_JJ T
knife POS_NN T
radiosurgery POS_NN T
( POS_( T
gks POS_NN T
) POS_) T
for POS_IN O
multiple POS_JJ D
cerebral POS_JJ D
metastases POS_NNS D
with POS_IN O
that POS_DT O
of POS_IN O
whole-brain POS_JJ T
radiation POS_NN WORDNET_body_part.n.01 MESH_TYPE_qualifier MESH_radiotherapy T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_radiotherapy MESH_therapy T
( POS_( T
wbrt POS_NN T
) POS_) T

patients POS_NNS O
with POS_IN O
limited-stage POS_JJ D
small-cell POS_JJ D
carcinoma POS_NN WORDNET_disease.n.01 D
of POS_IN D
the POS_DT D
lung POS_NN WORDNET_body_part.n.01 D
are POS_VBP O
treated POS_VBN O
with POS_IN O
combined-modality POS_NN T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
with POS_IN O
the POS_DT O
intent POS_NN O
to POS_TO O
cure POS_VB O

in POS_IN O
2 POS_CD O
studies POS_NNS O
, POS_, O
surgery POS_NN MESH_TYPE_qualifier MESH_surgery T
with POS_IN O
curative POS_JJ O
intent POS_NN O
was POS_VBD O
performed POS_VBN O
in POS_IN O
16 POS_CD O
and POS_CC O
51 POS_CD O
% POS_NN O
of POS_IN O
patients POS_NNS O
with POS_IN O
initially POS_RB O
unresectable POS_JJ D
liver POS_NN WORDNET_body_part.n.01 D
metastases POS_NNS D
following POS_VBG O
oxaliplatin/fluorouracil/folinic POS_JJ T
acid POS_JJ WORDNET_chemical.n.01 T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
; POS_: O
the POS_DT O
5-year POS_JJ O
survival POS_NN MESH_TYPE_qualifier MESH_mortality O
rates POS_NNS O
were POS_VBD O
40 POS_CD O
and POS_CC O
50 POS_CD O
% POS_NN O
, POS_, O
respectively POS_RB O

additional POS_JJ O
clinical POS_JJ O
investigation POS_NN O
of POS_IN O
oxaliplatin POS_NN T
in POS_IN O
patients POS_NNS O
with POS_IN O
other POS_JJ O
cancers POS_NNS D
is POS_VBZ O
warranted POS_VBN O
given POS_VBN O
the POS_DT O
promising POS_JJ O
results POS_NNS O
achieved POS_VBN O
in POS_IN O
early POS_JJ O
trials POS_NNS O
, POS_, O
most POS_JJS O
notably POS_RB O
in POS_IN O
patients POS_NNS O
with POS_IN O
platinum-pretreated POS_JJ O
ovarian POS_JJ O
cancer POS_NN WORDNET_disease.n.01 O

the POS_DT O
current POS_JJ O
study POS_NN O
was POS_VBD O
designed POS_VBN O
to POS_TO O
assess POS_VB O
the POS_DT O
prognostic POS_JJ O
value POS_NN O
of POS_IN O
immunomorphologic POS_JJ O
changes POS_NNS O
in POS_IN O
locoregional POS_JJ O
lymph POS_NN O
nodes POS_NNS O
and POS_CC O
lymphocytic POS_JJ O
infiltration POS_NN O
of POS_IN O
primary POS_JJ O
tumor POS_NN O
( POS_( O
li POS_NN O
) POS_) O
in POS_IN O
patients POS_NNS O
who POS_WP O
undergo POS_VBP O
resection POS_NN T
for POS_IN O
bronchogenic POS_JJ D
carcinoma POS_NN WORDNET_disease.n.01 D

several POS_JJ O
newer POS_JJR O
chemotherapeutic POS_JJ T
drugs POS_NNS T
have POS_VBP O
recently POS_RB O
been POS_VBN O
shown POS_VBN O
to POS_TO O
have POS_VB O
significant POS_JJ O
activity POS_NN O
in POS_IN O
patients POS_NNS O
with POS_IN O
untreated POS_JJ D
or POS_CC D
relapsed POS_VBN D
sclc POS_NN D

for POS_IN O
small POS_JJ WORDNET_body_part.n.01 D
cell POS_NN D
lung POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D
( POS_( D
sclc POS_NN D
) POS_) D
, POS_, O
which POS_WDT O
accounts POS_VBZ O
for POS_IN O
approximately POS_RB O
20 POS_CD O
% POS_NN O
of POS_IN O
cases POS_NNS O
of POS_IN O
lung POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 O
cancer POS_NN WORDNET_disease.n.01 O
, POS_, O
the POS_DT O
primary POS_JJ O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
is POS_VBZ O
chemotherapy POS_JJ WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_drug therapy T
and POS_CC O
in POS_IN O
the POS_DT O
majority POS_NN O
of POS_IN O
cases POS_NNS O
the POS_DT O
primary POS_JJ O
aim POS_NN O
is POS_VBZ O
to POS_TO O
control POS_VB MESH_TYPE_qualifier MESH_prevention & control O
the POS_DT O
disease POS_NN O
which POS_WDT O
generally POS_RB O
would POS_MD O
have POS_VB O
spread POS_VBN O
beyond POS_IN O
the POS_DT O
lungs POS_NNS O
at POS_IN O
the POS_DT O
time POS_NN O
of POS_IN O
presentation POS_NN O

methods POS_NNS MESH_TYPE_qualifier MESH_methods O
: POS_: O
non-small POS_JJ D
cell POS_NN D
lung POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D
cells POS_NNS O
were POS_VBD O
treated POS_VBN O
with POS_IN O
gemcitabine POS_NN T
, POS_, O
harvested POS_VBN O
, POS_, O
and POS_CC O
nuclear POS_JJ O
extracts POS_NNS O
analyzed POS_VBN O
for POS_IN O
nf-kappab POS_JJ O
dna POS_NN O
binding POS_NN O
by POS_IN O
electrophoretic POS_JJ O
mobility POS_NN O
shift POS_NN O
assays POS_NNS O

based POS_VBN O
on POS_IN O
these POS_DT O
results POS_NNS O
, POS_, O
the POS_DT O
irinotecan POS_JJ T
and POS_CC T
cisplatin POS_JJ T
combination POS_NN T
is POS_VBZ O
a POS_DT O
new POS_JJ O
standard POS_JJ O
regimen POS_NNS O
in POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
extensive-disease POS_JJ D
small-cell POS_JJ D
lung POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D

conclusions POS_NNS O
: POS_: O
the POS_DT O
maximum POS_NN O
tolerated POS_VBD O
dose POS_NN O
of POS_IN O
this POS_DT O
combination POS_NN O
for POS_IN O
patients POS_NNS O
with POS_IN O
resistant POS_JJ D
sclc POS_NN D
is POS_VBZ O
ifosfamide POS_JJ T
2000 POS_CD O
mg/m2 POS_NN O
in POS_IN O
combination POS_NN O
with POS_IN O
paclitaxel POS_JJ T
175 POS_CD O
mg/m2 POS_NN O
and POS_CC O
carboplatin POS_NN T
auc POS_VBP O
6 POS_CD O
mg/ml POS_NNS O
min POS_RB O
administered POS_VBN O
on POS_IN O
the POS_DT O
first POS_JJ O
day POS_NN O
of POS_IN O
a POS_DT O
21-day POS_JJ O
cycle POS_NN O

conclusions POS_NNS O
: POS_: O
this POS_DT O
study POS_NN O
is POS_VBZ O
the POS_DT O
first POS_JJ O
to POS_TO O
evaluate POS_VB O
planned POS_VBN T
sequential POS_JJ T
chemotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_drug therapy T
in POS_IN O
patients POS_NNS O
with POS_IN O
nsclc POS_JJ D

purpose POS_NN O
: POS_: O
this POS_DT O
randomized POS_JJ O
trial POS_NN O
was POS_VBD O
designed POS_VBN O
to POS_TO O
determine POS_VB O
whether POS_IN O
paclitaxel POS_JJ T
plus POS_CC T
carboplatin POS_NN T
( POS_( T
pc POS_NN T
) POS_) T
offered POS_VBD O
a POS_DT O
survival POS_JJ MESH_TYPE_qualifier MESH_mortality O
advantage POS_NN O
over POS_IN O
vinorelbine POS_JJ T
plus POS_CC T
cisplatin POS_NN T
( POS_( T
vc POS_NN T
) POS_) T
for POS_IN O
patients POS_NNS O
with POS_IN O
advanced POS_JJ D
non POS_NNS D
-- POS_: D
small-cell POS_JJ D
lung POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D

conclusion POS_NN O
: POS_: O
pc POS_NN T
is POS_VBZ O
equally POS_RB O
efficacious POS_JJ O
as POS_IN O
vc POS_NN T
for POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
advanced POS_JJ D
non POS_NN D
-- POS_: D
small-cell POS_JJ D
lung POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D

conclusions POS_NNS O
: POS_: O
the POS_DT O
intensification POS_NN T
of POS_IN T
platinum POS_NN T
dose POS_NN T
( POS_( T
cisplatin POS_JJ T
plus POS_CC T
carboplatin POS_NN T
) POS_) T
in POS_IN T
combination POS_NN T
chemotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_drug therapy T
significantly POS_RB O
increased POS_VBD O
the POS_DT O
complete POS_JJ O
response POS_NN O
rate POS_NN O
, POS_, O
overall POS_JJ O
survival POS_NN MESH_TYPE_qualifier MESH_mortality O
and POS_CC O
number POS_NN O
of POS_IN O
two-year POS_JJ O
survivors POS_NNS O
among POS_IN O
sclc POS_JJ D
patients POS_NNS O
with POS_IN O
limited POS_JJ O
disease POS_NN O
compared POS_VBN O
to POS_TO O
combination POS_VB T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
with POS_IN T
carboplatin POS_NN T
alone POS_RB T
, POS_, O
suggesting POS_VBG O
that POS_IN O
a POS_DT O
more POS_RBR O
aggressive POS_JJ O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
to POS_TO O
this POS_DT O
category POS_NN O
of POS_IN O
patients POS_NNS O
is POS_VBZ O
worthwhile POS_JJ O
, POS_, O
while POS_IN O
no POS_DT O
difference POS_NN O
in POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
outcome POS_NN O
was POS_VBD O
observed POS_VBN O
for POS_IN O
patients POS_NNS O
with POS_IN O
extensive POS_JJ O
disease POS_NN O

exploratory POS_JJ T
interventions POS_NNS T
, POS_, T
partial POS_JJ T
tumor POS_NN T
resections POS_NNS T
and POS_CC T
lung POS_NN WORDNET_body_part.n.01 T
resections POS_NNS T
for POS_IN O
metastasis POS_NN D
were POS_VBD O
more POS_RBR O
frequently POS_RB O
performed POS_VBN O
in POS_IN O
young POS_JJ O
patients POS_NNS O
than POS_IN O
in POS_IN O
older POS_JJR O
patients POS_NNS O

prophylactic POS_JJ T
cranial POS_JJ T
irradiation POS_NN T
( POS_( T
pci POS_NN T
) POS_) T
has POS_VBZ O
been POS_VBN O
demonstrated POS_VBN O
to POS_TO O
significantly POS_RB O
reduce POS_VB O
the POS_DT O
incidence POS_NN MESH_TYPE_qualifier MESH_epidemiology O
of POS_IN O
brain POS_NN WORDNET_body_part.n.01 O
relapse POS_NN O
from POS_IN O
limited POS_JJ D
disease POS_NN D
small-cell POS_NN D
lung POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D
( POS_( D
ld POS_JJ D
sclc POS_NN D
) POS_) D
, POS_, O
but POS_CC O
concerns POS_NNS O
about POS_IN O
neurologic POS_JJ O
toxicity POS_NN MESH_TYPE_qualifier MESH_toxicity O
remain POS_VBP O

amifostine POS_NN T
( POS_( O
340 POS_CD O
mg/m2 POS_NN O
) POS_) O
also POS_RB O
provided POS_VBD O
significant POS_JJ O
protection POS_NN O
against POS_IN O
pneumonitis POS_NN D
and POS_CC D
oesophagitis POS_NN D
in POS_IN O
patients POS_NNS O
with POS_IN O
lung POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D
receiving POS_VBG O
thoracic POS_JJ T
irradiation POS_NN T
in POS_IN O
a POS_DT O
preliminary POS_JJ O
report POS_NN O
from POS_IN O
a POS_DT O
phase POS_NN O
iii POS_JJ O
trial POS_NN O
( POS_( O
n POS_JJ O
= POS_NNP O
144 POS_CD O
) POS_) O

MTX POS_NNP T
in POS_IN O
a POS_DT O
low-dose POS_JJ O
regimen POS_NN O
is POS_VBZ O
useful POS_JJ O
in POS_IN O
refractory POS_NN D
RA POS_NNP D
and POS_CC O
superior POS_JJ O
to POS_TO O
low-dose POS_JJ O
purine POS_NN WORDNET_chemical.n.01 O
analogues POS_NNS O

Twelve POS_CD O
patients POS_NNS O
with POS_IN O
intractable POS_JJ D
rheumatoid POS_NN WORDNET_disease.n.01 D
arthritis POS_NN WORDNET_disease.n.01 D
were POS_VBD O
treated POS_VBN O
with POS_IN O
antilymphocyte POS_JJ T
globulin POS_NN WORDNET_chemical.n.01 T
( POS_( T
ALG POS_NNP T
) POS_) T
, POS_, T
prednisolone POS_NN T
and POS_CC T
a POS_DT T
cytotoxic POS_NN T
agent POS_NN T
, POS_, T
usually POS_RB T
azathioprine POS_VBP T
, POS_, O
and POS_CC O
were POS_VBD O
followed POS_VBN O
for POS_IN O
1 POS_CD O
year POS_NN O

Supramaximal POS_JJ T
medial POS_NN T
and POS_CC T
lateral POS_JJ T
rectus POS_NN WORDNET_body_part.n.01 T
surgery POS_NN MESH_TYPE_qualifier MESH_surgery T
was POS_VBD O
performed POS_VBN O
to POS_TO O
correct POS_VB O
horizontal POS_JJ D
deviations POS_NNS D
in POS_IN D
seven POS_CD D
cases POS_NNS D
of POS_IN D
sixth POS_JJ D
nerve POS_NN WORDNET_body_part.n.01 D
palsy POS_NN D
and POS_CC D
three POS_CD D
cases POS_NNS D
of POS_IN D
third POS_JJ D
nerve POS_NN WORDNET_body_part.n.01 D
palsy POS_NN D
, POS_, O
with POS_IN O
satisfactory POS_JJ O
results POS_NNS O
in POS_IN O
most POS_JJS O
cases POS_NNS O

Treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
advanced POS_JJ D
stage POS_NN D
mycosis POS_NN D
fungoides POS_NNS D
with POS_IN O
bleomycin POS_NN T
, POS_, T
doxorubicin POS_NN T
, POS_, T
and POS_CC T
methotrexate POS_NN T
with POS_IN T
topical POS_JJ T
nitrogen POS_NN WORDNET_chemical.n.01 T
mustard POS_NN WORDNET_chemical.n.01 T
( POS_( T
BAM-M POS_NNP T
) POS_) T

We POS_PRP O
feel POS_VBP O
that POS_IN O
pleuroperitoneal POS_NN T
shunting POS_NN T
is POS_VBZ O
a POS_DT O
valid POS_JJ O
new POS_JJ O
method POS_NN O
for POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
malignant POS_JJ D
pleural POS_JJ D
effusions POS_NNS D
which POS_WDT O
can POS_MD O
effectively POS_RB O
palliate POS_VB O
respiratory POS_NN O
symptoms POS_NNS MESH_TYPE_qualifier MESH_diagnosis O
with POS_IN O
low POS_JJ O
morbidity POS_NN MESH_TYPE_qualifier MESH_epidemiology O

When POS_WRB O
right POS_JJ WORDNET_body_part.n.01 D
ventricular POS_JJ D
failure POS_NN D
prohibits POS_VBZ O
separation POS_NN O
from POS_IN O
cardiopulmonary POS_JJ O
bypass POS_NN WORDNET_body_part.n.01 O
, POS_, O
standard POS_JJ T
methods POS_NNS MESH_TYPE_qualifier MESH_methods T
of POS_IN T
increasing POS_VBG T
pulmonary POS_JJ T
blood POS_NN MESH_TYPE_qualifier MESH_blood T
flow POS_NN T
should POS_MD O
be POS_VB O
employed POS_VBN O
, POS_, O
including POS_VBG O
correction POS_NN WORDNET_treatment.n.01 O
of POS_IN O
hypoxia POS_NN O
and POS_CC O
acidosis POS_NN O
, POS_, O
volume POS_NN O
loading POS_NN O
, POS_, O
and POS_CC O
inotropic POS_JJ O
support POS_NN O
of POS_IN O
the POS_DT O
right POS_JJ WORDNET_body_part.n.01 O
ventricle POS_NN WORDNET_body_part.n.01 O

For POS_IN O
refractory POS_NN D
right POS_JJ WORDNET_body_part.n.01 D
ventricular POS_JJ D
failure POS_NN D
following POS_VBG O
the POS_DT O
surgical POS_JJ O
repair POS_NN O
of POS_IN O
congenital POS_JJ MESH_TYPE_qualifier MESH_congenital O
cardiac POS_JJ O
defects POS_NNS MESH_TYPE_qualifier MESH_abnormalities O
in POS_IN O
which POS_WDT O
the POS_DT O
placement POS_NN O
of POS_IN O
right POS_JJ WORDNET_body_part.n.01 O
atrial POS_NN O
and POS_CC O
pulmonary POS_JJ WORDNET_body_part.n.01 O
artery POS_NN WORDNET_body_part.n.01 O
cannulae POS_NN O
is POS_VBZ O
not POS_RB O
technically POS_RB O
feasible POS_JJ O
, POS_, O
use POS_NN MESH_TYPE_qualifier MESH_utilization T
of POS_IN T
high-frequency POS_NN T
high-volume POS_JJ T
ventilation POS_NN T
appears POS_VBZ O
to POS_TO O
be POS_VB O
quite POS_RB O
promising POS_JJ O

Guiding POS_VBG O
surgical POS_JJ T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
of POS_IN O
ventricular POS_JJ D
tachycardia POS_NN D
by POS_IN O
preoperative POS_JJ O
endocardial POS_JJ O
catheter POS_NN O
mapping POS_VBG O
necessitates POS_NNS O
improvement POS_NN O
of POS_IN O
the POS_DT O
accuracy POS_NN O
of POS_IN O
localization POS_NN O
of POS_IN O
the POS_DT O
arrhythmogenic POS_JJ O
site POS_NN O

Coronary POS_NNP T
angioplasty POS_NN T
for POS_IN O
early POS_JJ D
postinfarction POS_NN D
unstable POS_JJ D
angina POS_NN WORDNET_disease.n.01 D

At POS_IN O
6 POS_CD O
months POS_NNS O
follow-up POS_RB O
26 POS_CD O
% POS_NN O
( POS_( O
14/53 POS_CD O
) POS_) O
of POS_IN O
all POS_PDT O
the POS_DT O
patients POS_NNS O
who POS_WP O
underwent POS_VBP O
angioplasty POS_JJ T
had POS_VBD O
recurrence POS_NN O
of POS_IN O
angina POS_NN WORDNET_disease.n.01 D
, POS_, O
which POS_WDT O
was POS_VBD O
successfully POS_RB O
treated POS_VBN O
with POS_IN O
repeat POS_NN T
angioplasty POS_NN T
, POS_, T
bypass POS_NN WORDNET_body_part.n.01 T
surgery POS_NN MESH_TYPE_qualifier MESH_surgery T
, POS_, T
or POS_CC T
medical POS_JJ T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T

Effect POS_NN O
of POS_IN O
zanamivir POS_NN T
on POS_IN O
duration POS_NN O
and POS_CC O
resolution POS_NN O
of POS_IN O
influenza POS_NN WORDNET_disease.n.01 D
symptoms POS_NNS MESH_TYPE_qualifier MESH_diagnosis O

A POS_DT O
comparison POS_NN O
of POS_IN O
a POS_DT O
five-day POS_JJ O
regimen POS_NN O
of POS_IN O
cefdinir POS_NN T
with POS_IN O
a POS_DT O
seven-day POS_JJ O
regimen POS_NN O
of POS_IN O
loracarbef POS_NN T
for POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
acute POS_JJ O
exacerbations POS_NNS O
of POS_IN O
chronic POS_JJ WORDNET_disease.n.01 D
bronchitis POS_NN WORDNET_disease.n.01 D

Corticosteroids POS_NNS T
for POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
croup POS_NN WORDNET_disease.n.01 D

The POS_DT O
PR POS_NNP O
was POS_VBD O
observed POS_VBN O
in POS_IN O
one POS_CD O
patient POS_NN O
with POS_IN O
non-functioning POS_JJ D
endocrine POS_NN D
pancreatic POS_JJ D
tumor POS_NN D
with POS_IN D
progressive POS_JJ D
liver POS_NN WORDNET_body_part.n.01 D
and POS_CC D
lymph POS_NN WORDNET_body_part.n.01 D
node POS_NN WORDNET_body_part.n.01 D
metastases POS_NNS D
after POS_IN O
16 POS_CD O
months POS_NNS O
of POS_IN O
i.m POS_NN T
. POS_. T
lanreotide POS_JJ T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T

CONCLUSIONS POS_NN O
: POS_: O
Octreotide POS_NNP T
LAR POS_NNP T
20 POS_CD O
mg POS_NN O
shows POS_NNS O
significant POS_JJ O
efficacy POS_NN O
in POS_IN O
terms POS_NNS O
of POS_IN O
objective POS_JJ O
response POS_NN O
rate POS_NN O
( POS_( O
PR POS_NNP O
+ POS_NNP O
SD POS_NNP O
) POS_) O
, POS_, O
biochemical POS_JJ O
and POS_CC O
symptomatic POS_JJ O
control POS_NN MESH_TYPE_qualifier MESH_prevention & control O
in POS_IN O
patients POS_NNS O
with POS_IN O
metastatic POS_JJ MESH_TYPE_qualifier MESH_secondary D
NETs POS_NNP D
of POS_IN O
the POS_DT O
GEP POS_NNP O
system POS_NN WORDNET_body_part.n.01 O
pretreated POS_VBD O
and POS_CC O
progressing POS_VBG O
on POS_IN O
slow POS_JJ O
release POS_NN O
lanreotide POS_NN O

Inchinko-to POS_NNP T
( POS_( T
TJ-135 POS_NNP T
) POS_) T
is POS_VBZ O
a POS_DT O
herbal POS_JJ O
medicine POS_NN O
consisting POS_NN O
of POS_IN O
three POS_CD O
kinds POS_NNS O
of POS_IN O
crude POS_NN O
drugs POS_NNS O
, POS_, O
and POS_CC O
in POS_IN O
Japan POS_NNP O
it POS_PRP O
is POS_VBZ O
administered POS_VBN O
mainly POS_RB O
to POS_TO O
patients POS_NNS O
with POS_IN O
cholestasis POS_NN D

These POS_DT O
results POS_NNS O
suggest POS_VBP O
that POS_IN O
con POS_JJ D
A-induced POS_NNP D
hepatitis POS_NN WORDNET_disease.n.01 D
was POS_VBD O
ameliorated POS_VBN O
by POS_IN O
pretreatment POS_NN O
with POS_IN O
TJ-135 POS_NNP T

Traditionally POS_RB O
, POS_, O
the POS_DT O
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
symptomatic POS_JJ D
bronchiectasis POS_NN D
is POS_VBZ O
based POS_VBN O
on POS_IN O
antibiotics POS_NNS T
, POS_, T
antibronchoobstructive POS_JJ T
medication POS_NN WORDNET_treatment.n.01 T
, POS_, T
and POS_CC T
chest POS_JJS T
physical POS_JJ WORDNET_treatment.n.01 T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T

Bilateral POS_NNP T
lung POS_NN WORDNET_body_part.n.01 T
transplantation POS_NN MESH_TYPE_qualifier MESH_transplantation T
should POS_MD O
be POS_VB O
considered POS_VBN O
in POS_IN O
younger POS_JJR O
patients POS_NNS O
with POS_IN O
severe POS_JJ O
, POS_, O
generalized POS_JJ O
bronchiectasis POS_NN D
and POS_CC D
respiratory POS_NN D
failure POS_NN D

Randomized POS_VBN O
trial POS_NN O
of POS_IN O
interferon-alpha POS_JJ T
plus POS_CC T
ursodeoxycholic POS_JJ T
acid POS_NN WORDNET_chemical.n.01 T
versus POS_NN O
interferon POS_NN T
plus POS_CC T
placebo POS_NN T
in POS_IN O
patients POS_NNS O
with POS_IN O
chronic POS_JJ D
hepatitis POS_NN WORDNET_disease.n.01 D
C POS_NNP WORDNET_disease.n.01 D
resistant POS_NN D
to POS_TO D
interferon POS_VB D

We POS_PRP O
describe POS_VBP O
a POS_DT O
rare POS_JJ O
case POS_NN O
of POS_IN O
spontaneous POS_JJ D
rupture POS_NN D
of POS_IN D
a POS_DT D
hepatic POS_JJ D
metastasis POS_NN D
from POS_IN D
renal POS_JJ D
cell POS_NN D
carcinoma POS_NN WORDNET_disease.n.01 D
that POS_WDT O
was POS_VBD O
treated POS_VBN O
successfully POS_RB O
by POS_IN O
hepatic POS_JJ T
arterial POS_JJ T
embolization POS_NN T

Although POS_IN O
hepatic POS_JJ O
rupture POS_NN O
due POS_JJ O
to POS_TO O
metastatic POS_JJ MESH_TYPE_qualifier MESH_secondary O
cancer POS_NN WORDNET_disease.n.01 O
is POS_VBZ O
extremely POS_RB O
rare POS_JJ O
, POS_, O
transcatheter POS_JJ T
arterial POS_JJ T
embolization POS_NN T
( POS_( T
TAE POS_NNP T
) POS_) T
is POS_VBZ O
an POS_DT O
appropriate POS_JJ O
and POS_CC O
useful POS_JJ O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
for POS_IN O
massive POS_JJ D
hemorrhage POS_NN D
caused POS_VBN D
by POS_IN D
spontaneous POS_JJ D
rupture POS_NN D
of POS_IN D
liver POS_NN WORDNET_body_part.n.01 D
metastasis POS_NN D

Patients POS_NNS O
with POS_IN O
classical POS_JJ O
symptoms POS_NNS MESH_TYPE_qualifier MESH_diagnosis O
such POS_JJ O
as POS_IN O
heartburn POS_NN D
and POS_CC D
regurgitation POS_NN D
may POS_MD O
be POS_VB O
treated POS_VBN O
pharmaceutically POS_RB T
combined POS_VBN T
with POS_IN T
life POS_NN T
style POS_NN WORDNET_body_part.n.01 T
counselling POS_VBG T

BACKGROUND POS_NN O
: POS_: O
An POS_DT O
increasing POS_VBG O
number POS_NN O
of POS_IN O
reports POS_NNS O
indicate POS_VBP O
symptomatic POS_JJ O
relief POS_NN O
of POS_IN O
biliary POS_JJ O
colic POS_NN O
symptoms POS_NNS MESH_TYPE_qualifier MESH_diagnosis O
after POS_IN O
cholecystectomy POS_NN T
for POS_IN O
biliary POS_JJ D
dyskinesia POS_NN D

Effectiveness POS_NN O
of POS_IN O
pseudoephedrine POS_JJ WORDNET_chemical.n.01 T
plus POS_CC T
acetaminophen POS_JJ T
for POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
symptoms POS_NNS MESH_TYPE_qualifier MESH_diagnosis O
attributed POS_VBN O
to POS_TO O
the POS_DT O
paranasal POS_NN O
sinuses POS_VBZ O
associated POS_VBN O
with POS_IN O
the POS_DT O
common POS_JJ D
cold POS_NN WORDNET_disease.n.01 D

OBJECTIVE POS_NN O
: POS_: O
This POS_DT O
retrospective POS_NN O
study POS_NN O
was POS_VBD O
designed POS_VBN O
to POS_TO O
confirm POS_VB O
that POS_IN O
aggressive POS_JJ T
pulmonary POS_JJ T
resection POS_NN T
can POS_MD O
provide POS_VB O
effective POS_JJ O
long-term POS_JJ O
palliation POS_NN O
of POS_IN O
disease POS_NN O
for POS_IN O
patients POS_NNS O
with POS_IN O
pulmonary POS_JJ D
aspergilloma POS_NN D

In POS_IN O
this POS_DT O
study POS_NN O
, POS_, O
we POS_PRP O
investigated POS_VBD O
the POS_DT O
expression POS_NN O
and POS_CC O
therapeutic POS_JJ O
potential POS_NN O
of POS_IN O
TRAIL POS_NNP T
in POS_IN O
cholangiocarcinoma POS_NN D
, POS_, O
one POS_CD O
of POS_IN O
the POS_DT O
most POS_RBS O
devastating POS_JJ O
human POS_JJ O
hepatic POS_JJ O
malignancies POS_NNS O

Induction POS_NN O
of POS_IN O
apoptosis POS_NN O
in POS_IN O
tumor POS_NN O
cells POS_NNS O
is POS_VBZ O
possible POS_JJ O
with POS_IN O
a POS_DT O
biologically POS_RB O
active POS_JJ O
TRAIL POS_NNP T
, POS_, O
and POS_CC O
suggests POS_VBZ O
that POS_IN O
this POS_DT O
cytokine POS_NN WORDNET_chemical.n.01 O
is POS_VBZ O
a POS_DT O
promising POS_JJ O
antitumor POS_NN O
agent POS_NN O
against POS_IN O
human POS_JJ D
cholangiocarcinoma POS_NN D

The POS_DT O
hemorrhage POS_NN D
was POS_VBD O
successfully POS_RB O
stopped POS_VBN O
by POS_IN O
microcoil POS_NN T
embolization POS_NN T

An POS_DT O
open-label POS_JJ O
study POS_NN O
of POS_IN O
lamivudine POS_NN T
for POS_IN O
chronic POS_JJ D
hepatitis POS_NN WORDNET_disease.n.01 D
B POS_NNP WORDNET_disease.n.01 D
in POS_IN O
six POS_CD O
patients POS_NNS O
with POS_IN O
chronic POS_JJ O
renal POS_JJ O
failure POS_NN O
before POS_IN O
and POS_CC O
after POS_IN O
kidney POS_NN WORDNET_body_part.n.01 O
transplantation POS_NN MESH_TYPE_qualifier MESH_transplantation O

PURPOSE POS_NN O
: POS_: O
Inhaled POS_VBN O
corticosteroids POS_NNS T
have POS_VBP O
beneficial POS_JJ O
effects POS_NNS O
on POS_IN O
pulmonary POS_JJ O
function POS_NN MESH_TYPE_qualifier MESH_physiology O
and POS_CC O
inflammation POS_NN O
in POS_IN O
patients POS_NNS O
with POS_IN O
asthma POS_JJ WORDNET_disease.n.01 D
, POS_, O
but POS_CC O
they POS_PRP O
also POS_RB O
cause POS_VBP O
systemic POS_JJ O
adverse POS_JJ MESH_TYPE_qualifier MESH_adverse effects O
effects POS_NNS MESH_TYPE_qualifier MESH_adverse effects O
, POS_, O
such POS_JJ O
as POS_IN O
adrenal POS_JJ O
suppression POS_NN O

We POS_PRP O
conclude POS_VBP O
that POS_IN O
antimicrobial/ POS_VBP T
antituberculous POS_JJ T
agents POS_NNS T
have POS_VBP O
only POS_RB O
a POS_DT O
minor POS_JJ O
short-term POS_JJ O
effect POS_NN O
in POS_IN O
long-lasting POS_JJ O
CGM POS_NNP D
of POS_IN O
undetermined POS_JJ O
cause POS_NN O

A POS_DT O
two-dose POS_JJ O
combined POS_JJ O
hepatitis POS_NN WORDNET_disease.n.01 D
A POS_NNP WORDNET_disease.n.01 D
and POS_CC D
B POS_NNP D
vaccine POS_NN T
would POS_MD O
facilitate POS_VB O
immunisation POS_NN O
programs POS_NNS O

We POS_PRP O
assessed POS_VBD O
the POS_DT O
prevalence POS_NN MESH_TYPE_qualifier MESH_epidemiology O
of POS_IN O
head POS_NN WORDNET_body_part.n.01 O
louse POS_NN O
infestation POS_NN O
and POS_CC O
the POS_DT O
effectiveness POS_NN O
of POS_IN O
1 POS_CD T
% POS_NN T
permethrin POS_NN T
against POS_IN O
head POS_NN WORDNET_body_part.n.01 D
lice POS_NN D
in POS_IN O
Kosovar POS_NNP O
refugees POS_NNS O

PURPOSE POS_NN O
: POS_: O
Macrolide POS_JJ T
antibiotics POS_NNS T
are POS_VBP O
frequently POS_RB O
prescribed POS_VBN O
to POS_TO O
patients POS_NNS O
with POS_IN O
symptoms POS_NNS MESH_TYPE_qualifier MESH_diagnosis D
of POS_IN D
a POS_DT D
common POS_JJ D
cold POS_NN WORDNET_disease.n.01 D

In POS_IN O
conclusion POS_NN O
, POS_, O
in POS_IN O
some POS_DT O
cases POS_NNS O
of POS_IN O
MDR POS_NNP D
TB POS_NNP D
, POS_, O
the POS_DT O
TP POS_NNP T
( POS_( O
if POS_IN O
there POS_EX O
are POS_VBP O
no POS_DT O
pleural POS_JJ O
adherences POS_NNS O
) POS_) O
may POS_MD O
lead POS_VB O
to POS_TO O
good POS_JJ O
results POS_NNS O

Acupuncture POS_NNP WORDNET_treatment.n.01 T
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
common POS_JJ D
cold POS_NN WORDNET_disease.n.01 D

All POS_DT O
children POS_NNS O
with POS_IN O
croup POS_NN WORDNET_disease.n.01 D
symptoms POS_NNS MESH_TYPE_qualifier MESH_diagnosis O
who POS_WP O
demonstrate POS_VBP O
increased POS_VBN O
work POS_NN O
of POS_IN O
breathing POS_VBG O
in POS_IN O
the POS_DT O
clinics POS_NNS O
or POS_CC O
emergency POS_NN O
departments POS_NNS O
should POS_MD O
be POS_VB O
treated POS_VBN O
with POS_IN O
glucocorticoids POS_NNS T

Clinical POS_JJ O
trials POS_NNS O
show POS_VBP O
levofloxacin POS_VBZ T
to POS_TO O
be POS_VB O
as POS_RB O
effective POS_JJ O
as POS_IN O
cephalosporins POS_NNS O
in POS_IN O
acute POS_JJ O
exacerbation POS_NN O
of POS_IN O
chronic POS_JJ WORDNET_disease.n.01 D
bronchitis POS_NN WORDNET_disease.n.01 D
and POS_CC O
as POS_RB O
effective POS_JJ O
as POS_IN O
co-amoxiclav POS_NN O
, POS_, O
cephalosporins POS_VBZ O
or POS_CC O
amoxycillin POS_NN O
in POS_IN O
community-acquired POS_JJ D
pneumonia POS_NN WORDNET_disease.n.01 D

Humoral POS_NNP O
immune POS_NN O
response POS_NN O
after POS_IN O
vaccination POS_NN T
against POS_IN O
influenza POS_NN WORDNET_disease.n.01 D
in POS_IN O
patients POS_NNS O
with POS_IN O
breast POS_NN WORDNET_body_part.n.01 WORDNET_disease.n.01 O
cancer POS_NN WORDNET_disease.n.01 O

A POS_DT O
combined POS_JJ T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
results POS_NNS O
in POS_IN O
eradication POS_NN O
of POS_IN O
the POS_DT O
bacterium POS_NN D
and POS_CC O
in POS_IN O
improvement POS_NN O
of POS_IN O
the POS_DT O
clinical POS_JJ O
symptoms POS_NNS MESH_TYPE_qualifier MESH_diagnosis O
in POS_IN O
a POS_DT O
significant POS_JJ O
majority POS_NN O
of POS_IN O
the POS_DT O
patients POS_NNS O

OBJECTIVE POS_NN O
: POS_: O
to POS_TO O
evaluate POS_VB O
the POS_DT O
possible POS_JJ O
existence POS_NN O
of POS_IN O
the POS_DT O
so-called POS_JJ O
< POS_JJ O
Roux-en-Y POS_NNP O
syndrome POS_NN O
> POS_NN O
in POS_IN O
a POS_DT O
group POS_NN O
of POS_IN O
21 POS_CD O
patients POS_NNS O
who POS_WP O
underwent POS_VBP O
surgery POS_NN MESH_TYPE_qualifier MESH_surgery T
to POS_TO O
correct POS_VB O
postoperative POS_JJ D
alkaline POS_NN D
reflux POS_NN D
gastritis POS_NN D

Quality-of-life POS_JJ O
assessments POS_NNS O
in POS_IN O
patients POS_NNS O
with POS_IN O
mild POS_JJ O
to POS_TO O
moderate POS_VB O
disease POS_NN O
show POS_NN O
that POS_WDT O
inhaled POS_VBD T
fluticasone POS_RB T
propionate POS_JJ T
achieved POS_VBD O
improvements POS_NNS O
which POS_WDT O
were POS_VBD O
deemed POS_VBN O
to POS_TO O
be POS_VB O
clinically POS_RB O
meaningful POS_JJ O
in POS_IN O
patients POS_NNS O
with POS_IN O
mild POS_JJ O
to POS_TO O
moderate POS_VB O
asthma POS_NN WORDNET_disease.n.01 D
; POS_: O
these POS_DT O
changes POS_NNS O
were POS_VBD O
significantly POS_RB O
greater POS_JJR O
than POS_IN O
those POS_DT O
achieved POS_VBN O
with POS_IN O
oral POS_JJ O
zafirlukast POS_NN O
, POS_, O
inhaled POS_VBD O
triamcinolone POS_NN O
acetonide POS_NN O
or POS_CC O
placebo POS_NN O

Ribavirin POS_NNP T
in POS_IN T
combination POS_NN T
with POS_IN T
IFN POS_NNP T
alpha POS_NN T
exerts POS_VBZ O
an POS_DT O
additional POS_JJ O
anti-viral/immunmodulatory POS_NN O
effect POS_NN O
which POS_WDT O
manifests POS_VBZ O
itself POS_PRP O
in POS_IN O
phase POS_NN O
2 POS_CD O
of POS_IN O
hepatitis POS_NN WORDNET_disease.n.01 D
C POS_NNP WORDNET_disease.n.01 D
viremia POS_NN D
decline POS_NN O

CONCLUSION POS_NN O
: POS_: O
In POS_IN O
patients POS_NNS O
with POS_IN O
asthma POS_JJ WORDNET_disease.n.01 D
receiving POS_VBG O
repeated POS_VBN T
inhaled POS_JJ T
doses POS_NNS T
of POS_IN T
FP POS_NNP T
, POS_, O
the POS_DT O
systemic POS_JJ O
exposure POS_NN O
( POS_( O
AUC POS_NNP O
) POS_) O
after POS_IN O
inhalation POS_NN O
from POS_IN O
the POS_DT O
Diskus POS_NNP O
was POS_VBD O
similar POS_JJ O
to POS_TO O
that POS_DT O
from POS_IN O
the POS_DT O
Diskhaler POS_NNP O
, POS_, O
with POS_IN O
no POS_DT O
difference POS_NN O
between POS_IN O
the POS_DT O
DPIs POS_NNP O
in POS_IN O
the POS_DT O
effects POS_NNS O
on POS_IN O
cortisol POS_NN O
suppression POS_NN O

We POS_PRP O
examined POS_VBD O
the POS_DT O
remnant POS_JJ O
stomach POS_NN WORDNET_body_part.n.01 O
for POS_IN O
H. POS_NNP O
pylori POS_FW O
infection POS_NN O
after POS_IN O
gastrectomy POS_NN T
for POS_IN O
gastric POS_JJ D
cancer POS_NN WORDNET_disease.n.01 D
or POS_CC D
peptic POS_JJ D
ulcer POS_NN D
between POS_IN O
October POS_NNP O
1992 POS_CD O
and POS_CC O
July POS_NNP O
1997 POS_CD O

The POS_DT O
current POS_JJ O
report POS_NN O
considers POS_VBZ O
the POS_DT O
additional POS_JJ O
benefit POS_NN O
of POS_IN O
combination POS_NN T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
( POS_( T
interferon POS_JJ T
alfa POS_NN T
and POS_CC T
ribavirin POS_NN T
) POS_) T
compared POS_VBN O
with POS_IN O
monotherapy POS_NN O
( POS_( O
interferon POS_JJ O
alfa POS_NN O
alone POS_RB O
) POS_) O
for POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
patients POS_NNS O
with POS_IN O
chronic POS_JJ D
hepatitis POS_NN WORDNET_disease.n.01 D
C POS_NNP WORDNET_disease.n.01 D

CONCLUSION POS_NN O
: POS_: O
Although POS_IN O
tacrolimus POS_NN T
is POS_VBZ O
effective POS_JJ O
induction POS_NN O
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy O
for POS_IN O
severe POS_JJ D
ulcerative POS_JJ D
or POS_CC D
Crohn POS_NNP D
's POS_POS D
colitis POS_NN D
, POS_, O
fewer POS_JJR O
than POS_IN O
50 POS_CD O
% POS_NN O
of POS_IN O
patients POS_NNS O
treated POS_VBN O
will POS_MD O
successfully POS_RB O
achieve POS_VB O
a POS_DT O
long-term POS_JJ O
remission POS_NN O

Cytomegalovirus POS_NNP D
( POS_( D
CMV POS_NNP D
) POS_) D
infection POS_NN D
was POS_VBD O
one POS_CD O
of POS_IN O
the POS_DT O
most POS_RBS O
common POS_JJ O
opportunistic POS_JJ O
infections POS_NNS O
in POS_IN O
AIDS POS_NNP WORDNET_disease.n.01 O
patients POS_NNS O
, POS_, O
leading POS_VBG O
to POS_TO O
blindness POS_VB O
or POS_CC O
life-threatening POS_JJ O
disease POS_NN O
in POS_IN O
about POS_RB O
40 POS_CD O
% POS_NN O
of POS_IN O
patients POS_NNS O
in POS_IN O
the POS_DT O
later POS_JJ O
stages POS_NNS O
of POS_IN O
AIDS POS_NNP WORDNET_disease.n.01 O
before POS_IN O
highly POS_RB T
active POS_JJ T
antiretroviral POS_JJ T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
( POS_( T
HAART POS_NNP T
) POS_) T

Side POS_JJ WORDNET_body_part.n.01 MESH_TYPE_qualifier MESH_adverse effects O
effects POS_NNS MESH_TYPE_qualifier MESH_adverse effects O
from POS_IN O
influenza POS_JJ WORDNET_disease.n.01 D
vaccination POS_NN T
: POS_: O
differences POS_NNS O
between POS_IN O
returned POS_VBN O
and POS_CC O
random POS_JJ O
surveys POS_NNS O

Patient POS_JJ O
1 POS_CD O
demonstrated POS_VBN O
dramatic POS_JJ O
clearing POS_NN O
of POS_IN O
his POS_PRP$ O
MCV POS_NNP D
lesions POS_NNS D
when POS_WRB O
intravenous POS_JJ T
cidofovir POS_NN T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
was POS_VBD O
started POS_VBN O
for POS_IN O
his POS_PRP$ O
treatment-resistant POS_JJ D
bilateral POS_JJ D
CMV POS_NNP D
retinitis POS_NN D
and POS_CC O
because POS_IN O
of POS_IN O
cidofovir POS_NN T
's POS_POS T
possible POS_JJ O
activity POS_NN O
against POS_IN O
MCV POS_NNP D

In POS_IN O
case POS_NN O
3 POS_CD O
, POS_, O
intravenous POS_JJ T
cidofovir POS_NN T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
was POS_VBD O
started POS_VBN O
both POS_DT O
for POS_IN O
CMV POS_NNP D
retinitis POS_NN D
and POS_CC O
in POS_IN O
an POS_DT O
attempt POS_NN O
to POS_TO O
clear POS_VB O
90 POS_CD O
% POS_NN O
facial POS_JJ WORDNET_body_part.n.01 O
MCV POS_NNP D
involvement POS_NN O
; POS_: O
after POS_IN O
1 POS_CD O
month POS_NN O
of POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
, POS_, O
all POS_DT O
clinical POS_JJ O
evidence POS_NN O
of POS_IN O
MCV POS_NNP D
had POS_VBD O
resolved POS_VBN O

OBJECTIVE POS_NN O
: POS_: O
This POS_DT O
study POS_NN O
aimed POS_VBD O
to POS_TO O
determine POS_VB O
the POS_DT O
effect POS_NN O
of POS_IN O
external POS_JJ T
beam POS_NN T
radiation POS_NN WORDNET_body_part.n.01 MESH_TYPE_qualifier MESH_radiotherapy T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_radiotherapy MESH_therapy T
on POS_IN O
choroidal POS_JJ D
neovascularization POS_NN D
( POS_( D
CNV POS_NNP D
) POS_) D
secondary POS_JJ MESH_TYPE_qualifier MESH_secondary O
to POS_TO O
age-related POS_JJ WORDNET_disease.n.01 D
macular POS_JJ WORDNET_disease.n.01 D
degeneration POS_NN WORDNET_disease.n.01 D
( POS_( D
AMD POS_NNP D
) POS_) D

We POS_PRP O
systematically POS_RB O
reviewed POS_VBD O
the POS_DT O
evidence POS_NN O
concerning POS_VBG O
the POS_DT O
ability POS_NN O
of POS_IN O
five POS_CD O
systemic POS_JJ T
treatments POS_NNS T
to POS_TO O
induce POS_VB O
remission POS_NN O
in POS_IN O
patients POS_NNS O
with POS_IN O
severe POS_JJ D
psoriasis POS_NN WORDNET_disease.n.01 D
: POS_: O
ultraviolet POS_NN T
B POS_NNP T
( POS_( T
UVB POS_NNP T
) POS_) T
, POS_, O
photochemotherapy POS_NN T
( POS_( T
PUVA POS_NNP T
) POS_) T
, POS_, O
methotrexate POS_NN T
( POS_( T
MTX POS_NNP T
) POS_) T
, POS_, O
retinoids POS_NNS T
( POS_( T
RET POS_NNP T
) POS_) T
and POS_CC O
cyclosporin POS_VB T
A POS_NNP T
( POS_( T
CYA POS_NNP T
) POS_) T

PURPOSE POS_NN O
: POS_: O
We POS_PRP O
report POS_VBP O
a POS_DT O
multicenter POS_NN O
experience POS_NN O
using POS_VBG O
tubularized POS_VBN T
incised POS_JJ T
plate POS_NN WORDNET_body_part.n.01 T
urethroplastym POS_NN T
for POS_IN O
proximal POS_JJ D
hypospadias POS_NN D

CONCLUSIONS POS_NN O
: POS_: O
Tubularized POS_VBN T
incised POS_JJ T
plate POS_NN WORDNET_body_part.n.01 T
urethroplasty POS_NN T
is POS_VBZ O
a POS_DT O
versatile POS_JJ O
operation POS_NN O
that POS_WDT O
corrects POS_VBZ O
proximal POS_JJ D
hypospadias POS_NNS D
defects POS_NNS MESH_TYPE_qualifier MESH_abnormalities D
with POS_IN O
few POS_JJ O
complications POS_NNS MESH_TYPE_qualifier MESH_complications O
and POS_CC O
superior POS_JJ O
cosmetic POS_JJ O
results POS_NNS O

Women POS_NNS O
randomised POS_VBD O
to POS_TO O
screen-and-treat POS_JJ O
received POS_JJ O
appropriate POS_NN O
antibiotics POS_NNS T
only POS_RB O
if POS_IN O
screening POS_VBG MESH_TYPE_qualifier MESH_diagnosis O
proved POS_VBD O
positive POS_JJ O
for POS_IN O
one POS_CD O
or POS_CC O
more POS_JJR O
infection POS_NN D

Besides POS_IN O
the POS_DT O
well-known POS_JJ O
nonsteroidal POS_JJ T
antiinflammatory POS_NN T
drugs POS_NNS T
( POS_( T
NSAID POS_NNP T
) POS_) T
for POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
rheumatic POS_JJ D
pain POS_NN D
herbal POS_JJ T
medicine POS_NN T
can POS_MD O
also POS_RB O
be POS_VB O
applied POS_VBN O
successfully POS_RB O

High-dose POS_NNP T
intravenous POS_JJ T
immunoglobulin POS_NN WORDNET_chemical.n.01 T
( POS_( T
hdIVIg POS_NN T
) POS_) T
is POS_VBZ O
increasingly POS_RB O
used POS_VBN O
to POS_TO O
treat POS_VB O
a POS_DT O
range POS_NN O
of POS_IN O
inflammatory POS_NN D
and POS_CC D
autoimmune POS_NN D
diseases POS_NNS D

METHODS POS_NN MESH_TYPE_qualifier MESH_methods O
: POS_: O
During POS_IN O
a POS_DT O
19-month POS_JJ O
period POS_NN O
, POS_, O
seven POS_CD O
children POS_NNS O
with POS_IN O
empyema POS_JJ WORDNET_disease.n.01 D
underwent POS_JJ O
thoracoscopy POS_NN T

However POS_RB O
, POS_, O
recent POS_JJ O
clinical POS_JJ O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
monoclonal POS_JJ T
antibodies POS_NNS T
( POS_( T
mAbs POS_NN T
) POS_) T
in POS_IN O
patients POS_NNS O
with POS_IN O
low-grade POS_JJ D
or POS_CC D
transformed POS_VBN D
low-grade POS_JJ D
NHL POS_NNP D
has POS_VBZ O
resulted POS_VBN O
in POS_IN O
less POS_JJR O
toxicity POS_NN MESH_TYPE_qualifier MESH_toxicity O
than POS_IN O
conventional POS_JJ O
treatments POS_NNS O
, POS_, O
as POS_RB O
well POS_RB O
as POS_IN O
response POS_NN O
rates POS_NNS O
that POS_WDT O
are POS_VBP O
comparable POS_JJ O
or POS_CC O
superior POS_JJ O
to POS_TO O
those POS_DT O
achieved POS_VBN O
with POS_IN O
chemotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_drug therapy T

RESULTS POS_NN O
: POS_: O
Clinical POS_JJ O
trials POS_NNS O
of POS_IN O
UFT POS_NNP T
published POS_VBN O
in POS_IN O
the POS_DT O
Western POS_JJ O
world POS_NN O
have POS_VBP O
included POS_VBN O
581 POS_CD O
patients POS_NNS O
with POS_IN O
colorectal POS_JJ D
cancer POS_NN WORDNET_disease.n.01 D

< POS_JJ O
TO_SEE POS_NNP O
> POS_NNP O
As POS_IN O
concomitant POS_JJ D
thrombocytosis POS_NN D
persisted POS_VBD O
despite POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
with POS_IN O
hydroxyurea POS_NN T
, POS_, O
the POS_DT O
new POS_JJ O
megakaryocyte POS_NN T
inhibitor POS_NN T
anagrelide POS_NN T
( POS_( T
Agrelin POS_NNP T
) POS_) T
was POS_VBD O
administered POS_VBN O
and POS_CC O
led POS_VBN O
to POS_TO O
normalization POS_NN O
of POS_IN O
the POS_DT O
platelet POS_NN O
count POS_NN O
within POS_IN O
11 POS_CD O
days POS_NNS O

Studies POS_NNS O
with POS_IN O
various POS_JJ O
interferon POS_NN T
alpha POS_NN T
preparations POS_NNS T
, POS_, O
including POS_VBG O
interferons POS_NNS T
induced POS_VBN O
in POS_IN O
human POS_JJ O
leukocytes POS_NNS O
, POS_, O
interferon POS_NN T
alfa-N1 POS_NN T
, POS_, O
interferon POS_VB T
alfa-2a POS_NN T
, POS_, O
and POS_CC O
interferon POS_VB T
alfa-2b POS_NN T
, POS_, O
have POS_VBP O
all POS_DT O
provided POS_VBN O
evidence POS_NN O
for POS_IN O
modest POS_JJ O
but POS_CC O
reproducible POS_JJ O
antitumor POS_NN O
activity POS_NN O
in POS_IN O
advanced POS_JJ D
renal POS_JJ D
cell POS_NN D
carcinoma POS_NN WORDNET_disease.n.01 D

Preliminary POS_JJ O
evidence POS_NN O
suggests POS_VBZ O
that POS_IN O
interferons POS_NNS T
beta POS_NNS T
and POS_CC T
gamma POS_NN T
may POS_MD O
also POS_RB O
induce POS_VB O
regression POS_NN O
of POS_IN O
metastatic POS_JJ MESH_TYPE_qualifier MESH_secondary D
renal POS_NN D
cell POS_NN D
carcinoma POS_NN WORDNET_disease.n.01 D

Splenectomy POS_NNP T
presumably POS_RB O
alleviates POS_VBZ O
the POS_DT O
pancytopenic POS_JJ O
effect POS_NN O
of POS_IN O
hypersplenism POS_NN D
by POS_IN O
removing POS_VBG O
the POS_DT O
preferred POS_JJ O
site POS_NN O
of POS_IN O
leukemic POS_JJ O
cell POS_NN O
proliferation POS_NN O

Recombinant POS_NNP O
and POS_CC O
natural POS_JJ O
forms POS_NNS O
of POS_IN O
interferon POS_NN T
alpha POS_NNS T
have POS_VBP O
been POS_VBN O
shown POS_VBN O
to POS_TO O
bring POS_VB O
about POS_RP O
tumor POS_NN O
regressions POS_NNS O
in POS_IN O
patients POS_NNS O
with POS_IN O
low-grade POS_JJ D
non-Hodgkin POS_NN D
's POS_POS D
lymphoma POS_NN WORDNET_disease.n.01 D

PATIENTS POS_NNS O
AND POS_CC O
METHODS POS_NNP MESH_TYPE_qualifier MESH_methods O
: POS_: O
Twenty-three POS_JJ O
previously POS_RB O
untreated POS_JJ O
patients POS_NNS O
with POS_IN O
stage POS_NN D
III POS_NNP D
or POS_CC D
IV POS_NNP D
SCCHN POS_NNP D
and POS_CC O
Eastern POS_NNP O
Cooperative POS_NNP O
Oncology POS_NNP WORDNET_medicine.n.01 O
Group POS_NNP O
functional POS_JJ O
status POS_NN O
less POS_JJR O
than POS_IN O
or POS_CC O
equal POS_JJ O
to POS_TO O
2 POS_CD O
were POS_VBD O
treated POS_VBN O
with POS_IN O
TPFL5 POS_NNP T

The POS_DT O
inhibitory POS_JJ O
effect POS_NN O
of POS_IN O
n-3 POS_JJ T
polyunsaturated POS_JJ T
fatty POS_JJ T
acids POS_NNS T
on POS_IN O
human POS_JJ D
colorectal POS_NN D
cancer POS_NN WORDNET_disease.n.01 D
has POS_VBZ O
been POS_VBN O
speculated POS_VBN O
on POS_IN O
from POS_IN O
epidemiological POS_JJ O
data POS_NNS O
and POS_CC O
animal POS_NN O
studies POS_NNS O

Gene POS_NNP T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
of POS_IN O
malignant POS_JJ D
brain POS_NN WORDNET_body_part.n.01 D
tumors POS_NNS D

New POS_NNP O
technique POS_NN O
for POS_IN O
mesh POS_JJ T
repair POS_NN T
of POS_IN O
paracolostomy POS_NN D
hernias POS_NN D

Extended POS_VBN O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
glatiramer POS_NN T
acetate POS_NN WORDNET_chemical.n.01 T
( POS_( T
Copaxone POS_NNP T
) POS_) T
is POS_VBZ O
well POS_RB O
tolerated POS_VBN O
and POS_CC O
maintains POS_VBZ O
its POS_PRP$ O
clinical POS_JJ O
effect POS_NN O
on POS_IN O
multiple POS_JJ WORDNET_disease.n.01 D
sclerosis POS_NN WORDNET_disease.n.01 D
relapse POS_NN O
rate POS_NN O
and POS_CC O
degree POS_NN O
of POS_IN O
disability POS_NN O

Assessment POS_NN O
of POS_IN O
atrioventricular POS_JJ T
junction POS_NN T
ablation POS_NN T
and POS_CC T
VVIR POS_NNP T
pacemaker POS_NN WORDNET_body_part.n.01 T
versus POS_NN O
pharmacological POS_JJ T
treatment POS_NN MESH_TYPE_qualifier MESH_therapy T
in POS_IN O
patients POS_NNS O
with POS_IN O
heart POS_NN WORDNET_body_part.n.01 D
failure POS_NN D
and POS_CC D
chronic POS_JJ D
atrial POS_JJ D
fibrillation POS_NN D
: POS_: O
a POS_DT O
randomized POS_NN O
, POS_, O
controlled POS_VBD O
study POS_NN O

Repair POS_NN O
of POS_IN O
ventral POS_JJ D
hernias POS_NN D
with POS_IN O
expanded POS_JJ T
polytetrafluoroethylene POS_NN T
patch POS_NN T

Endoscopic POS_NNP T
excision POS_NN T
of POS_IN O
a POS_DT D
forehead POS_JJ D
mass POS_NN D

Effect POS_NN O
of POS_IN O
photodynamic POS_JJ T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
in POS_IN T
combination POS_NN T
with POS_IN T
mitomycin POS_JJ T
C POS_NNP T
on POS_IN O
a POS_DT O
mitomycin-resistant POS_JJ D
bladder POS_NN WORDNET_body_part.n.01 D
cancer POS_NN WORDNET_disease.n.01 D
cell POS_NN O
line POS_NN O

Current POS_JJ O
surgical POS_JJ T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
for POS_IN O
bronchiectasis POS_NN D

Surgical POS_JJ T
treatment POS_NN MESH_TYPE_qualifier MESH_therapy T
for POS_IN O
lung POS_NN WORDNET_body_part.n.01 D
hydatid POS_NN D
disease POS_NN D

Sex POS_NN O
differences POS_NNS O
in POS_IN O
the POS_DT O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
asthma POS_JJ WORDNET_disease.n.01 D
drugs POS_NNS T
: POS_: O
cross POS_NN O
sectional POS_NN O
study POS_NN O

Adrenal-sparing POS_JJ T
surgery POS_NN MESH_TYPE_qualifier MESH_surgery T
for POS_IN O
phaeochromocytoma POS_NN D

A POS_DT O
modified POS_JJ O
technique POS_NN O
of POS_IN O
tubeless POS_NN O
anaesthesia POS_NN O
for POS_IN O
microlaryngoscopy POS_NN T
and POS_CC T
bronchoscopy POS_NN T
in POS_IN O
young POS_JJ O
children POS_NNS O
with POS_IN O
stridor POS_NN D

Recombinant POS_JJ T
glycoprotein POS_NN WORDNET_chemical.n.01 T
vaccine POS_NN T
for POS_IN O
the POS_DT O
prevention POS_NN MESH_TYPE_qualifier MESH_prevention & control O
of POS_IN O
genital POS_JJ D
HSV-2 POS_JJ D
infection POS_NN D
: POS_: O
two POS_CD O
randomized POS_VBD O
controlled POS_VBN O
trials POS_NNS O

< POS_JJ O
TO_SEE POS_NNP O
> POS_NNP O
Fatal POS_NNP D
acute POS_JJ D
haemolysis POS_NN D
in POS_IN O
an POS_DT O
AIDS POS_NNP WORDNET_disease.n.01 D
patient POS_NN O
treated POS_VBD O
with POS_IN O
lindinavir POS_NN T

Gene POS_NNP T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
for POS_IN O
myocardial POS_JJ D
angiogenesis POS_NN D

Dipyridamole POS_NNP T
plus POS_CC T
aspirin POS_NN WORDNET_chemical.n.01 T
in POS_IN O
cerebrovascular POS_JJ D
disease POS_NN D

The POS_DT O
effects POS_NNS O
of POS_IN O
oral POS_JJ T
liarozole POS_NN T
on POS_IN O
epidermal POS_JJ O
proliferation POS_NN O
and POS_CC O
differentiation POS_NN O
in POS_IN O
severe POS_JJ D
plaque POS_NN D
psoriasis POS_NN WORDNET_disease.n.01 D
are POS_VBP O
comparable POS_JJ O
with POS_IN O
those POS_DT O
of POS_IN O
acitretin POS_NN T
. POS_. O

Safety POS_NN O
and POS_CC O
potential POS_JJ O
effectiveness POS_NN O
of POS_IN O
daunorubicin-containing POS_JJ T
liposomes POS_NNS T
in POS_IN O
patients POS_NNS O
with POS_IN O
advanced POS_JJ D
recurrent POS_NN D
malignant POS_JJ D
CNS POS_NNP D
tumors POS_NNS D

Lutein POS_NNP T
improves POS_VBZ O
visual POS_JJ O
function POS_NN MESH_TYPE_qualifier MESH_physiology O
in POS_IN O
some POS_DT O
patients POS_NNS O
with POS_IN O
retinal POS_JJ D
degeneration POS_NN D
: POS_: O
a POS_DT O
pilot POS_NN O
study POS_NN O
via POS_IN O
the POS_DT O
Internet POS_NNP O

Our POS_PRP$ O
results POS_NNS O
in POS_IN O
the POS_DT O
surgical POS_JJ T
treatment POS_NN MESH_TYPE_qualifier MESH_therapy T
of POS_IN O
habitual POS_JJ D
shoulder POS_NN WORDNET_body_part.n.01 D
dislocation POS_NN D
with POS_IN O
special POS_JJ O
reference POS_NN O
to POS_TO O
occupational POS_JJ O
disability POS_NN O

Alkaline POS_NNP O
phosphatase POS_NN WORDNET_chemical.n.01 O
in POS_IN O
neutrophil POS_JJ O
leukocytes POS_NNS O
of POS_IN O
patients POS_NNS O
with POS_IN O
infectious POS_JJ WORDNET_disease.n.01 D
mononucleosis POS_NN WORDNET_disease.n.01 D
and POS_CC O
the POS_DT O
effect POS_NN O
of POS_IN O
corticosteroid POS_NN T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T

The POS_DT O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
quinidine POS_NN T
sulphate POS_NN T
for POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
atrial POS_JJ D
fibrillation POS_NN D
in POS_IN O
twelve POS_NN O
horses POS_NNS O

Blood POS_NN MESH_TYPE_qualifier MESH_blood O
volume POS_NN O
measurements POS_NNS O
in POS_IN O
burn POS_NN D
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T

The POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
autoimmune POS_JJ D
hemolytic POS_JJ D
anemia POS_NN D
with POS_IN O
heparin POS_NN WORDNET_chemical.n.01 T

Effects POS_NNS O
of POS_IN O
clomiphene POS_NN T
citrate POS_NN WORDNET_chemical.n.01 T
on POS_IN O
endometrial POS_JJ D
hyperplasia POS_NN D
in POS_IN O
the POS_DT O
premenopausal POS_NN O
female POS_NN O

Prolonged POS_VBN O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
methyldopa POS_NN T
in POS_IN O
severe POS_JJ D
hypertension POS_NN D
in POS_IN O
pregnancy POS_NN O

Glutathione POS_NNP O
S-transferase POS_NNP O
activity POS_NN O
in POS_IN O
epithelial POS_JJ D
ovarian POS_JJ D
cancer POS_NN WORDNET_disease.n.01 D
: POS_: O
association POS_NN O
with POS_IN O
response POS_NN O
to POS_TO O
chemotherapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_drug therapy T
and POS_CC O
disease POS_NN O
outcome POS_NN O

Flutamide POS_NNP T
plus POS_CC T
castration POS_NN T
in POS_IN O
patients POS_NNS O
with POS_IN O
previously POS_RB O
untreated POS_JJ O
prostate POS_NN WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D

Anal POS_NNP O
continence POS_NN O
after POS_IN O
surgery POS_NN MESH_TYPE_qualifier MESH_surgery T
for POS_IN O
rectal POS_NN D
prolapse POS_NN D

Dosing POS_VBG O
of POS_IN O
amoxicillin/clavulanate POS_NN T
for POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
lower POS_JJR WORDNET_body_part.n.01 D
respiratory POS_NN WORDNET_body_part.n.01 D
tract POS_NN WORDNET_body_part.n.01 D
infection POS_NN D

Another POS_DT O
potential POS_JJ O
use POS_NN MESH_TYPE_qualifier MESH_utilization O
of POS_IN O
troglitazone POS_NN T
in POS_IN O
noninsulin-dependent POS_JJ D
diabetes POS_NNS WORDNET_disease.n.01 D
mellitus POS_VBP WORDNET_disease.n.01 D

The POS_DT O
protective POS_JJ O
effect POS_NN O
of POS_IN O
condoms POS_NNS T
and POS_CC O
nonoxynol-9 POS_JJ T
against POS_IN O
HIV POS_NNP D
infection POS_NN D

The POS_DT O
effect POS_NN O
of POS_IN O
an POS_DT O
endothelin-receptor POS_JJ T
antagonist POS_NN WORDNET_body_part.n.01 T
, POS_, T
bosentan POS_NN T
, POS_, O
on POS_IN O
blood POS_NN MESH_TYPE_qualifier MESH_blood O
pressure POS_NN O
in POS_IN O
patients POS_NNS O
with POS_IN O
essential POS_JJ D
hypertension POS_NN D
. POS_. O

Long-term POS_JJ O
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy O
with POS_IN O
long-acting POS_JJ T
octreotide POS_NN T
( POS_( T
Sandostatin-LAR POS_NNP T
) POS_) T
for POS_IN O
the POS_DT O
management POS_NN O
of POS_IN O
acromegaly POS_NN D

Montelukast POS_NNP T
, POS_, T
a POS_DT T
leukotriene-receptor POS_JJ T
antagonist POS_NN WORDNET_body_part.n.01 T
, POS_, T
for POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
mild POS_JJ D
asthma POS_NNS WORDNET_disease.n.01 D
and POS_CC D
exercise-induced POS_JJ D
bronchoconstriction POS_NN D

Percutaneous POS_JJ T
transluminal POS_JJ T
angioplasty POS_NN T
in POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
renovascular POS_JJ D
hypertension POS_NN D
: POS_: O
sequential POS_JJ O
prospective POS_NN O
study POS_NN O

Pathological POS_JJ O
staging POS_NN O
and POS_CC O
biochemical POS_JJ O
recurrence POS_NN O
after POS_IN O
neoadjuvant POS_JJ T
androgen POS_NN T
deprivation POS_NN T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
in POS_IN O
combination POS_NN O
with POS_IN O
radical POS_JJ T
prostatectomy POS_NN T
in POS_IN O
clinically POS_RB O
localized POS_JJ O
prostate POS_NN WORDNET_disease.n.01 D
cancer POS_NN WORDNET_disease.n.01 D

Acute POS_NNP O
effect POS_NN O
of POS_IN O
lorazepam POS_NN T
on POS_IN O
respiratory POS_NN O
muscles POS_NNS O
in POS_IN O
patients POS_NNS O
with POS_IN O
chronic POS_JJ WORDNET_disease.n.01 D
obstructive POS_JJ WORDNET_disease.n.01 D
pulmonary POS_JJ WORDNET_disease.n.01 D
disease POS_NN WORDNET_disease.n.01 D

5-year POS_JJ O
outcome POS_NN O
of POS_IN O
surgical POS_JJ T
resection POS_NN T
and POS_CC O
watchful POS_JJ O
waiting POS_VBG O
for POS_IN O
men POS_NNS O
with POS_IN O
moderately POS_RB O
symptomatic POS_JJ O
benign POS_NN D
prostatic POS_JJ D
hyperplasia POS_NN D
: POS_: O
a POS_DT O
Department POS_NNP O
of POS_IN O
Veterans POS_NNP O
Affairs POS_NNP O
cooperative POS_NN O
study POS_NN O

IDA-FLAG POS_NNP T
( POS_( T
idarubicin POS_NN T
, POS_, T
fludarabine POS_NN T
, POS_, T
cytarabine POS_NN T
, POS_, T
G-CSF POS_NNP T
) POS_) T
, POS_, O
an POS_DT O
effective POS_JJ O
remission-induction POS_NN T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
for POS_IN O
poor-prognosis POS_NN D
AML POS_NNP D
of POS_IN D
childhood POS_NN D
prior POS_RB O
to POS_TO O
allogeneic POS_VB O
or POS_CC O
autologous POS_JJ O
bone POS_NN WORDNET_body_part.n.01 O
marrow POS_NN WORDNET_body_part.n.01 O
transplantation POS_NN MESH_TYPE_qualifier MESH_transplantation O
: POS_: O
experiences POS_NNS O
of POS_IN O
a POS_DT O
phase POS_NN O
II POS_NNP O
trial POS_NN O

Open POS_JJ T
capsulorrhaphy POS_NN T
with POS_IN T
suture POS_NN WORDNET_body_part.n.01 T
anchors POS_NNS T
for POS_IN O
recurrent POS_NN D
anterior POS_JJ D
dislocation POS_NN D
of POS_IN D
the POS_DT D
shoulder POS_NN WORDNET_body_part.n.01 D

Randomised POS_VBN O
trial POS_NN O
of POS_IN O
irinotecan POS_JJ T
versus POS_NN O
fluorouracil POS_NN T
by POS_IN O
continuous POS_JJ O
infusion POS_NN O
after POS_IN O
fluorouracil POS_JJ O
failure POS_NN O
in POS_IN O
patients POS_NNS O
with POS_IN O
metastatic POS_JJ MESH_TYPE_qualifier MESH_secondary D
colorectal POS_NN D
cancer POS_NN WORDNET_disease.n.01 D

Antibiotics POS_NNS T
after POS_IN O
dog POS_NN D
bite POS_NN D

Stereotactic POS_JJ T
radiosurgery POS_NN T
for POS_IN O
acoustic POS_JJ D
neuroma POS_NN D
: POS_: O
a POS_DT O
Canadian POS_JJ O
perspective POS_NN O

Hematopoietic POS_JJ T
stem-cell POS_NN T
transplantation POS_NN MESH_TYPE_qualifier MESH_transplantation T
for POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
severe POS_JJ WORDNET_disease.n.01 D
combined POS_VBN WORDNET_disease.n.01 D
immunodeficiency POS_NN WORDNET_disease.n.01 D

Low-dose POS_JJ T
clozapine POS_NN T
for POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
drug-induced POS_JJ D
psychosis POS_NN D
in POS_IN D
Parkinson POS_NNP D
's POS_POS D
disease POS_NN D

Hyperbaric POS_NNP T
or POS_CC T
normobaric POS_JJ T
oxygen POS_NN T
for POS_IN O
acute POS_JJ D
carbon POS_NN WORDNET_chemical.n.01 D
monoxide POS_NN WORDNET_chemical.n.01 D
poisoning POS_NN MESH_TYPE_qualifier MESH_poisoning D
: POS_: O
a POS_DT O
randomised POS_VBN O
controlled POS_JJ O
clinical POS_JJ O
trial POS_NN O

Vaccination POS_NN T
against POS_IN O
Schistosoma POS_NNP D
mansoni POS_JJ D
infection POS_NN D
using POS_VBG O
74 POS_CD O
kDa POS_JJ O
Schistosoma POS_NNP O
protein POS_NN WORDNET_chemical.n.01 O
antigen POS_NN O

Protection POS_NN O
of POS_IN O
swine POS_NN O
from POS_IN O
foot-and-mouth POS_JJ WORDNET_disease.n.01 D
disease POS_NN WORDNET_disease.n.01 D
with POS_IN O
one POS_CD O
dose POS_NN O
of POS_IN O
an POS_DT O
all-D POS_JJ T
retro POS_NN T
peptide POS_NN WORDNET_chemical.n.01 T

Mutants POS_NNS O
of POS_IN O
cholera POS_NN WORDNET_disease.n.01 O
toxin POS_NN O
as POS_IN O
an POS_DT O
effective POS_JJ O
and POS_CC O
safe POS_JJ O
adjuvant POS_NN O
for POS_IN O
nasal POS_JJ WORDNET_body_part.n.01 D
influenza POS_JJ WORDNET_disease.n.01 D
vaccine POS_NN T

Field POS_NNP O
evaluation POS_NN O
of POS_IN O
the POS_DT O
clinical POS_JJ O
effectiveness POS_NN O
of POS_IN O
vaccines POS_NNS T
against POS_IN O
pertussis POS_NN D
, POS_, D
measles POS_NNS WORDNET_disease.n.01 D
, POS_, D
rubella POS_NN D
and POS_CC D
mumps POS_NNS WORDNET_disease.n.01 D
: POS_: O
comments POS_NNS O

Echocardiography-guided POS_JJ T
ethanol POS_NN T
septal POS_JJ T
reduction POS_NN T
for POS_IN O
hypertrophic POS_JJ D
obstructive POS_CD D
cardiomyopathy POS_NN D

Carbon POS_NNP WORDNET_chemical.n.01 D
monoxide POS_NN WORDNET_chemical.n.01 D
poisoning POS_VBG MESH_TYPE_qualifier MESH_poisoning D
treated POS_VBN O
with POS_IN O
hyperbaric POS_JJ T
oxygen POS_NN T
: POS_: O
metabolic POS_JJ O
acidosis POS_NN O
as POS_IN O
a POS_DT O
predictor POS_NN O
of POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
requirements POS_NNS O

Surgical POS_JJ T
management POS_NN T
of POS_IN O
severe POS_JJ D
secondary POS_JJ MESH_TYPE_qualifier MESH_secondary D
peritonitis POS_NN D

< POS_JJ O
TO_SEE POS_NNP O
> POS_NNP O
Pompholyx POS_NNP D
( POS_( D
vesicular POS_JJ D
eczema POS_NN WORDNET_disease.n.01 D
) POS_) D
after POS_IN O
i.v POS_NN T
. POS_. T
immunoglobulin POS_NN WORDNET_chemical.n.01 T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
for POS_IN O
neurologic POS_JJ D
disease POS_NN D

Phase POS_NNP O
III POS_NNP O
randomized POS_VBD O
study POS_NN O
of POS_IN O
cisplatin POS_NN T
versus POS_NN O
paclitaxel POS_NN T
versus POS_NN O
cisplatin POS_NN T
and POS_CC T
paclitaxel POS_NN T
in POS_IN O
patients POS_NNS O
with POS_IN O
suboptimal POS_JJ O
stage POS_NN O
III POS_NNP O
or POS_CC O
IV POS_NNP O
ovarian POS_JJ D
cancer POS_NN WORDNET_disease.n.01 D
: POS_: O
a POS_DT O
gynecologic POS_JJ O
oncology POS_NN WORDNET_medicine.n.01 O
group POS_NN O
study POS_NN O

Low-molecular-weight POS_JJ T
heparin POS_NN WORDNET_chemical.n.01 T
vs POS_NN O
heparin POS_NN WORDNET_chemical.n.01 T
in POS_IN O
the POS_DT O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
patients POS_NNS O
with POS_IN O
pulmonary POS_JJ D
embolism POS_NN D

Methadone POS_NNP T
maintenance POS_NN T
vs POS_NN O
180-day POS_JJ O
psychosocially POS_RB O
enriched POS_VBN O
detoxification POS_NN WORDNET_treatment.n.01 T
for POS_IN O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
opioid POS_JJ D
dependence POS_NN D
: POS_: O
a POS_DT O
randomized POS_NN O
controlled POS_VBN O
trial POS_NN O

Issues POS_NNS O
and POS_CC O
challenges POS_NNS O
with POS_IN O
antithrombotic POS_JJ T
therapy POS_NN WORDNET_treatment.n.01 MESH_TYPE_qualifier MESH_therapy T
in POS_IN O
diabetic POS_JJ O
patients POS_NNS O
with POS_IN O
acute POS_JJ D
coronary POS_JJ D
syndromes POS_NNS D

The POS_DT O
role POS_NN O
of POS_IN O
fibric POS_JJ T
acid POS_NN WORDNET_chemical.n.01 T
derivatives POS_NNS MESH_TYPE_qualifier MESH_analogs & derivatives T
in POS_IN O
the POS_DT O
secondary POS_JJ MESH_TYPE_qualifier MESH_secondary O
prevention POS_NN MESH_TYPE_qualifier MESH_prevention & control O
of POS_IN O
coronary POS_JJ D
heart POS_NN WORDNET_body_part.n.01 D
disease POS_NN D

Special POS_JJ O
report POS_NN O
: POS_: O
pressure-reducing POS_JJ T
support POS_NN T
surfaces POS_NNS T
in POS_IN O
the POS_DT O
prevention POS_NN MESH_TYPE_qualifier MESH_prevention & control O
and POS_CC O
treatment POS_NN MESH_TYPE_qualifier MESH_therapy O
of POS_IN O
pressure POS_NN D
ulcers POS_NNS D
: POS_: O
group POS_NN O
1 POS_CD O
technologies POS_NNS O

Intravenous POS_JJ T
immune POS_NNS T
globulin POS_NN WORDNET_chemical.n.01 T
for POS_IN O
recurrent POS_NN D
spontaneous POS_JJ D
abortion POS_NN D

